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Abstract 
Surgery with cardiopulmonary bypass (CPB) is associated with post-operative complications 
due to systemic inflammation.  However, the intracellular signalling pathways that promote 
inflammation in cardiac surgery with CPB are uncertain.  The studies presented in this thesis 
were designed to illuminate these molecular mechanisms, thereby informing the development 
of novel anti-inflammatory strategies. 
 
This was addressed through a clinical trial to determine the effects of CPB on inflammatory 
signalling in leukocytes (Chapter 4).  In this study, the induction of reactive oxygen species 
(ROS) and the activation of NF-κB and p38 MAP kinase within leukocytes was compared in 
patients exposed to miniaturised CPB (mCPB; an optimised form of CPB designed to 
attenuate systemic inflammatory activation) or conventional CPB (cCPB).  Twenty-six 
patients undergoing surgical revascularisation for advanced coronary artery disease were 
randomised to undergo surgery with either cCPB or mCPB.  Blood samples were collected 
pre-operatively and at various times after the initiation of CPB and analysed by intracellular 
staining and flow cytometry for intracellular markers of activation.  p38 MAP kinase 
phosphorylation in granulocytes was enhanced in patients receiving cCPB compared to 
mCPB (p<0.05).  Levels of ROS in lymphocytes were elevated in cCPB compared to mCPB 
(p<0.01) whereas ROS levels in granulocytes and monocytes were similar between groups.  
NF-κB phosphorylation in leukocyte sub-sets, leukocyte tissue migration as well as 
conventional markers of inflammation were comparable between the investigative groups.  
 
A porcine model was also established to study the signalling pathways that promote systemic 
inflammation in response to cardiac surgery with CPB under well-controlled experimental 
conditions.  The influence of sulforaphane, an anti-inflammatory compound derived from 
green vegetables, on inflammation and injury in response to CPB was also studied.  It was 
observed that pre-treatment of animals with sulforaphane reduced p38 MAP kinase (p<0.05) 
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and NF-κB (p<0.05) phosphorylation in leukocytes exposed to CPB and protected porcine 
kidneys from exhibiting histological features of early injury. 
 
A small clinical study demonstrated biologically significant levels of sulforaphane could be 
determined in plasma, with lower levels of p38 MAP kinase (p<0.01) and attenuated ROS 
(p<0.01) in the early stages following consumption. 
 
In conclusion, systemic inflammatory responses following CPB were associated with 
activation of p38 MAP kinase and NF-κB pathways in circulating leukocytes in both porcine 
and clinical studies.  Inflammatory responses to CPB can be reduced by miniaturisation of the 
CPB circuit and pharmacologically using sulforaphane. 
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CHAPTER 1. INTRODUCTION 
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1.1 ATHEROSCLEROSIS AND ISCHAEMIC HEART DISEASE 
Cardiovascular diseases are a significant health burden in the Western world1-4.  
Approximately 180,000 deaths occurred due to cardiovascular disease, accounting for a third 
of all deaths in the UK, in 20105.  Coronary artery disease, the most prevalent cardiovascular 
disease, resulted in over 94,000 deaths a year in the UK with an economic cost estimated at 
over £1.7 billion annually2,6.  The British Heart Foundation reported the total prevalence of 
angina was over 140,000 cases in men and over 116,000 cases in women living in the UK in 
2009, the principle symptom of ischaemic coronary artery disease7. 
 
The common drive for cardiovascular disease is atherosclerosis1,8-10.  As a lipid-driven 
chronic inflammatory disease of medium and large arteries, the accumulation of macrophages, 
smooth muscle cells, lipids and extracellular matrix results in thickening of the blood vessel 
wall8,10-12.  This can result in intraluminal plaque formation, reduction in blood flow and 
ischaemia13.  Consequently, end-organ perfusion is compromised.  Plaque material may 
become unstable and embolise causing tissue infarction or the presence of a fissure within a 
plaque can promote clot formation around the fissured defect resulting in a catastrophic rapid 
reduction in blood flow14.  The deposition of plaque within a vessel wall can also compromise 
the wall integrity and pre-disposes to aneurysm formation, particularly in large calibre 
vessels15,16. 
 
The process of atherosclerosis typically progresses for many decades before clinical 
symptoms become apparent17,18.  In advanced coronary artery disease, the usual presenting 
features can be exertional angina (chest pain) with or without dyspnoea (difficulty breathing) 
as a result of the impaired function of the myocardium.  When there is sudden plaque rupture 
or rapid total occlusion of a vessel, myocardial infarction occurs with irreversible necrosis of 
tissue and loss of function19.   Compromise to the left coronary system can impair myocardial 
contractility, reducing stroke volume and cardiac output with accompanying regional wall 
motion abnormalities and pulmonary oedema20.  Disruption of the right coronary system may 
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interfere with the electrical conduction system of the heart causing dysrhythmias21, loss of 
right-heart contractility with venous portal congestion22.  Additional consequences of 
coronary artery disease are new valvular leak (arising from disturbance to the intra-cardiac 
valve apparatus)23; ventricular aneurysm formation24; ventricular septal defects25 and myo-
/peri- carditis26.  Any disturbance of myocardial function leads to deleterious knock-on effects 
on all other organs of the systemic circulation. 
 
With improvements in the understanding of the mechanisms responsible for atherosclerosis, 
adverse mortality rates have fallen27,28.  Health benefits are achieved by the reduction in major 
risk factors such as smoking cessation, exercise, and improvements in preventative measures 
(e.g. enhanced blood pressure control; lipid lowering agents; long-term anti-platelet therapy 
and optimised blood glucose) in conjunction with healthy eating29-33.  With advanced arterial 
disease, already under optimal medical treatment, the additional therapeutic options include; 
interventional percutaneous balloon angioplasty and intra-coronary artery stenting34; 
definitive surgical revascularisation in complex multi-vessel disease35-37 or utilisation of an 
emerging combined hybrid approach of both surgery and stents37-40. 
1.1.1 Percutaneous coronary intervention 
The coronary circulation can be accessed percutaneously, through the skin, via peripheral 
arteries.  Radiological imaging guidance, the use of guide-wires and over-the-wire catheters 
can be employed for coronary artery interventions (PCI).  The stenosed coronary vessel can 
be mechanically opened to enhance intra-luminal blood flow41.  Implantation of intra-
coronary stents (approximately 95% of current clinical practice6) can maintain vessel patency, 
with or without drug elution to prevent in-stent stenosis and neo-intimal hyperplasia.   
 
There are 117 PCI centres within the United Kingdom6.  In 2009, there were a total of 83,130 
PCI procedures performed in the UK.  The rate of primary PCI to treat acute ST-elevation 
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myocardial infarction (STEMI) in place of thrombolysis continues to rise.   However, the 
overall mortality rate before discharge from hospital following PCI is gradually rising, 
perhaps from changing case mix.  This is in contrast with the improving mortality rates 
observed with surgical treatments which show an improvement from 2.3% in 2001 to 1.5% in 
2008 for isolated first time coronary artery surgery despite advanced age and co-morbidity42.  
However, the absolute risks from undergoing this procedure remain relatively low overall.  
Specifically, for stable elective patients, PCI carries a 0.15% mortality risk; for stable angina 
the risk is 0.6% and for STEMI patients, the risk is 4%6.  
1.1.2 Coronary artery bypass graft surgery 
When coronary artery disease is extensive or disease anatomy is complex and unfavourable to 
PCI (e.g. with tight left main stem disease lesions), coronary artery bypass graft (CABG) 
surgery is employed for symptomatic and prognostic benefits35,36,43.  This is the surgical 
process of placing a vascular conduit carrying oxygenated blood beyond a culprit coronary 
lesion directly onto a coronary artery.  Placement of bypass grafts to the targeted mid 
coronary vessel protects whole zones of vulnerable myocardium and protects against the 
development of new proximal disease. 
 
Alexis Carrel (1873-1944) performed aorto-coronary bypass grafts in canine models and 
recognised the link between coronary artery stenosis and angina pectoris44 and was 
acknowledged with the Nobel prize in 1912 for his work on vascular techniques.  One of the 
earliest surgical treatments for angina pectoris was total thyroidectomy, to reduce the 
sympathetic drive to the heart, described by Elliot Cutler (1888 - 1947)45.  Arthur Vineberg 
(1903-1988), a Canadian surgeon, directly implanted the internal thoracic artery onto the 
myocardium in the 1940s as a means to improve blood flow with limited success46.  The first 
direct coronary procedure was performed by William Longmire (1913-2003), without 
radiological angiographic planning, in 1958 after performing a coronary artery 
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endarterectomy to the right coronary artery during one of his procedures47.  David Sabiston 
(1924-2009) of Duke University performed the first intentional saphenous vein graft to 
coronary vessel in 196248 and Vasilii Kolesov (1904-1992) performed the first internal 
thoracic artery anastomosis to the left anterior descending  artery in 196449.  Alain Carpentier 
(1933- ) was the first to champion the use of the radial artery as a conduit in 197350  with 
Rene Favaloro (1923-2000) championing the use of vein grafts51. 
 
The current technique of coronary artery bypass grafting uses a combination of either 
pedicled (internal mammary, right gastro-epiploic) or free arterial grafts (radial, inferior 
epigastric) or venous conduits (long saphenous, short saphenous) to anastomose distal to an 
atherosclerotic lesion in order to restore blood supply to the myocardium.  The selection of 
conduit is dependent upon the surgeon and influenced by patient factors including age, co-
morbidity and accessibility of grafts.  The pedicled internal mammary artery is commonly 
regarded as the most optimal conduit in large cohort studies52,53. 
 
In the 5 year period between March 2003 and April 2008, there were 114,300 isolated CABG 
operations performed in the UK in 55 hospitals (6th National Adult Cardiac Surgical Database 
Report, 2008)42.  The activity of surgery has plateaued at nearly 23,000 cases per annum.  As 
a treatment modality in its 5th decade of clinical implementation, CABG remains the most 
intensively scrutinized surgical procedure in the history of medicine.  Although commonly 
performed with the use of CPB, in the UK approximately 17-25% of all CABG operations are 
performed “off-pump”42,54,55 without the need for extra-corporeal circulation support.  The 
outcome for patients undergoing CABG surgery electively in the UK is excellent with the 
mortality rate for patients under the age of 70 years old less than 1%42.  Medium-term 
survival is also favourable with a greater than 90% survival rate at 5 years post-surgery42. 
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1.2 VALVULAR DISEASE AND SURGICAL DISEASES OF THE AORTA 
The mainstay of cardiothoracic surgery worldwide is surgery on the coronary circulation for 
ischaemic heart disease.  The remainder of adult surgical practice is directed towards 
replacement or repair of diseased intra-cardiac valves, surgery on the thoracic aorta and organ 
transplantation in specialist centres.  All these procedures require the use of CPB systems for 
support.  A brief outline of current UK surgical practice is given below but further detailed 
discussion is beyond the scope of this thesis. 
 
The aortic valve functions as a one-way valve at the outlet of the left ventricle to the systemic 
circulation.  The common pathologies of the aortic valve are stenosis (commonly due to 
calcific degeneration or congenital bicuspid abnormalities) or regurgitation (due to rheumatic 
heart disease or infective endocarditis)56.  Currently, no effective medical (pharmacological) 
therapy exists for severe aortic stenosis or regurgitation other than valve replacement, or 
implantation57.  Between April 2003 and March 2008, there were 30,127 recorded isolated 
aortic valve operations42.  It is common to perform both aortic valve replacement and CABG 
at the same time as both disease pathologies commonly exist, so the workload is much more 
than indicated.  Additionally, pathology in the thoracic aorta (such as aneurysm formation) 
can involve the aortic valve apparatus leading to the requirement for performing complex 
reconstructive procedures58. The aortic workload has increased by 50% between 2001 and 
2008 with a 34% reduction in operative mortality, over 5 years reflecting improvements in 
patient care42.  Transcatheter aortic valve implantation (TAVI) is an emerging option in the 
treatment of aortic valve disease, currently under evaluation in those patients considered 
unsuitable for operative management59-62. 
 
The mitral valve is a bicuspid valve acting as a one-way valve between the left atrium and left 
ventricular chambers and is the most complex of the 4 valves of the heart63.  Surgery becomes 
necessary when there is stenosis of the valve (due to rheumatic disease) or regurgitation 
(commonly due again to rheumatic disease, ischaemic heart disease and infective 
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endocarditis)64 .  Between 2003 and 2008 there were 19,545 isolated mitral valve procedures 
performed in the UK42.  In a similar profile to aortic valve surgery, there has been a doubling 
of the number of mitral valve repair procedures between 2001 and 2008.  The mortality 
associated with valve repair is excellent (approximately 2% of all patients).  The comparable 
risk that arises from mitral valve replacement is higher (at 6.1%), reflecting a much greater 
risk population42. 
 
The aorta is the largest calibre blood vessel in the body.  It is the arterial blood conduit 
supplying the systemic circulation.  The first branches of the aorta are the coronary arteries 
arising above the cusps of the aortic valve, within the left and right coronary ostia.  The arch 
of the aorta gives rise to the head and neck blood vessels; upper limb circulation; supply 
blood to the thoracic structures and provides spinal blood flow.  The descending aorta then 
becomes the abdominal aorta as it traverses the diaphragm, and thus enters the management 
domain of the vascular surgeons.  Data is available for 5,245 cases of surgery on the thoracic 
aorta including thoracic aneurysms and aortic dissection.  The mortality for patients 
undergoing urgent or emergency surgery (e.g. for rapidly expanding aneurysms, leaking 
aneurysms or acute dissections) was 23% for the UK42. 
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1.3 CARDIOPULMONARY BYPASS 
Since being introduced in the 1950s, cardiopulmonary bypass (CPB) has revolutionised 
cardiothoracic practice by facilitating surgery on and within the heart65-67.  CPB circuits 
maintain the function of the heart and lung by achieving forward flow of blood, regulation of 
gas exchange and control of blood temperature68.  Between 2003 and 2008, more than 
145,000 cardiac surgical procedures were performed in the UK requiring the use of CPB42.  
The utility of CPB lies in its ability divert the circulation away from the heart to provide a 
bloodless operating field that is essential to the successful conduct of cardiac surgery.  In 
addition, the use of K+-containing cardioplegic solution to arrest the heart in diastole or, 
alternatively, using cross-clamp electrical myocardial fibrillation, renders the operating field 
motionless.  CPB can also be utilised as an invasive re-warming technique in accidental deep 
hypothermia69; as a means of maintaining oxygenation where complex airway challenges 
exist70,71 and as an adjunct in pulmonary embolectomy72.   
1.3.1 The Development of Cardiopulmonary Bypass 
It has been 386 years since the first description of the flow and pulsatile nature of the vascular 
system.  Before then, Galen (AD 129- c200) in De Usu Partium Corporis Humani had 
originally considered the liver - and not the heart - as the centre of the circulation73.  His 
classical teachings influenced European medical instruction from the Roman era until the 
time of the Renaissance.  This anatomical circulatory world view was finally widely 
challenged by William Harvey (1578-1657).  Published in the city of Frankfurt in 1628, De 
Motu Cordis detailed the action of the heart and correctly postulated the direction of flow of 
blood within the circulation74.  This was a postulation as Harvey was not directly able to 
visualise the capillary microcirculation that connected the arterial and venous systems.  
Marcello Malpighi (1628-1694) recorded observations four years after Harvey’s death which 
confirmed Harvey’s hypothetical assertions of a link between the two components of the 
circulation75.  These studies described the systemic circulation but it was Michael Servetus 
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(1511-1553) who is credited with the first accurate description of the pulmonary circulation in 
his theological treatise Christianismi Restitutio76,77.  However, unknown in the west until his 
writings were discovered in Berlin in 1924, the Syrian physician Avicenna (also known as Ibn 
Al Nafis, 1213-1288) had also rudimentarily described the pulmonary circulation, much 
before Servetus78.  This informed the knowledge basis for the pulsatile pump nature of the 
heart and the importance of the pulmonary circulation for gas exchange.   
 
It would be another 250 years before any advancements would be made on interventions on 
the human heart successfully.  In the early phases of development of what would later be 
known as extracorporeal circulation technology, the first heart-lung machine that was capable 
of oxygenating blood was developed by Max von Frey (1852-1932) and Max Gruber (1853-
1927) in Leipzig in their organ perfusion studies in 188579.  Building upon this foundation, 
the Russian scientist Sergei Brukhonenko (1890-1960) maintained the circulation of isolated 
dogs’ heads using donor lungs for gas exchange and bellows-type pumps for circulating blood 
in 192980.  However, the individual who applied this technological concept successfully to 
humans was John Gibbon (1903-1973), at the Massachusetts General hospital in the USA.  In 
1931, he was monitoring the condition of a critically ill patient who had suffered from a 
pulmonary embolism.  This patient subsequently died following an emergency pulmonary 
embolectomy procedure.  Gibbon was convinced that an extracorporeal circuit could have 
saved the patient’s life and realised the utility of this concept for all patients undergoing heart 
surgery.  After 22 years of experimental animal work, Gibbon utilised cardiopulmonary 
bypass successfully for 26 minutes to repair an atrial septal defect in an 18 year old woman in 
May 195366.  His work made use of the discovery of heparin to anticoagulate the blood in 
1916 by a medical student Jay McLean (1890-1957) and William Howell (1860-1945, of 
Howell-Jolly body fame)81 at the John Hopkins medical school and the reversal of heparin 
with protamine in 1949, via the work of Friederich Mischer (1844-1895)82.  These 
developments were facilitated by an improved understanding of circulatory physiology; the 
effects of hypothermia as well as a better understanding of bioengineering.   
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The early use of CPB met with limited success.  Following his first success, the subsequent 
three other patients operated on by Gibbon using CPB did not survive and he abandoned all 
future surgery after these events.  An alternative, limited, concept of ‘controlled cross-
circulation’ was employed by Walton Lillehei (1915-1999) in the early 1950s.  This involved 
connecting a child to the parent’s circulation to provide both oxygenation and perfusion and a 
total of 45 such operations were performed83.  John Kirklin (1917-2004) at the Mayo clinic 
performed the first series of operations using CPB in 195565 and the pioneers in Europe were 
led by Denis Melrose (1921-2007), William Cleland (1912-2005) and Hugh Bentall (1920-
2012) in the UK in the mid-1950s at the Hammersmith Hospital in London84.  Gibbon’s heart-
lung machine was adapted, refined and adopted for widespread use in the field of 
cardiothoracic surgery over the next fifty years throughout the world67.   
1.3.2 The conventional cardiopulmonary bypass circuit 
Before being connected to a patient during surgery, the CPB tubing lines are looped in a 
single circuit.  These lines are filled, in a process called “priming”, with a variety of fluids -  
commonly Hartmann’s solution with heparin before the lines are ‘divided’ into their 
respective arterial and venous components ready for connection to the patient.  CPB is 
instituted following cannulation of the arterial circulation (typically the aorta, or femoral 
artery) and the venous circulation (typically the right atrium or the superior and inferior vena 
cavae or femoral vein).  This permits the drainage of blood from the patient under gravity to 
the CPB apparatus where the blood gas content and temperature is regulated prior to being 
pumped back to the systemic circulation in the body to perfuse the organs (Figure 1.1).  As a 
consequence of the gas regulation of the blood by the CPB circuit, both mechanical lung 
ventilation and oxygenation during CPB are no longer required.   
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Venous return within the reservoir is actively channelled using roller pumps through a 
membrane oxygenator to enable oxygen and carbon dioxide gaseous exchange.  This blood is 
then passed through a heat exchanger which permits thermal control.  Particulate material 
within the circuit is filtered before the blood is passed back into the circulation.  The 
ascending aorta is cross-clamped proximally to the arterial cannulation site once 
cardiopulmonary bypass has been achieved to exclude it from the circulation (Figure 1.2).  
Thus the aortic cannula then directs blood flow away from the heart to the rest of the body.  
Cardioplegic arrest to reversibly stop the motion of the heart is achieved with a combination 
of topical myocardial cooling and infusion of potassium-rich solutions through the use of a 
cannula.  The cardioplegia cannula can be placed either (a) proximal to the cross clamp within 
the aortic root thus facilitating ‘antegrade’ cardioplegic solution flow down the coronary 
vessels or (b) within the coronary sinus thus facilitating ‘retrograde’ cardioplegic solution 
flow. The result of this hyperkalaemic solution is arrest of cardiac tissue in diastole. 
 
An alternative means of arresting the heart and maintaining the circulation is ‘cross clamp 
fibrillation’.  It is estimated that up to 15% of UK cardiac surgeons employ this technique 
during surgery85.  When this form of arrest of the myocardium is employed, the heart is 
excluded from the circulation by the application of a cross-clamp, whilst rapid electrical 
impulses are delivered directly to the heart.  This induces myocardial fibrillation and renders 
the tissues motionless. 
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Figure 1.1 Conventional cardiopulmonary bypass circuit 
Deoxygenated blood returning from the body is drained into the venous reservoir under gravitational 
forces via a cannula in the right atrium or central vein.  This blood is then circulated using a 
conventional roller-pump to the heat-exchange device before moving the gas-exchange device for 
temperature and oxygen-carbon dioxide regulation.  Oxygenated blood is then channelled into the 
systemic circulation via the arterial cannulation site, typically located within the arch of the aorta.  
Arterial and venous monitors in addition to filters provides a layer of safety within the circuit.  Shed 
blood within the operative field can be recirculated via the cardiotomy sucker and intra-cardiac blood 
can be evacuated with the use of the vent.  Cardioplegic solution can be delivered antegradely to the 
coronaries via an aortic cannula or retrogradely via a cannula in the coronary sinus. 
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Figure 1.2 Cannulation of the heart with cross-clamp circulatory exclusion 
The venous circuit is established via cannulation of the right atrium and the arterial circuit is 
completed via cannulation of the ascending aorta.  Once secured in place, extracorporeal circulation 
can commence.  The heart can be excluded from the circulation by application of an aortic cross-
clamp placed proximal to the arterial cannulation site.  Cardioplegia can then be given to arrest the 
myocardium.  
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1.3.3 Organ damage in association with surgery and cardiopulmonary bypass 
Surgery on the heart may be associated with adverse changes in the function of organ systems 
which can be initiated at the time of surgery and persist into the post-operative period of 
recovery.  The pathogenic mechanisms that lead to organ injury are multifactorial including 
haemodynamic, inflammatory and direct damage (e.g. embolic to the heart, brain and gut or 
nephrotoxic to the kidney).  A brief overview of some of the clinical correlates and exposure 
to cardiopulmonary bypass are given below.  
 
The lung is perhaps the organ most susceptible to injury following cardiac surgery with the 
use of CPB.  The lung may be susceptible due to the inherently large vascular bed and the 
prolonged transit time of leukocytes86.  It is uncertain if CPB itself is directly responsible for 
lung injury as post-operative lung dysfunction is similar in OPCAB CABG surgery87,88.  The 
majority of patients manifest a subclinical picture of lung dysfunction and there is a relatively 
low incidence of acute respiratory distress syndrome (ARDS) occurring in less than 2% of 
patients89,90.  However, the mortality rate of post-CPB ARDS can be >50%90.  The 
mechanisms that drive lung dysfunction are numerous.  The lungs are not ventilated during 
the conduct of CPB.  This hypoventilation predisposes to atelectasis of lung units which 
becomes difficult to re-ventilate post-surgery due to the altered chest dynamics resulting from 
median sternotomy91,92.  This is compounded by the alterations in the production of surfactant 
as a result of alveolar under-ventilation and also as a result of CPB induced inflammation93.    
Relative lung ischaemia occurs during CPB, and this may be an important factor in lung 
injury as the bronchial blood supply remains the only source of arterial blood during the 
conduct of bypass94.  Conversely, improved respiratory parameters in CPB scenarios where 
perfusion is maintained (with the use of the Drew-Anderson technique) are associated with 
reduction in pro-inflammatory IL-6 and IL-8 levels in plasma95.  Furthermore the interaction 
between putative lung ischaemia, a damaged endothelium and then reperfusion of this organ 
with the contributions of cytokine release leads to enhanced pulmonary capillary 
permeability96.  At the end of surgery, broncheoalveolar lavage fluid in patients subject to 
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CPBs showed enhanced numbers of neutrophils, as well as increased concentrations of pro-
inflammatory cytokines (IL-6, IL-8, TNFα) and neutrophil elastase97.   Increases in cellular 
permeability and the additional fluid load of CPB leads to increased extravascular lung water 
and pulmonary oedema98.  This scenario can be further exacerbated by blood transfusions and 
associated transfusion-associated lung injury in the post-operative period.  The end result is 
the development of intrapulmonary shunts with mismatch between lung perfusion and 
alveolar ventilation as a consequence of hypoxic vasoconstriction.  This results in a higher 
fraction of inspired oxygen (FiO2) requirement in the post-operative period and prolonged 
stay in ITU. In addition to the respiratory function that are interrupted, the lungs are also 
responsible for the metabolism of noradrenaline99 and sequestration of opioids100; both of 
which are perturbed by extracorporeal circulation, and complicate the clinical picture in 
recovery. 
 
Kidney injury has a consensus definition according to the Risk-Injury-Failure-Loss-End stage 
(RIFLE) classification101.  Up to 30% of cardiac surgery patients develop clinically evident 
kidney injury with 1% requiring dialysis102.  Haemodynamic / ischaemia-reperfusion 
mechanisms are important in kidney injury as CPB can reduce renal perfusion by 30% (which 
may be beyond the normal auto-regulatory range of the kidney to maintain adequate 
function)103.  Thus, experimentally, antagonists of endogenous vasoconstrictors ameliorate 
renal ischaemic injury in animal models104.  Research also suggests that pulsatile perfusion 
(rather than conventional laminar flow) has as protective effect on the kidney during 
cardiopulmonary bypass105.  From an inflammatory perspective, kidney parenchymal up-
regulation of NF-κB was observed in rat models of renal ischaemia106.  Following on from 
this, cardiopulmonary bypass exposure in a large animal model resulted in increases in 
urinary levels of IL-18 as well as vascular endothelial cell dysfunction and reduced nitric 
oxide tissue bio-availability107. Conventional blood markers of renal function such as 
creatinine are not elevated until >90% renal injury, and do not manifest clinically for a few 
days post-operatively.  Newer biomarkers of injury have been studied. Neutrophil gelatinase-
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associated lipocalin (NGAL) is released in renal tubular damage and is utilised as an early 
biomarker of kidney injury in cardiac surgery, having predictive value at 2 hours post- 
cardiopulmonary bypass108. 
 
Perioperative myocardial damage can be a significant problem. The incidence of post-
operative myocardial infarction occurs in 2-3% of patients following cardiac surgery109.  
During cardiac surgery, the aorta is usually cross-clamped and the heart is rendered ischaemic.   
If the heart continues to beat, there is progressive consumption of high-energy phosphates 
from intracellular stores, with protection provided by cardioplegia or intermittent cross-clamp 
release 110.  Ischaemic myocardium during surgery results in microstructural and functional 
changes (previously discussed in 1.1, page 19).  Cardio-specific proteins (CK-MB) and 
troponins are the mainstay markers of cellular damage111.  Additionally, heart-type fatty-acid-
binding protein hFABP is an emerging rapid marker of myocardial infarction112.  There are 
consistently higher markers of myocardial injury in association with on-pump surgery 
compared to off-pump surgery111,113.  This trend is also observed with optimised bypass 
systems, compared to conventional bypass systems114-118.  
 
Changes in regional blood flow and flow characteristics during cardiopulmonary bypass can 
be associated with hypoperfusion of the splanchnic circulation119. These can be compounded 
by the use of vasoconstrictor agents and by the embolization of material or atheroma from the 
aorta into the mesenteric circulation occluding blood flow.  The gut circulation can be 
significantly reduced even when whole-body perfusion indices are ‘normal’ as the release of 
vasoactive substances (such as vasopressin and catecholamines) leads to the alterations in 
blood flow away from the gut in preference of other organ systems120.  Gastrointestinal 
mucosal blood flow can be reduced with the use of CPB and can remain hypoperfused in the 
post-operative period121.  These mechanisms combined with the inflammation from SIRS 
disrupt the barrier and absorptive functions of the gut122.  Increased intestinal mucosal 
permeability may be a mechanism that allows the translocation of bacterial endotoxins into 
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the vasculature to propagate the inflammatory response and organ damage123.  Approximately 
2-4% of patients have a GI complication following surgery, with a particularly high mortality 
of 30%124,125.  The complications are gastrointestinal bleeding, peritonitis or bowel obstruction.   
 
The incidence rates of stroke are around 2-3% following cardiac surgery with increased risk 
in elderly patients126.  The mechanisms for injury to the brain during cardiac surgery with 
cardiopulmonary bypass can occur via reduction in blood flow and embolism127.  The effect 
of systemic inflammation is in dispute and the inflammatory response is not considered a 
primary driver of neurocognitive injury128. 
 
These deleterious events that occur in association with cardiopulmonary bypass are an 
important consideration for patients undergoing cardiac surgery.  The key mechanistic aspects 
of the inflammatory response and its contribution to morbidity and mortality are discussed in 
the next part of this chapter. 
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1.4 THE INFLAMMATORY RESPONSE 
Derived from the latin inflammare meaning literally ‘to set alight’, inflammation is a response 
of the body to harmful injury or infection.  Activation of the inflammatory response involves 
the appropriate recognition of an adverse event.  This is followed by the concerted co-
ordinated release of pro-inflammatory molecules and immune-modulatory agents to protect 
against the deleterious stimuli.  These molecules also direct the healing processes when 
inflammation resolves. 
 
There are five classical signs of inflammation.  Four of these were characterised by the 
Roman physician Aulus Cornelius Celsus (ca. 25 BC – 50 AD) in his treatise De Medicina129.  
These are rubor (redness), calor (heat), dolor (pain) and of tumor (swelling).   The fifth sign 
of functio laesa (loss of function) was later contributed to by the Greek physician Galen (AD 
129 - c200)130 and also variously attributed to the German physician Rudolf Virchow (1821-
1902)131.  The classical features of inflammation occur due to increased blood flow into the 
area of injury from vasodilatation resulting in heat and redness.  The movement of cells from 
the intravascular blood compartment into interstitial tissue compartment (occurring as a result 
of increased vascular permeability) results in tissue swelling and nerve compression causing 
pain with loss of function.  
 
The inflammatory process can be broadly considered as either acute or chronic in nature.  In 
the initial acute phase of the response, leukocytes migrate to the area of injury and neutralise 
the inflammatory stimulus.  Once this process is complete and the responsible stimulus for 
leukocyte activation and migration has been removed, damaged tissues undergo repair.  
Following on from this, a return to basal homeostatic conditions occurs with the termination 
of the inflammatory response.  In the situation where there is a persistence of the 
inflammatory stimulus, or the inflammatory response fails to resolve, chronic inflammation 
may occur132.  The pathological state of chronic inflammation, and the molecular mechanisms 
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that underlie this status are important in a number of diseases including, inflammatory bowel 
disease133-135, arthritis136,137, vasculitis138, cancer139-141 and atherosclerosis1,8-10.     
1.4.1 Systemic inflammation following CPB 
The benefits of CPB have also brought challenges in terms of its potentially deleterious 
effects on the immune system and the haematological manipulations necessary for safe 
conduct.  As such, there is emerging research into techniques of coronary artery 
revascularisation avoiding the use of CPB, known as off-pump surgery, and movement 
towards the optimisation of CPB systems. 
 
There is a systemic, generalised, inflammatory response associated with cardiac surgery and 
use of extracorporeal circulation142-147.   This can result in both morbidity and mortality for the 
patient.  In part, systemic inflammation occurs due to the exposure of circulating blood to 
artificial surfaces and un-physiological shear stresses during CPB148.  Thus there is activation 
of the complement cascade following bypass149-151 in a biphasic pattern both during and after 
CPB152 which is compounded by the changes of ischaemia and reperfusion of the myocardium 
and other end organs.   The consequence of conventional cardiopulmonary bypass is a 
disruption of coagulation, activation of leukocytes and complement and release of 
inflammatory and vasoactive substances into the circulation144,145,153-156.   Microembolic 
particles composed of platelet aggregates and fibrin (with a combination of other particles 
introduced into the circulation) are produced which can obstruct the distal 
microcirculation157,158.  The final outcome from this milieu is a disruption of haemodynamic 
homeostasis and organ failure at the most extreme end of injury.   
 
The magnitude of the inflammatory response to CABG with CPB depends on a number of 
factors including: the biomaterials used in the components of the bypass circuit159; the rate 
and characteristics of blood flow160,161; oxygenator components148; biomaterial surface area in 
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direct contact with blood with benefits observed with heparin-coated circuits162-164.   Patient 
factors such as (age, medical co-morbidities, surgical preparation165) and surgical factors 
(such as the duration of surgery166, the type of surgery), administration of heparin-protamine, 
hypothermia167-169 and lung ventilatory arrest170 are also important elements.  The effects of 
surgical access (incisions, sternotomy and electrocautery dissection) are important 
determinants of leukocyte activation as trauma (and other forms of physical injury) contribute 
to pro-inflammatory activation171-174.  In addition, the immune-modulating effects of 
anaesthetic agents175-177; perioperative myocardial protection techniques178,179; and use of 
pharmacological cardiovascular support180 all influence the characteristics and propagation of 
the immune response. 
 
The process of acute inflammation predominates in the field of cardiothoracic surgery.  This 
ranges from the minor local effects around a surgical incision site to the most severe 
manifestations of a body-wide ‘systemic inflammatory response syndrome’ (SIRS)143,155,181.  
Surgically relevant triggers of SIRS are physical trauma, infection, anaphylaxis, burns and the 
use of extracorporeal circulation144,145,171,172.   SIRS can result in haemodynamic instability146 
and morbidity182,183 contributing to an adverse clinical profile for patients.  As a serious 
clinical entity, SIRS can drive multiple organ failure with disastrous consequences.   
 
There are defined clinical criteria for the diagnosis of SIRS.  These clinical features are (1) 
body temperature less than 36˚C or greater than 38˚C (2) heart rate greater than 90 beats per 
minute (3) tachnypnoea with a rate above 20 breaths per minute and (4) a leukocyte count of 
less than 4×109 cells/l or greater than 12×109 cells/l in a patient’s whole blood 184,185.  SIRS is 
considered to be present when two or more of these explicit criteria are met185.    
 
In association with the use of cardiopulmonary bypass, activation of the circulating neutrophil 
pool can be demonstrated within 15 minutes of the bypass commencement by elevated 
expression of CD11b/CD18 integrin186.  This cellular activation is driven by a host of pro-
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inflammatory agents including: cytokines (including IL-1β, TNF-α, IL-8); arachidonic acid 
derivatives (leukotriene B4, thromboxane A2); contact proteins (kallikrein); the complement 
system molecules (C5a), heparin, histamine and DAMPs149,187-190.  CPB also enhances 
neutrophil activity by inhibiting neutrophil apoptosis signals191.  Periods of ischaemia and 
reperfusion associated with CPB enhances leukocyte transmigration due to altered blood flow 
enabling neutrophils to marginate.  Ischaemia promotes endothelial cell activation leading to 
rapid expression of adhesion molecules, (e.g. P-selectin and ICAM-1)192.  This facilitates the 
process of extravasation into tissues.  Cells of the monocyte/macrophage lineage are activated 
between 2-24h post-bypass and at 24 hours post-bypass, elevated numbers of cells can be 
detected in broncheoalveolar lavage fluid193,194.  When assessing the direct effect of 
cardiopulmonary bypass on leukocyte egress using the cantharidin technique, exposure to 
CPB triggered a 381% increase in leukocyte extravasation into skin blisters compared to 
reference blisters.  In patients exposed to CPB for a mean of 76 minutes, the total leukocyte 
count increased from 4.84 to 24.48 × 105/blister; neutrophils increased from 2.79 to 14.37 × 
105/blister; monocytes increased from 1.16 to 6.37 × 105/blister and lymphocyte count 
increased from 0.4 to 1.02 × 105/blister 195.  The regulatory mechanisms that lead to the 
activation, phenotypic changes and migratory capacity of leukocytes will be further explored 
in detail in later portions of this introduction. 
 
Despite these inflammatory events, our clinical experience of cardiac surgery with short-term 
CPB exposure has shown that the use of extracorporeal circulation use is relatively safe.  This 
may be a reflection of the body’s ability to compensate for these effects and also in the 
parallel advance of post-operative recovery monitoring and intervention.  However, the drive 
to optimise CPB is both crucial and necessary as the patient population undergoing cardiac 
surgery become more complex, possess greater co-morbidity and less physiological reserve in 
concert with requiring more advanced procedures and longer CPB runs. 
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1.4.2 Initiation of the inflammatory response 
Cell death and tissue injury are triggers for inflammation.  Of emerging importance is the 
release into the circulation of damage associated molecular patterns (DAMPs) which are 
generated following injury, in the context of cardiac surgery, from a variety of scenarios.  
These DAMPs function as the early promoters of the innate immune response196. 
 
The innate immune response is directed by a family of pattern recognition receptors (PRRs) 
196-201,202-205,160,161.  These receptors are distributed on cell surfaces as well as being located 
within cells.  PRRs detect highly conserved molecules known as pathogen-associated 
molecular patterns (PAMPs) which share characteristics with endogenous damage-associated 
molecular patterns (DAMPs) (Table 1.1).  PAMPs are molecules associated with groups of 
pathogens, and their corresponding receptors are highly conserved throughout nature as a 
result of their intrinsic importance in survival.  PAMP molecules include components such as 
bacterial cell wall glycoproteins, single and double stranded RNA fragments and bacterial 
flagellin which are clearly absent in the host.  When detected, these components are able to 
provide clear  unambiguous signals alerting the immune system to the presence of something 
pathogenic to direct a co-ordinated response197.  Similarly, DAMPs are molecules / molecular 
substrates derived from host cells that can arise from injury in the absence of infection.  They 
can be classified as protein (e.g. S100 proteins, heat shock proteins (HSP), HMGB1) or non-
protein (e.g. ATP, uric acid, heparin sulphate, RNA, DNA, mitochondrial fragments) in 
origin165,173,181,201,206-209.  
 
PAMPs and DAMPs are recognised by several families of PRRs including the Toll-like 
receptors (TLRs)210,211; NOD-like receptors (NLRs)212-214; Formyl peptide receptors (FPRs)202-
205, RIG-I-like (RLRs) receptors, AIM2-like receptors (ALRs) and activation of the Receptor 
for Advanced Glycation Endproducts (RAGE) 196-200.  These receptors (receptor families) are 
found on circulating leukocytes, platelets, endothelial cells and mesenchymal cells, with 
emerging various subclasses of receptors being reported in the literature.  Interactions 
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between DAMPs and PPRs regulate the induction of SIRS by CPB and a wide variety of 
DAMPs and associated signalling cascades are being identified as being directly relevant to 
the process of cardiothoracic surgery.  The best characterised PPRs are the TLR family of 
proteins given their name due to the structural similarity they shared with the Toll gene in 
Drosophila.  TLRs are highly conserved components of the immune system across species, 
and even in plants, with 11 classes of TLRs identified in humans thus far.  TLR1, -2, -4, - and 
-6 are located on cell surfaces whereas TLR3, -7 and -9 are found intracellularly.  They detect 
DAMPS including DNA, and mitochondrial DNA207,210 nucleic acid fragments which are 
released following trauma and stress molecules such as heat shock proteins (HSP)181, high-
mobility group protein Box-1 (HMGB1)209 generated following cellular stresses including 
haemorrhagic shock215 and especially with ischaemia-reperfusion216,217 with corresponding up 
regulation of TLR receptor expression on immune cells218,219 and alveolar macrophages220 
with cardiac surgery or no effect on immune cell receptor expression221.   
 
Detection of DAMP/PAMP molecules by their respective receptors leads to the activation of 
intracellular signalling cascades which interface via secondary adaptor proteins and signalling 
molecules.  When the DAMP/PAMP signals favour a pro-inflammatory response, the 
cascades ultimately converge on the activation of the AP-1 family of transcription factors (via 
activation of the mitogen-activated protein (MAP) kinases, NF-κB activation and are 
modulated by other redox-sensitive signalling molecules (see 1.5, page 56).  These pathways 
regulate the activation and propagation of inflammatory cellular processes by enhancing 
leukocyte survival by inhibiting apoptosis signals222-224, and also by activating vascular 
endothelial cells. 
 
Access to the heart and great vessels within the chest is achieved surgically usually via a 
median sternotomy using a vibrating saw and electrocautery for dissection.  This causes the 
release of cellular tissue fragments, bone components and fat globules to be released into the 
circulation, from localised electro-physical trauma.  It is plausible that early release of 
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DAMPS during surgery results in the up-regulation of genes responsible for the release of 
TNFα and IL-1 pro-inflammatory cytokines from injured endothelial cells to create a 
chemokine gradient to attract cells of the immune system.    
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Table 1.1 Damage associated molecular pattern receptors with corresponding ligands 
 
Receptor PAMP DAMP 
TLR-1 Triacyl lipopeptides  
TLR-2 
Lipoprotein, LPS, PGN, LTA, zymosan, 
trypanosmal phospholipids 
HSP60, HSP70, defensins 
TLR-3 dsRNA mRNA 
TLR-4 
LPS, pseudomonas exoenzyme, RSV F protein, 
MMTV envelope protein, trepansomal lipids, 
taxol 
HSP60, HSP70, HSP90, HMBB-1, hyaluronic 
acid, fibrinogen, fibronectin, fx1-defensin, 
heparin sulphate 
TLR-5 Flagellin  
TLR-6 Diacyl lipopeptides  
TLR-7 ssRNA, imiquimod  
TLR-8 ssRNA, resquimod  
TLR-9 Bacterial/viral DNA, CpG DNA 
Unmethylated CpG DNA, mitochondrial 
DNA 
TLR-10 Unknown  
TLR-11 Ureobacteria, toxoplasma LPS  
NLRC1 Meso-DAP  
NLRC2 Muramyl dipeptide  
NLRP3 Muramyl dipeptide, CpG DNA, dsRNA ATP, uric acid crystals 
FPR N-formyl peptides  
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1.4.3 Regulation, circulating levels and phenotypic effects of DAMPS 
The control and clearance of DAMPs depends on the context of their generation (i.e. single 
insult such as CPB or isolated traumatic injury, or conversely a chronic ongoing disease 
process) and on the mechanisms of their removal from the circulation.  A suggestion from this 
thesis is that the release of DAMPS could be an initiating stimulus for CPB-associated 
activation in response to trauma or injury.  However, there is a relative paucity of 
experimental human data that characterises the precise pharmacokinetics for many of the 
DAMPs in the circulation in the specific context of cardiac surgery.  The studies reported in 
the literature give only glimpses at the mechanistic links and are described below. 
 
Following major trauma, mitochondrial DNA fragments and formyl peptide fragments are 
released from injured tissues into the circulation173,208.  These are known to activate 
leukocytes via TLR and FPR receptors181,217,225.  Concentrations of mitochondrial DNA 
release also positively correlated with increased phosphorylation of p38 and ERK MAP 
kinases as well as IL-8207, suggesting a mechanistic link in the leukocyte activation cascade173.  
Exposure to mitochondrial DNA enhances ICAM-1 and E-selectin on endothelial cells as well 
as CD18 and L-selectin on leukocytes to promote adhesion of leukocytes to vascular 
endothelium226.  Mitochondrial DNA levels in trauma patients with high injury severity scores 
(ISS>25) were 2.7 ± 0.94 µg/mL (thousands of fold increase compared to healthy controls) 
and remained elevated at 24 hours post index injury event, in plasma207.  This elevation of 
mitochondrial DNA was also evident in processed reamed bone fragments from femoral 
repair, in data from the same group.  Circulating plasma cell-free DNA concentrations have 
also been shown to be significantly increased in severely injured patients in other studies (β-
globin gene 80840 kilogenome-equivalents/L, ISS>25)208.  These levels decrease within 2 
hours (relative to the index injury) towards reference values with a second increase in plasma 
concentrations in the following days, coinciding with organ failure208.  Correspondingly, 
elevated plasma cell-free DNA levels have been associated with worse clinical outcomes in 
severely injured patients227.  The mechanisms for this increase of cell-free DNA in plasma 
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may be due to necrosis with direct tissue and cellular injury as the main precipitating source 
given plasma elevation changes are evident within 30 minutes of insult228; apoptosis as a 
secondary delayed phenomena229, active release into the plasma230  and impaired clearance 
from organ damage (given that fetal cell-free circulating DNA has a normal half-life of  16 
minutes231).  Circulating cell-free DNA in the plasma is mainly removed rapidly by the 
liver232, with levels not being altered by chronic kidney disease or dialysis233.  The release of 
mitochondrial DNA into the circulation has also been correlated with the development of 
SIRS234.  Thus it is possible that elevated mitochondrial DNA may initiate inflammation 
following trauma.  The plasma kinetic changes of mitochondrial DNA in the context of 
cardiopulmonary bypass has not yet been characterised although a study has demonstrated 
elevated levels of mitochondrial DNA transcripts in cardiomyocytes in aortic valve surgery 
using sevoflurane (compared to propofol) as a cardioprotective agent235. 
 
The DAMP High-mobility group protein B1 (HMGB1) is released from apoptotic, necrotic 
and activated immune cells in the context of ischaemia re-perfusion and binds to TLR-2, -4 
and RAGE197.   Plasma HMGB1 levels were elevated more than 30-fold above healthy 
controls within 1 hour of injury (median 57.8 ng/mL), peaking between 2-6 hours (median 
526.2 ng/mL) following insult in ISS>15 populations.  HMGB1 is released into the plasma in 
a variety of cardiac operations surgery with the use of CPB (valve replacements, septal 
closure, CABG), as well as in off-pump coronary revascularisation with peak levels after 
aortic-declamping or completion of anastomoses209.  The peak levels were recorded at one 
hour following aortic declamping, in surgery with CPB (11.5±7.9 ng/mL) and at 30 minutes 
following revascularisation in OPCAB (8.4±3.9 ng/mL) remaining elevated at 1hour 
following admission to ITU in both groups, before returning to baseline at 24 hours209.  
Together, these studies suggest HMGB1 may be an integral part of the early inflammatory 
response to trauma and have a positive predictive effect for survival236.  Release of HMGB1 
has been shown to lead to activation of neutrophils and IL-8 and TNFα cytokine expression 
via both -p38 MAP kinase and -NF-κB pathways237. With the presumption that DAMPs are 
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derived from apoptotic and necrotic cells, enhancing the normal physiological clearance of 
these cells or prevention of their accumulation may provide a therapeutic window.  For 
example impaired clearance of apoptotic cells is associated with elevated levels of HMGB1 in 
bone marrow of leukaemic patients238. 
 
Another DAMP, Heat Shock Protein 70 (HSP70), is induced in response to myocardial 
ischaemia and binds with PRRs.  In patients undergoing CPB, levels of circulating HSP70, a 
ligand for TLR4, were enhanced at peak levels immediately after operative intervention in 
plasma (1809 pg/mL immediately after surgery; 1879 pg/mL 5 hours after surgery, returning 
to baseline at 19 hours post-surgery) with an up-regulation of monocyte TLR-2 and TLR-4 
surface expression 181.  This was coupled with the observation of enhanced levels of IL-6 in 
plasma up until 2 days following surgery, following the HSP70 peak release181. Investigation 
of HSP70 release at earlier timepoints showed no release after heparin, before CPB nor 
enhancement at 30 minutes after CPB but only after protamine reversal with enhanced release 
into the plasma both in the context of off-pump (3700 pg/mL) and on-pump surgery (5100 
pg/ml239.  In the same paper, differential expression of intracellular HSP70 was observed in 
leukocytes suggesting a faster reaction of monocytes and granulocytes than lymphocytes to 
the effects of CPB239.  The receptor for HSP70, TLR-4, has been demonstrated to influence 
the mediation myocardial injury via activation of downstream MAPK225 and NF-κB240 
signalling pathways.  Another member of this DAMP family, HSP72, is induced in patients 
with unstable angina undergoing CABG, and is additionally associated with up-regulation of 
NF-κB and AP-1 gene expression within the myocardium241.   
 
The S100 protein family are known to be expressed in cells of myeloid origin and are found 
in high concentrations in inflamed tissues, acting as DAMPs242.  These family of proteins can 
signal via RAGE receptors to promote the inflammatory response243.  The pro-inflammatory 
effects of S100 signalling can occur both via p38 MAP kinase244 and NF-κB dependent 
systems245.  Within endothelial cells, S100 enhances the expression of adhesion molecules 
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such as ICAM-1 and the expression of integrins such a Mac-1 on leukocytes246.  S100 
proteins are detected in higher concentrations following brain injury and stroke247,248.  
Consequently, the S100 proteins have been suggested as a biological marker of brain injury in 
cardiac surgery.  S100 is detectable after 30 minutes post-CPB and becomes undetectable 
within 24 hours249.  The highest levels of S100 in plasma were reported as 0.5g/L, dependent 
upon the duration of exposure to CPB249.  It is suggested that there may be predictive value of 
this marker to identify hitherto undetected neurological injury. 
 
In addition to the release of DAMPs, the complementary phenomena of up-regulation of 
expression of TLR receptors is seen following exposure to CPB in adults162,163 and children250 
in leukocytes.  Experimentally, genetic deletions of TLRs251 or inhibition of TLR-MyD88252 
signalling or receptor blockade253 has promise in the minimisation of warm hypoxic injury in 
the myocardium with reduction in infarct size and attenuated p38 MAP kinase and NF-κB 
activation in tissues.   
 
Overall, these studies suggest that release of DAMPs may promote systemic inflammatory 
responses following surgery with signalling mediated via PPRs and secondary signalling 
cascades.  These have different individual characteristics and further work to elucidate their 
mechanisms of release and biological characteristics is warranted in the field of cardiac 
surgery.  
1.4.4 DAMPs and secondary messenger signalling cascades 
DAMPs along with their corresponding receptors work in unison with intracellular signalling 
mechanisms to orchestrate the immune response (Figure 1.3).  For example, TLRs signal via 
the adaptor protein myeloid differentiation factor 88 (MyD88) to control downstream 
regulation of signals that activate NF-κB165.  Alternatively, TLR activation pathways (TLR3) 
leads to the recruitment of an adaptor protein known as TIR domain-containing-adaptor 
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which is capable of inducing IFNβ (TRIF).  In turn, TRIF activates the kinases TBK1 and 
RIP1.  The TBK1 kinase signals via IRF3 phosphorylation to induce IFN1.  Activation of the 
RIP1 kinase leads to polyubiquitination and activation of TAK1, leading to activation of NF-
κB via IKKβ200.  The protein MyD88 alternatively phosphorylates TNF receptor-associated 
factor 6 (TRAF6) in a pathway which can lead to the activation of MAPKs also via the 
polyubiquitination of the protein TAK1200.    The downstream effectors of FPR activation 
include the MAPKs ERK1/2, JNK and p38  via PI3K204.  In addition, activation of NLR 
subclasses leads to RIP2 activation (via RIPK2) and enhances activation of MAPK and NF-
κB pathways214.   
 
Their precise role of DAMPs and these pathways in cardiac surgery and their relative 
influence during cardiopulmonary bypass remain to be elucidated.  These brief illustrative 
examples highlight the links between DAMPs/immune receptor signalling cascades to the 
phosphorylation of p38 MAP kinase and activation of NF-κB, of importance to this thesis.  
This evidence provides cohesion with the experimental plans described in later portions of 
this work. 
????
?
  
Figure 1.3 DAMP signalling relationships with inflammatory cell signalling pathways 
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1.4.5 Mechanisms of leukocyte activation 
1.4.5.1 Cellular components of inflammation 
The function of leukocytes in the acute phase of an inflammatory response is to neutralise and 
remove harmful agents such as microbes, antigens and cellular debris to limit the spread of 
injury and to pave the way for healing and resolution.  Leukocytes are recruited locally (under 
chemokine/cytokine, DAMPs influence) from the circulation and also mobilised from the 
bone marrow (promoted under LTB4, C5a, IL-8 influence, and controlled by stromal cell-
derived factor-1, SDF-1, or granulocyte colony-stimulating factor, G-CSF)189,190.  A schematic 
for these interactions is given in Figure 1.4. 
 
The leukocyte population that responds early to injury are the neutrophils which are recruited 
to sites of inflammation within minutes.  These polymorphonuclear cells comprise the most 
abundant subpopulation of leukocytes and have an approximate lifespan of  5 days254.  They 
migrate under the influence of chemotactic mediators (such as C5a, IL-8, IFNγ and bacterial 
cell wall components) and marginate and migrate to the site of injury via selectin-dependent 
capture and integrin-dependent adhesion255.  Recognition of an inflammatory stimulus occurs 
through opsonisation, with immunoglobulins or complement, thus leading to phagocytosis256.  
This process results in the formation of a phagocytic vacuole which internalises cellular 
debris and foreign particles which are then exposed to lysosomal enzymes (elastase, 
myeloperoxidase, lactoferrin) ensuring their destruction.  Neutrophils are also capable of 
generating reactive oxygen species and utilise a “respiratory burst” (involving NADPH 
oxidase generating superoxide) to kill infected or damaged cells257. After performing their 
function, neutrophils undergo programmed cell death leading to the down regulation of the 
inflammatory cellular response.   
 
Derived from bone marrow monoblasts, monocytes comprise approximately 8% of the total 
leukocyte population and, on leaving the circulation, differentiate into macrophages in tissue.  
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Monocytes can migrate to the site of inflammation within 8-12 hours of injury to produce 
cytokines, to present antigens and to perform phagocytic functions.  They are important in the 
pro-inflammatory response and also in the resolution of inflammation by clearing cellular 
debris and apoptotic neutrophils (under the influence of TGFβ, PGE2 and PAF)258.  They 
function to clear cellular debris via phagocytosis and regulate fibroblasts, smooth muscle and 
endothelial cells via tissue growth factors (FGF, PDGF) for the production and organisation 
of the extracellular matrix with the aim of complete resolution.  This results in scar formation 
characterised by the deposition of large amounts of fibrin which cannot be easily removed. 
 
All lymphocytes are derived from a common lymphoid progenitor in the bone marrow.  
Lymphocytes are broadly divided into B- and T-cell subtypes.  The B-cell subset matures in 
the bone marrow whereas T-cells mature and undergo selection within the thymus gland.  
Once established, lymphocytes are found in the circulation in small numbers and peripheral 
lymphoid organs – namely the spleen and lymph nodes.  They play an essential role in 
adaptive immunity by releasing antibodies (B-cells); direct cellular cytotoxicity (cytoxic T-
cells, NK cells) or by signalling to other cells of the immune system (helper T-cells).  In 
contrast to other leukocytes, lymphocytes can persist for a whole lifetime and are important in 
the regulation of the immune response, self-tolerance to tissue specific antigens and in the 
development of ‘immunity’ to pathogens. 
 
Platelets are cellular fragments of the precursor megakaryocyte within the bone marrow with 
a life span of 5-9 days and possess important haemostatic and inflammatory functions where 
their predominant role is to respond to damaged endothelium259.  They outnumber all other 
leukocytes by a factor of 10.  Considering their immune functions, platelets can bind to 
leukocytes (e.g. via P-selectin) and lead to pro-inflammatory rolling and activation260.  
Activated platelets release a wide variety of pro-inflammatory (e.g. IL-1β, IL-8), anti-
inflammatory (e.g. C1-inhibitor, alpha 1-antitrypsin), mitogenic factors (e.g. platelet derived 
growth factor, transforming growth factor β) and angiogenic factors (e.g. vascular endothelial 
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growth factor)  into the circulation when stimulated261.  These megakaryocyte fragments also 
possess TLR-4, important in platelet-neutrophil pro-inflammatory interactions and responses 
to DAMPs and other molecular triggers262. 
1.4.5.2 Leukocyte interactions with the vascular endothelium 
The vascular endothelial cells (EC) form a semi-permeable barrier that regulates the transport 
of macromolecules and fluids across the vascular wall.  This endothelial barrier is maintained 
by intercellular junctions – the gap junctions which allow passage of small molecular weight 
solutes between cells (formed by connexins (Cx) i.e. Cx43, Cx40, Cx37 – organised as 
connexions acting as channels for molecular movements); the adherens junctions which play 
an important role in contact inhibition and EC growth (zonula adherens, which are composed 
of transmembrane proteins of the cadherin family, VE-cadherin, N-cadherin and PECAM-1) 
and the tight junctions which maintain paracellular permeability (zonula occludens, which are 
composed of Occludin-1, Claudins-1/-2, junctional adhesion molecule (JAM)-A/B 
components)263. 
 
Activation of the inflammatory response leads to recruitment of leukocytes at sites of local 
injury or infection via the release of cytokines and chemokines or other activating signal (e.g. 
TNFα, IL-1, IL-8, DAMPs, leukotrienes, complement components) from sentinel cells (e.g. 
dendritic cells, endothelial cells, mast cells) into the plasma to initiate the leukocyte 
recruitment cascade and also the vascular endothelium facilitating leukocyte extravasation to 
the site of injury255.  The vascular endothelium exhibits increased permeability during periods 
of acute and chronic inflammation, with the site of the post-capillary venule being the main 
site of inducibility and leukocyte interactions.  Up-regulation of adhesion molecules such as 
P-selectin and E-selectin in endothelial cells transiently bind to up-regulated ligands on 
leukocytes, including P-selectin glycoprotein ligand-1 (PSGL-1) and E-selectin glycoprotein 
ligand-1 (ESL-1), resulting in tethering and rolling of inflammatory cells on the vascular 
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endothelium264,265.  Guided by the chemokine/cytokine inflammatory gradient, interactions of  
integrins (e.g. LFA-1, VLA-1, Mac-1) on leukocytes with their corresponding ligands on 
endothelium (e.g. ICAM-1, ICAM-2, VCAM-1) results in arrest and transmigration into 
tissues266,267.  Endothelial membrane protein including PECAM-1, ESAM-1 aid leukocyte 
movement across membranes, with reverse migration prevented by endothelial JAM-C255,268.   
There can be considerable overlap between the stages of leukocyte extravasation with close 
co-ordination between adhesion molecules and ligands269. 
????
?
  
Figure 1.4 Overview of cellular interactions in inflammation 
The molecular mediators that regulate the adherence of endothelial cells to circulating leukocytes is 
complex and multi-step.  The selectins (E- and P- selectin) initiate the capture and rolling of circulating 
leukocytes.  The integrin ligands (ICAM-1 and VCAM-1) enable the arrest of rolling leukocytes.  The 
expression of these molecules by endothelial cells in vitro is regulated by inflammatory factors such as 
IL-1 and TNFα.  Additionally, the sheer-stress profile of flowing blood alters endothelial cell activation 
and the ultimate transmigration of arrested leukocytes between (paracellular) or through 
(transcellular) the endothelial barrier. 
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1.4.6 Assessment of leukocyte migration 
Human in-vivo models of leukocyte migration have been studied using the skin.  Other 
experimental animal (e.g. peritonitis270, cremasteric vessels271, air pouch272) models do not 
possess a favourable translation profile for adaption into human subjects.  The human skin is 
an innate barrier to protect against the environment.  This organ is composed of distinct layers: 
namely the superficial epidermis with the basement membrane above the dermis.   The 
epidermis is composed of an impermeable layer of dead cells on the surface, the stratum 
corneum.  The remainder of the epidermis is relatively avascular with blood coming from 
dermal capillaries.   
 
Historically, a “skin window” model was used to assess leukocyte migration; in removing the 
outer epidermal layer from skin, leukocyte egression could be studied into this particular 
tissue compartment.  Early studies utilised a scalpel to remove the stratum corneum layer of 
skin with lesions being covered with glass coverslips with subsequent assessment of 
adherence of leukocytes onto the glass273.  Alternative techniques used include skin abrasions 
using a drill274,275 and tape-stripping to cause superficial lesions276.  However, these 
techniques were difficult to standardise in terms of reproducibility of size and depth of lesions 
created, as well as complications of bleeding.  An alternative means of assessment of 
leukocyte movement into skin is to use a ‘skin blister’ model using mechanical or 
pharmacological means to induce the separation of the epidermis from the dermis.  The 
technique of applying a negative-pressure suction device onto the skin allows for the 
harvesting of blister fluid, but this can be traumatic and yields small volumes277.   
 
Pharmacologically, reproducible and effective volumes of blister fluid can be developed using 
the topical blistering agent cantharidin278.  Cantharidin is a protein phosphatase 1 and 2 
inhibitor found in the hemolymph of blister beetles (Meloidae coleoptera)279.  When applied 
to the skin, it causes separation of the superficial layer of cells (acantholysis) and blister 
formation.  Cantharidin is an odourless and colourless agent that has been used medically to 
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remove warts280,281 and unwanted tattoos282 with more than one million prescriptions having 
been dispensed without serious adverse effects283.   
 
Experimentally, cantharidin can be used in humans to study leukocyte emigration and 
cytokine production in the skin195,278,284,285.  The cantharidin technique has been previously 
validated by our group as a tool for analysing the inflammatory response to standard CPB and 
anti-inflammatory interventions by comparing blisters in patients receiving aprotinin with 
those receiving saline195 as well as defining changes in cell surface receptor expression 
changes285. The approach lends itself well to the investigation, development and validation of 
alternative anti-inflammatory strategies related to surgery. 
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1.5 PRO-INFLAMMATORY INTRACELLULAR SIGNALLING PATHWAYS 
In the earlier parts of this chapter, the initiating events of DAMPs generation was considered 
and how these pathways were connected illustrated in the context of leukocyte activation, 
relating to cardiac surgery.  Inflammation is controlled by key intracellular signalling 
cascades regulating the AP-1 superfamily and NF-κB family members.  Importantly, the 
relative influence of particular signalling intermediates/pathways varies according to cellular 
and environmental context. In the following section, this thesis will focus on delineation of 
the MAP kinases and NF-κB, and the relative influence of ROS on leukocyte activation, as a 
mechanism to explain the injury that can occur following cardiac surgery with the use of 
cardiopulmonary bypass. A descriptive overview of the generation, physiological importance 
and regulation/modulation of ROS, p38 MAP kinase and NF-κB in inflammation is given 
below.   
1.5.1 Reactive oxygen species 
Oxygen is an essential molecule for all aerobic organisms facilitating the production of 
energy via the oxidative phosphorylation pathway.  Derivatives of oxygen known as reactive 
oxygen species (ROS) are generated by all cell types as a by-product of this process and are 
important early signalling mediators for cellular pathways including transcriptional regulation, 
proliferation and differentiation and apoptosis286-288.  These species are becoming increasingly 
important in clinical fields of heart failure289 and cardioprotection290.  ROS are acknowledged 
to be important in inflammatory signalling but the precise roles/mechanism and kinetics of 
influence are not fully understood.  ROS can be deleterious at high concentrations leading to 
protein oxidation and damage DNA291.  At lower concentrations, ROS can function as 
signalling molecules292.   
 
ROS can exist broadly in two forms as free radicals with unpaired electrons or as non-radical 
forms.  The sources of intracellular ROS differ under physiological and pathophysiological 
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conditions.  Within mitochondria, the superoxide radical (·O2
-) is generated via the leakage of 
electrons from the electron transport chain or alternatively by catalysis via NADPH or 
xanthine oxidase.  The superoxide radical can be converted by dismutation, enhanced by 
superoxide dismuates enzymes, to hydrogen peroxide (H2O2) which can in turn be converted 
into highly reactive hydroxyl radicals (·OH)292.   Other sources of ROS include, peroxisomes, 
the plasma membrane, cytosol and endoplasmic reticulum.  Within these systems, ROS are 
formed via the action of the cytochrome P450, NADPH oxidases and enzymes important in 
arachidonic acid metabolism286.   
 
The half-lifes of ROS are extremely short - the superoxide radical (·O2
-) is 1 µs292; hydrogen 
peroxide (H2O2) is 1 ms
293 and the hydroxyl radical (·OH) 1 ns293.  Due to their reactivity and 
short half-lives, ROS have a limited range (distance) of influence within cells.  However 
mechanisms exist to facilitate the movement of certain ROS species.  For example, H2O2 can 
be transported across biological membranes via aquaporin channels giving a potential for 
transference between cells in direct contact294.   Voltage-dependent anion channels in 
mitochondrial membranes regulates the release of superoxide into the cytosol295.  
 
The production of ROS is important in the inflammatory response.  ROS are generated by 
cells of the immune system leading to oxidation of signalling molecules as well as in the 
process of phagocytosis.  At sites of inflammation where neutrophils are abundant, H2O2 with 
chloride is converted by the enzyme myeloperoxidase into hypochlorus acid (HOCl) 
important in the respiratory burst296.  Superoxide radical generation is important in the killing 
of microbial organisms of the phagolysosomes of macrophages in humans, as part of the 
repertoire of ROS responses.  Consistent with this, mutations in the genes for NADPH 
oxidases, ordinarily responsible for the generation of superoxide radicals, has been associated 
with chronic granulomatous disease associated with greater susceptibility to fungal and 
bacterial infections.297.  Experimentally, phorbol esters (PMA)298, TNFα298 and LPS299 
mechanistically are known to induce the phosphorylation of the NADPH oxidase complexes, 
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and thus enhance ROS.  This induction of phosphorylation occurs via many mechanisms 
including p38 MAP kinase300. 
 
Oxidative stress and ROS signalling regulates the expression of cell adhesion molecules by 
direct activation (e.g. direct release of P-Selectin from Weibel-Palade bodies) and by 
transcription-dependent mechanisms.  For example, HUVEC treated with H2O2
 for 1 hour 
showed enhanced P-selectin expression and increased PMN adhesion301.  Similarly, H2O2 
treatment of HUVEC enhanced transcription of ICAM-1302.  ROS are known to enhance NF-
κB activation and up-regulate expression of ICAM-1, VCAM-1 and E-Selectin to promote 
leukocyte binding286.  Enhanced ROS activity following TNFα stimulation of PMNs was 
associated with up-regulation of leukocyte cell surface adhesion molecule CD11b/Mac-1303.  
Enhanced ROS generation also influence endothelial permeability by increasing tyrosine 
kinase activity (e.g. c-Src, PYK2) leading to VE-cadherin phosphorylation and destabilisation 
of adherens junctions, as interaction of β-catenin and p120 catenin are prevented292.  
Treatment of endothelial cells with hydrogen peroxide enhanced endothelial cell permeability 
by disruption of occludin on the cell surface and dissociation from ZO-1 protein, via MAP 
kinase dependent mechanism, altering tight junctions304.  Taken together, these studies 
highlight some potential mechanism for ROS to enhance leukocyte adhesion to endothelial 
cells and migration into tissues. 
 
Antioxidant defence mechanisms that modulate the activity of ROS have been linked to 
inflammatory responses.  For example, superoxide dismutase (SOD) dismutates superoxide to 
hydrogen peroxide; the enzymes catalase and glutathione peroxidase are responsible for 
conversion of hydrogen peroxide to water whereas additional ROS scavenging can be 
facilitated by peroxiredoxins305.  SOD has tissue specific distribution, with the highest levels 
in lung with knock-out animals exhibiting enhanced susceptibility to lung injury306.  Catalase 
is highly expressed in liver and erythrocytes307.  However, the congenital absence of catalase 
is reportedly a benign condition292.   The family of glutathione peroxidases (GPx) deals with 
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hydrogen peroxide by oxidising glutathione into dimeric glutathione disulphide, which is then 
converted back by glutathione reductase.  The depletion of glutathione is associated with 
enhanced immune airways responses308,309.  The peroxiredoxins convert hydrogen peroxide to 
water and are found particularly expressed in lung tissues310.  In animal peroxiredoxin 
knockout studies, there was enhanced susceptibility to hyper-oxic injury311,312.  The 
thyorexodin (Trx) system is an important defence mechanism against oxidative stress via its 
disulphide reductase activity and provides electrns to the thiol-dependent peroxidases to 
remove ROS313  The absence of thyoredoxin is associated with oxidative stress in 
dopaminergic cells, of importance in neurogenerative diseases such as Parkinson’s disease314.  
The induction of the genes for these cytoprotective mechanisms is regulated by the 
transcription factor NF-E2-related factor 2 (Nrf2)315-322, which is discussed in further detail in 
section 1.6.4 (page 85).  This illustrates the multiple systems that exist to regulate and 
modulate the activities of ROS in biological systems and their importance in inflammation. 
 
Ischaemia-reperfusion occurring from cardiac surgery, is recognised as a key event in ROS-
mediated injury323,324.  ROS levels, and plasma markers of ROS-mediated injury, are elevated 
following CPB178,325-327.  This has been particularly associated with the historical use of 
bubble oxygenators/gas exchange devices328.  In the scenario of off-pump surgery, there is 
less oxidative stress illustrating the relative ROS-generating effect of CPB exposure329.  In 
parallel with these enhanced levels of ROS, studies have shown an association with 
reduction/depletion of radical scavenging molecules post-operatively330.  These perturbations 
in ROS following CPB influence inflammatory processes since clinical studies with N-
acetylcysteine, an anti-oxidant and glutathione precursor, have been shown to attenuate 
myocardial ROS331 and apoptosis markers332 following CPB.   
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1.5.2 MAP Kinases 
MAP kinases regulate multiple diverse physiological processes.  Aberrant MAP kinase 
signalling is implicated in cancer biology, inflammatory disorders333,334 neurological 
diseases335,336 as well as altered development and function of the heart337,338.  The MAP kinase 
signalling cascade is illustrated in Figure 1.5.  Three major families have been identified: the 
extracellular signal-related kinases (ERK); c-Jun NH2-terminal protein kinases (JNK – also 
known as stress-activated protein kinase, SAPK) and the p38 kinases.  p38 MAP kinase was 
identified as a 38-kDa protein that shared approximately 49% homology with ERK. There are 
four members of the p38 MAP kinase family: p38α (MAPK14), p38β (MAPK11), p38γ 
(MAPK12) and p38δ (MAPK13).  These are all activated by dual phosphorylation on 
threonine (T) and tyrosine (Y) within the motif Thr-Gly-Tyr within the kinase subdomain 
VIII.  p38 MAP kinase regulates the activity of multiple transcription factors by 
phosphorylation (e.g. ATF-2, Elk-1 and CHOP) which induce the expression of many genes, 
including pro-inflammatory response genes (e.g. VCAM-1, IL-6339, IL-8340).  The p38 MAP 
kinases are expressed in multiple cell types including vascular endothelium, smooth muscle 
cells, cardiomyocytes and leukocytes.  p38 MAP kinase can be activated by a variety of 
stimuli including physiological stresses (e.g. ROS, mechanical forces), microbial products 
(e.g. LPS), cytokines (e.g. TNFα, IL-1) and other molecules336,341-343.  Pro-inflammatory p38 
MAP kinase signalling can be mediated via phosphorylation of MAP kinase kinases 3 and 6 
(MKK 3/6).  These are themselves activated by MAP kinase kinase kinases (e.g. TAK1, 
ASK1, MEKK3).  The MAP kinase phosphatases are negative regulators of these 
molecules344,345 by the simultaneous de-phosphorylation of both phospho-threonine and 
phospho-tyrosine residues as a mechanism for control. 
 
The activation of p38 MAP kinases is in the order of minutes for phosphorylation to occur, 
dependent on the stimulus agent and duration of treatment.  For example, stimulation of 
macrophages with LPS (1µg/ml) demonstrated p38 phosphorylation after 1 minute and peak 
activation at 30 minutes346.  Human neutrophils exhibited p38 phosphorylation after 5 minutes 
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treatment with TNFα (25ng/ml) or with PMA (20ng/ml)347.  Polymorphonuclear cells treated 
for 10 minutes were maximally activated with TNFα at 5ng/ml concentrations348. 
 
Previous studies suggest that MAP kinases may be activated by cardiac surgery in a variety of 
tissue compartments.  Ischaemia-reperfusion, use of cardiopulmonary bypass and heart-lung 
transplantation increase phosphorylated forms of the ERK1/2 and p38 MAP kinases in 
myocardium349 and lung tissue350-352.   The effects on phosphorylation in right atrial tissue 
following cardiopulmonary bypass appear to occur irrespective of the administration of 
methylprednisolone pre-surgery353.  There appears to be a genetic variation in p38 MAP 
kinase activation in monocytes 24hs following CPB, particularly prominent in South Asians, 
compared to Caucasians (and corresponding up-regulation of TLR4 expression)354.  In adult 
surgery, the termination of CPB was associated with an attenuation of p38 MAP kinase 
signalling in leukocytes by western blotting, a phenomenon preserved in Off-pump patients355.  
There are no other reports in the literature regarding neither leukocyte p38 MAP kinase 
activity, nor a detailed kinetic analysis in the context of cardiac surgery with the use of 
cardiopulmonary bypass. 
 
Within other compartments, following cardioplegic arrest, p38 MAP kinase activation 
regulates myocardial function through immunomodulatory heat shock proteins356 with p38 
MAP kinase suppression associated with improved myocardial contractile function349.   In 
congenital paediatric surgery with the use of CPB, ex-vivo leukocytes subject to LPS-induced 
stress showed attenuated levels of p38 MAP kinase (as well as down regulation of TLR2/4)357 
and an attenuated inflammatory response, after CPB.  In paediatric tetralogy surgery, remote 
ischaemic pre-conditioning  using a blood pressure cuff on the lower limb did not alter p38 
MAP kinase activity post-surgery in sampled myocardial tissue, with a finding that these 
proteins were already in a predominantly phosphorylated form at a basal level358. 
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Despite these insights, the function of MAP kinases in the response to cardiac surgery is 
uncertain and critical appraisal of data needs to be made especially in consideration to the 
duration of exposure to CPB and the timing of tissue / cellular sampling as well as the tissue 
compartment, as these appear to have markedly differing characteristics.  Although MAP 
kinases are known to be activated in cardiac and other tissues during cardiac surgery, their 
regulation and function in leukocytes is uncertain and is an important subject for this thesis. 
????
?
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1.5.3 Nuclear Factor-κB  
Nuclear factor-κB (NF-κB) is a central regulator of expression of inflammation, cellular 
proliferation, programmed cell death and other processes359,360. NF-κB activation, recruitment 
to target genes and post transcriptional events are tightly regulated361. The signalling cascades 
for NF-κB are illustrated in Figure 1.6.  In mammals, the NF-κB family contains five proteins: 
RelA (p65), RelB, c-Rel, NF-κB1 (p50/p105) and NF-κB2 (p52/p100)362.  Each of these 
proteins is characterized by a Rel homology domain (RHD) which is involved in homo- and 
hetero-dimerisation; interactions with regulatory molecules, nuclear localisation and DNA 
binding363.  In addition to this, RelA, RelB and c-Rel all contain a transcriptional activation 
domain (TAD) on the C-terminus which is important in transcriptional activation.  In basal 
conditions, the NF-κB complex is located within the cytoplasm.  This state is maintained via 
associations with specific inhibitory molecules known as the inhibitors of NF-κB (IκB).  This 
family consists of: IκBα, IκBβ, IκBγ, IκBε, IκBζ, Bcl-3, p100, p105.  Functionally, these 
molecules mask the nuclear localisation sequence of NF-κB  binding via ankryn repeats 
retaining it in cytoplasm364. 
 
The kinetics of activation of NF-κB varies according to the stimulus.  For example, 
leukocytes treated with TNFα (10pM) for 30 minutes or hydrogen peroxide (250µM) for 2 
hours exhibited phosphorylation365.   At 0.5nM TNFα concentrations, NF-κB activation was 
observed as early as 15 minutes before declining at 4 hours of stimulation in leukocytes365. 
 
A variety of stimuli can activate NF-κB by triggering its release from IκB and subsequent 
cytoplasmic to nuclear translocation364.  Two major pathways in the activation of NF-κB have 
been described – the canonical (classical) and non-canonical (alternative) pathways.  In the 
canonical pathway (triggered by physiological stressors, pro-inflammatory cytokines, 
microbial molecules, reactive oxygen species intermediates366, hypoxia and mechanical 
forces367), activation of p50/RelA and p50/c-Rel occurs via IKKβ.  This kinase modifies IκBα 
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via phosphorylation at Ser-32 and Ser-36.  The resultant phosphorylation promotes the 
ubiquitination of the IκB proteins at lysine residues 21 and 22 resulting in proteosomal 
degradation via the 26S proteosome.  This exposes the nuclear localisation signals on the p50-
p65 heterodimer to promote nuclear translocation.  In the non-canonical pathway, activation 
of p52/RelB is dependent on NF-κB-inducing kinase (NIK) which functions together with a 
downstream kinase, IKKα368.  Transcriptional activation of NF-κB relies on several post-
translational modifications including phosphorylation and acetylation which promote DNA 
binding and recruitment of co-activators of transcription.  NF-κB is negatively regulated at 
multiple levels by molecules such as A20 and Cezanne369.  
 
NF-κB activation and its effects on transcription are complex and can be both pro- and anti-
inflammatory in nature359,370.  NF-κB enhances the expression of adhesion molecules on 
endothelial cell surfaces by promoting E-selectin, VCAM-1 and ICAM-1 gene expression 
during acute inflammation in association with leukocyte sequestration371.  The synthesis of 
pro-inflammatory cytokines such as TNFα, IL-1β, IL-6 and IL-8 are also regulated by NF-
κB372.  NF-κB can be both pro- and anti-apoptotic depending on the cell type and interactions, 
and is implicated in a range of diseases including atherosclerosis, rheumatoid arthritis, 
multiple sclerosis, asthma, inflammatory bowel disease372.  However, there are no reports in 
the literature regarding leukocyte NF-κB activity during cardiac surgery, nor a detailed kinetic 
analysis in the context of cardiac surgery with the use of cardiopulmonary bypass. 
????
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1.5.4 Cross-talk between signalling pathways 
The inflammatory signalling pathways are complex with functional overlap and regulation.  
For example, ROS enhances the activation of NF-κB, p38 MAP kinase and by regulating 
inhibitory MKP signalling pathways286,373-375.  Neutrophil survival is enhanced by p38 MAP 
kinase through reciprocal NF-κB attenuation376 and propagates injury in tissues including 
lung377.   ROS signalling occurs following ischaemia/reperfusion with both protective290 and 
damaging effects378 depending on the circumstances and ROS species involved.   The release 
of DAMPs from surgical trauma196,199,216 whilst signalling via TLR pathways can also 
interface with various oxidative stress pathways379.   ROS can enhance MAP kinase induction 
via the inhibition of MAP kinase phosphatases (MKP) which negatively regulates p38 MAP 
kinase activity373,380.  ROS can also enhance NF-κB activation directly via IκBα 
phosphorylation20,365.  Functional NF-κB transcription activity can be activated by p38 MAP 
kinase through RelA phosphorylation381.  Alternatively, NF-κB induces MKP-1, GADD45β 
and XIAP which regulate p38 and JNK MAP kinases286. Within leukocytes, these changes 
promote the expression of cellular adhesion molecules as well as cellular release of cytokines 
into the plasma that promote the inflammatory response, and tissue migration.  Interactions 
are highlighted in Figure 1.3. 
1.5.5 Leukocyte priming 
The focus of this thesis is on the activation of early pro-inflammatory signalling events within 
leukocytes by the process of surgery and CPB exposure.  Leukocytes can be primed so that 
they mount an enhanced response to subsequent stimuli.    Primed populations of leukocytes 
have been reported in patients with acute bacterial infection with enhanced responsiveness to 
hydrogen peroxide stress382.  This phenomenon has also been reported in the context of 
sepsis383, ARDS384, term/preterm labour385 and significant traumatic injury386. The mediators 
that are implicated in this process include TNFα, IL-8, IL-1β and growth factors such as GM-
CSF387 as well as activated endothelium388.  These are an important considerations in the 
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context of surgical access, cardiopulmonary bypass, ischaemia-reperfusion and post-surgical 
recovery in the context of cardiothoracic practice as these are inflammatory events.  
 
Priming may exist to modulate the chemotactic potential of leukocytes to promote recruitment 
to an inflamed focus.  A “two-hit” hypothesis of an enhanced immune response following 
significant injury has been proposed389.  This hypothesis suggests that once primed, immune 
cells can produce enhanced levels of cytokines and signalling mediators which can be both 
beneficial and harmful.   For example, mice that were burn-injured demonstrated improved 
resistance to microbial infections390 whereas those subject to a polymicrobial challenge 
exhibited a higher mortality rate391.   
 
Phenotypically, primed neutrophils exhibit an enhanced respiratory burst388,392.  Functionally, 
priming alters leukocyte behaviour characteristics and expression of cellular surface markers.  
For example, PAF and TNFα had concentration-dependent effects on neutrophil adhesion - at 
low priming concentrations TNFα and PAF enhanced neutrophil binding where this was not 
observed at higher concentrations393. By varying hypoxic cellular stressors neutrophils were 
primed to exhibit differing cell surface Mac-1 expression303.   Moreover, PMA-treated or 
fMLP-treated primed leukocytes exhibited L-selectin shedding and reduced leukocyte 
recruitment under flow-stress conditions394.  Primed neutrophils have altered shape and 
reduced cellular deformability395.  Priming may require transcriptional mechanisms since 
messenger RNA of pro-inflammatory transcripts of IL-1β, IL-8, MCP-1 and TLR-2 are 
enhanced with leukocyte priming385 in vivo in pre-term labour.  Primed leukocytes also 
exhibit a reduced apoptotic index following traumatic injury396. 
 
Given the large vascular bed and the prolonged transit time of leukocytes in lungs86, this 
organ may be a site for physiological ‘neutrophil de-priming’387.  Clinically, patients with 
lung injury exhibit a greater transpulmonary hydrogen peroxide ROS gradient in systemic 
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arterial blood:pulmonary blood compared to reference control patients397.  This suggests a 
failure of the de-priming mechanism in lungs in disease.  This may represent a novel 
consideration in lung pathology that whilst severe lung injury is associated with primed 
leukocytes, the critically ill patient with functional pulmonary vasculature will conversely not 
manifest with a clinically severe picture398.  This is an important consideration for cardiac 
surgical patients. The mortality rate from cardiac surgery with the use of cardiopulmonary 
bypass is low42.  This is in part due to improvements in intensive care medicine, end-organ 
support and accurate diagnostic investigations which are key in the assessment and 
management of all patients following surgery. When inflammatory activation, and therefore 
by implication, pre-activation, is excessive, clinically patients may manifest a SIRS, in 
particular with ARDS90,145,156,384.  However, when the response is appropriate and balanced 
inflammation is more likely a proportionate response which assists in fighting infection, 
wound healing and return to a normal physiological state.  Thus, what is important is the 
targeted modulation of the response to favour healing and resolution, rather than inappropriate 
amplification and propagation when the physiological state does not warrant this.   
 
From a clinical standpoint, in-vivo priming of leukocytes was evidenced by higher ROS 
generation post cardiac surgery to an ex-vivo PMA stimulus399.  This priming effect was 
further enhanced by ex-vivo priming with PAF followed by PMA treatment, suggesting a 
synergistic effect and these findings that correlated with increased plasma levels of IL-6 and 
IL-8399.  Significant leukocyte priming was observed up till 12 hours following CPB with 
enhanced ROS activity and elastase release400. This observation suggests that a vulnerable 
window post-surgery exists where patients may be at increased risk of developing adverse 
effects should a second event (e.g. chest re-opening, bleeding or sepsis) can tip the balance of 
recovery into organ failure.  The process of priming is complex and the responsiveness of 
cells is not precisely delineated.  It is unclear what the exact priming or activating stimuli are 
but potential candidates have been reviewed in earlier sections of this thesis (DAMPs, 
cytokines, oxidative stress), as known molecular triggers of inflammation.  It would, therefore, 
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be of paramount importance to prevent a secondary hit phenomenon, and to be able to 
identify patients at risk. 
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1.6 STRATEGIES TO ATTENUATE THE INFLAMMATORY RESPONSE IN 
CARDIAC SURGERY 
Given the mechanistic cascade of pro-inflammatory activation discussed in the earlier parts of 
this chapter, there are 4 broad points during the scenario of surgery with the use of 
cardiopulmonary bypass that can be targets for modulating and attenuating the immune 
response.  Firstly, there is the aim in reducing DAMP generation – achieved by better surgery, 
small access incisions, optimised cardiopulmonary bypass technology or avoiding surgery 
altogether, if possible through percutaneous interventions.  Secondly, there is targeting of 
DAMP receptor signalling, for example in the form of TLR receptor antagonists and targeting 
FPRs.  Thirdly are targets of intracellular signalling cascades prior to the final intervention 
step of modulating the migration of leukocytes (Table 1.2).   
 
The work in this thesis examines stage 1 and 3.  A brief overview is given below, focusing on 
miniaturisation of cardiopulmonary bypass and the agent sulforaphane, of particular relevance 
to this thesis. 
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Table 1.2 Anti-inflammatory interventions in cardiac surgery 
The four steps of intervention in the leukocyte activating cascade are shown.  Some illustrative 
examples are highlighted. 
 
Target Therapeutic intervention 
Reduction in  
DAMP generation 
Miniaturised CPB
114,401-405
,
298,299
 
 
Off pump surgery
306,307
 
Active lung ventilation
91,170,406-408
 
Active lung perfusion
95
 
IABP counterpulsation / pulsatile flow
409,410
 
Hypothermia
167,168
 
Targeting DAMP  
receptor signalling 
TLR antagonists 
FPR targeting 
Modulating intracellular  
signalling 
Sulforaphane
263,411,412,312-315,318-320
 
 
Glutathione
331,332
 
Aspirin
413
 
Statins
414-416
 
ACE-inhibitors
415
 
Steroids
417,418
 
Aprotinin
419-422
 
p38 MAP kinase inhibitors
416,423-429
 
NF-κB modulation
369,413,417,418,430
 
Modulating leukocyte  
migration 
Adhesion molecule targeting  
Leukocyte depleting filters 
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1.6.1 Minimising organ injury and DAMPs generation 
The concept of minimising tissue injury has been a key aim in the development of surgery.  
Shorter durations of inpatient stay, reduced pain and a more rapid return of function are all 
achievable with limited access coronary surgery, minimally invasive surgery and robot-
assisted surgery.  Each is progressively less invasive but has an increasing cost and learning 
curve.  The most readily and easily changed component of cardiac surgery is the 
cardiopulmonary bypass circuit.  Essential for intra-cardiac work, cardiopulmonary bypass 
can be completely avoided in off-pump coronary revascularisation, or optimised for all other 
clinical applications. 
1.6.1.1 Off pump beating heart surgery 
Coronary revascularisation can be performed without the use of CPB in what is known as “off 
pump” coronary artery bypass (OPCAB) 42,54,55, a technique which dates back to the late 
1980s431.  This technique avoids the potentially deleterious effects of CPB, although 
randomised trial data shows little difference between on and off pump surgery for morbidity 
and mortality as well as criticism for inadequate revascularisation432,433.  Performed via a 
traditional median sternotomy, conduits are harvested as for conventional CABG and 
formation of the anastomoses are facilitated by the use of stabilisation devices (Figure 1.7).  
As no extracorporeal circuit is involved, there is approximately 1/3 of the dosing requirement 
for anticoagulation.  Coronary flow is maintained by the use of shunts and the operating field 
is kept clear with sparing use of a CO2 blower, to minimise damage to the coronary 
endothelium and gas embolization.   The success of OPCAB is critical on surgical and 
anaesthetic teamwork especially when the heart is placed in unfavourable haemodynamic 
positions.   
????
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Figure 1.7 Beating heart surgery is facilitated by stabilisation devices 
Off pump surgery is performed with the aid of stabilisation apparatus, such as the octopus (illustrated) 
or starfish (not illustrated) device, to ensure that the target area, in this case the left anterior 
descending artery, is immobilised during the construction of anastomoses.  The most difficult vessels 
to operate upon are those on the inferior and posterior surfaces of the heart as careful positioning of 
these vessels is paramount in maintaining cardiac output and haemodynamic stability.  Myocardial 
blood flow can be controlled by the use of vascular slings to kink the coronary arteries whilst the 
maintenance of distal flow is achieved with intra-coronary shunts during the fashioning of 
anastomoses (inset). 
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1.6.1.2 Other interventions to minimise physical injury 
Lung injury that occurs following cardiopulmonary bypass varies from minor aberrations 
through to fulminant adult respiratory distress syndrome (ARDS).  This carries a significant 
mortality association90.  How the generalised inflammatory response translates into specific 
lung injury is uncertain.  The absence of ventilation and relative pulmonary tissue ischaemia  
with the use of conventional CPB may be significant aetiological factors in addition to the 
trauma of opening of the pleura during mammary artery harvest and cold cardioplegia may 
have contributing effects compounded with lung collapse and atelectasis occurring in under-
ventilated lung units.  There has been a concerted drive to elucidate the optimal strategy for 
the management of the non-functioning lung through a number of clinical trials170.  These 
have included repeated vital capacity manoeuvres to improve alveolar recruitment at the end 
of bypass91; intermittent ventilation and continuous positive pressure airway pressure (CPAP) 
during bypass434.  The Drew-Anderson cannulation technique has been employed to maintain 
perfusion of the lungs so that they can act as a physiological oxygenator and has been shown 
to be associated with a reduction in pro-inflammatory cytokine release95.  Continuously 
ventilated patients exhibit enhanced preservation of postoperative dynamic lung 
compliance406 and reduction in the extravascular water index407.  The maintenance of 
continuous pulsatile blood flow throughout the process of cardiopulmonary bypass with the 
use of a mechanical intra-aortic balloon pump has also been shown to attenuate the 
inflammatory response409,410.  The precise mechanism for this is uncertain although we 
understand that flow stress and shear dynamics are important in modulating the behaviour of 
endothelial cells in blood vessels.  In large animal models of conventional CPB followed by 
reperfusion, active pulsatile perfusion within the lung resulted in attenuation of both AP-1 and 
NF-κB  within pulmonary tissues408. 
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1.6.2 Miniaturised cardiopulmonary bypass 
Miniaturised bypass is an advanced concept applied to the conduct of extracorporeal 
circulation (Figure 1.8).  Miniaturised cardiopulmonary bypass circuits come in a number of 
different forms from a variety of manufacturers.  This technology is central to experiments 
presented in this thesis and an overview of the range of technologies involved is given in the 
following section.  A summary of some of the different miniaturised cardiopulmonary bypass 
systems reported in the literature is given in Table 1.3. 
 
The concept of the miniaturised CPB circuit features:  
1. An improved efficiency gas-exchange device which reduces the surface area that 
interfaces with blood, compared to that of a conventional oxygenator435,436.  
2. Smaller diameter tubing (3/8’ tubing compared to ½ inch tubing)435 and other circuit 
length optimisations437 leading to the reduction of fluid priming volumes within the 
circuit and thus decreasing blood haemodilution from approximately 1.5 litres in 
conventional systems to 500mls, or less.  
3. Biocompatible coatings (e.g. phosphorylcholine or bonded-heparin) that are designed to 
attenuate blood contact activation438,439.    
4. No blood-air contact interface that is inherent in the design of the conventional bypass 
circuit is negated as the venous reservoir is removed from the system.  This has the 
additional effect of removing size and additional volume from the circuit.   
5. Centrifugal pump mechanisms that are designed to minimise mechanical trauma of blood 
cells are employed in contrast to occlusive roller pump mechanisms in miniaturised 
circuits437.   
6. Incorporated safety features (arterial filters, bubble traps, venous air removal devices) to 
reduce the risk of clot and air embolization (Figure 1.6).   
7. Parallel autologous blood salvage system which recovers erythrocytes from operative 
shed blood (removing leukocytes and vasoactive substances) prior to re-transfusion into 
the patient.  This is in keeping with the concept of a closed system without a blood-air 
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interface.  Re-transfusion of blood from the operative field has been shown to be a 
contributor to the inflammatory process440,441. 
 
In parallel with the benefits of the use of miniature cardiopulmonary bypass, there are 
secondary considerations relating to safety and potential disadvantages with its use.  The 
miniaturised CPB circuit is a ‘closed’ system, as the venous blood reservoir component 
(ordinarily presenting direct blood exposure to air) has been removed.  Therefore, care in 
avoiding the introduction of air in to the system is paramount in conducting safe surgery.  The 
absence of a venous reservoir also means that blood is not readily available to infuse into the 
patient should the situation arise during a surgical procedure when rapid volume transfusion 
would be beneficial.  Blood that is lost in the operating field may not be directly re-circulated 
in miniaturised cardiopulmonary bypass circuits that do not feature ‘sump suction’, 
alternatively using blood salvage devices, and therefore greater care is necessary to avoid 
bleeding at the time of surgery. 
 
The Hammersmith Hospital Cardiothoracic unit has particular expertise with the use of 
extracorporeal circulation optimized (ECCO) miniaturised CPB from the Sorin Group utilised 
during this research project404,405,435,436,442.  This system features low prime volumes, low heat 
generation, reduced index of haemolysis with low blood transit time.  The reported learning 
curve for the introduction of miniaturised bypass was optimally achieved after 50 cases in 
reports from the practice at Hammersmith404.  The conduct of surgery does not appear to be 
influenced by the use of miniaturised bypass with similar cross clamp and bypass times in 
miniaturised and comparative bypass groups for both coronary revascularisation115-
117,402,437,443-448 and aortic valve surgery116,402,445,449,450.  In the following section, a review of all 
clinical experimental evidence related to the use of miniaturised bypass systems is presented. 
 
In terms of adverse outcomes, there was no increase in peri-operative mortality associated 
with the use of miniaturised cardiopulmonary bypass systems115,402,437,443,446,450.  The 
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cumulative overall mortality associated with mini CPB is 1.1% vs 2.2% in conventional CPB 
with an OR of 0.58 (95% CI 0.23 to 1.47, p=0.25) in a meta-analysis of thirteen randomised 
trials by Biancari in 2009451.  Immer reported the length of ITU stay was 22.6±6.3 hours with 
mCPB compared to 30.9±35.2 hours in cCPB and a total hospital stay of 7.5±2.1 days in 
mCPB compared to 8.8±3.8 days in cCPB groups114.  In keeping with these observations, 
shorter durations of ventilation have also been reported with the use of mCPB (11.8±7.3h 
mCPB vs 17.4±26.8h CPB)114.  
 
Miniaturised CPB has been consistently shown to be associated with reduced perioperative 
blood loss with fewer red-cell and platelet transfusion requirements post-
operatively116,402,443,445,449,452.  This may be due to the benefits in reduction of blood priming 
volumes in these circuits with cost savings and removing the risk from blood transfusions453 
and of benefit in Jehovah’s Witnesses454. 
 
The degree of myocardial injury has been reported to be lower with the use of mCPB as 
evidenced by lower troponin within the first 6 hours following surgery (7.9±6.1 vs 18.8±21.9 
ng/L)114, 12 hours and 24 hours116,445 .  Similarly, CK-MB trends following surgery with CPB 
are lower at 1 hour (9.7±7.5 vs 11.9±3.6 U/L)115, 6 and 12 hours116 as well as peak CK-MB in 
mCPB groups117.  This corresponds with a lower incidence of peri-operative myocardial 
infarction in mCPB groups reported in the literature (1.9% vs 3.3%)118.  However, other 
groups have reported no difference in troponin,  but their published data indicate trends 
towards favouring mCPB117,403.  The mechanisms of myocardial injury following cardiac 
surgery is likely to occur from a variety of factors and may in part occur due to inadequacy of 
cardioprotection resulting in metabolic myocardial stress455 and ischaemia-reperfusion456.  
The differences in markers of cardiac injury observed may be also attributed to the absence of 
re-transfusion of blood from the operative field, as a driver for inflammation440,441.  As a 
consequence of myocardial injury, low cardiac output states (with reduced measured cardiac 
index) are more frequently observed in cCPB compared to mCPB groups118,403 with increases 
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in serum lactate118 as a marker of metabolic stress.  Correspondingly, perioperative inotropic 
requirements are higher in patients undergoing surgery with cCPB systems when compared to 
mCPB114,443.  Additionally, cardiac rhythm disturbances may be more frequently observed in 
the context of myocardial injury.  Peri-operative atrial fibrillation (AF) was reported to be 
higher in CABG patients cCPB114,118,443 whereas no difference in the incidence of AF was 
reported by Remadi in patients undergoing valve replacement450.  
 
A lower incidence of urinary haemofiltration443 and better preservation of renal function443 
was reported with the use of mCPB. 
 
Cerebral blood oxygenation measured by near-infrared spectroscopy was shown to be reduced 
during cardiac surgery, but this was better preserved with mCPB with fewer micro-emboli 
counts457.  In the early phase following CPB, cCPB circuits exhibited higher numbers of 
plasmin-antiplasmin complexes, prothrombin fragments and higher d-dimer levels458. Some 
groups have reported lower incidence of peri-operative stroke with the use of mCPB118,443 
whereas no stroke difference were reported by other groups114.  Meta-analysis suggests that 
mCPB may be associated with an overall reduced risk of stroke451.   
 
In terms of alterations in the inflammatory process, lower peak plasma SC5b-9 complement 
levels are detected following mCPB114,115.   Furthermore, lower levels of IL-6444,459,460, IL-8402, 
TNFα444, MCP-1459, neutrophil elastase are detected following weaning off CPB402,444 
suggesting less activation of the immune system with mCPB.  A mechanistic link for this may 
be due to reduced generation of DAMPS.  To exemplify this, the DAMP molecule S100 is 
found in higher concentrations in cCPB compared to mCPB115,444.  In addition to this, levels 
of oxidative stress and ROS activity, indicated by elevated malondialdehyde levels, were 
lower in mCPB patients461. To complement the observations of altered pro-inflammatory 
cytokine release, attenuated DAMP generation and reduced pro-inflammatory signalling, 
reduced conventional clinical markers of inflammation have been demonstrated. For instance, 
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Huybregts reported lower post-operative white cell counts in blood445.  CRP levels were 
reported to be lower, up till 48 hours following surgery, with mCPB compared to cCPB by 
Remadi443.  Levels of urinary IL-6, thromboxane B2, N-acetyl-glucosaminidase were 
attenuated in patients undergoing surgery with mCPB compared to cCPB445.  However, in 
contrast, other researchers reported no differences in white count nor CRP between CPB 
systems403,437,443,444.  In association with immune system changes, and perhaps a better 
preservation of immune function in mCPB patients, a lower incidence of respiratory infection 
(0.8% vs 3.1%) reported by Wiesenack118.    
 
It should be noted that there are significant differences between miniaturised systems.  This 
heterogeneity in technology can make direct comparisons difficult.  In the studies conducted, 
surgery and scientific evaluation have only been performed in low-risk patients, whereas it 
may be posited that studies of high-risk patients and prolonged CPB times may be of more 
scientific merit.  In addition, no long-term data from the trials have been reported and 
therefore the later benefits (or detrimental effects) of miniaturised bypass have not been 
assessed. 
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Figure 1.8 Miniaturised optimised extracorporeal cardiopulmonary bypass circuit 
Blood is drained from the atrium or great venous vessel directly into the miniaturised circuit via the 
venous air removal device (VARD).  If any air is entrained in the circuit, the VARD is activated and this 
blood is purged into a soft shell reservoir.  Otherwise, venous blood is actively circulated using a 
centrifugal pump into the gas- and heat- exchange device to regulate blood oxygen content and 
temperature.  Oxygenated blood is then fed into the systemic circulation via the arterial cannulation 
site usually via the arch of the aorta.  Blood from the operative field is removed to a cell-salvage 
device in parallel to the CPB circuit (not shown) with recovery and re-transfusion of the isolated 
erythrocyte component. 
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Table 1.3 Overview of miniaturised bypass systems 
Optimised extracorporeal circulatory support systems reported in the literature are shown.  Relative 
surface areas of individual components of the support systems are shown along with total surface 
areas for the entire circuits, where published.  
System Oxygenator Pump Tube coating 
Prime 
volume 
Total 
surface 
area 
ECCO 
(Sorin)
279,280,313-315462
 
Eos 
oxygenator 
1.1m
2
 
Revolution 
centrifugal 
pump 
Phosphorylcholine 380mls - 
Synergy 
(Sorin)
445,463
 
Synergy 
integrated 
oxygenator 
Revolution 
integrated 
centrifugal 
pump 
Phosphorylcholine 680mls 2.0m
2
 
Resting Heart 
(Medtronic)
446,447,459
 
Carmeda 
Affinity NT 
oxygenator 
Affinity pump 
Carmeda attached 
heparin 
990mls 2.5m
2
 
MECC 
(Maquet/Jostra)
116,117,
443,444,449,464,465
 
Quadrox-I 
Adult 
oxygenator 
1.8m
2
 
Rotaflow 
32mls 
0.19m
2
 
Bioline 
(polypeptide and 
heparin) 
550mls - 
CORx 
(CardioVention)
115,448,
458
 
 
Integrated 
oxygenator 
system  
<1.2m
2
 
Integrated 
impeller-
designed 
centrifugal 
pump 
Conventional 3/8’ 
polyvinylchloride 
tubing.  Uncoated 
820mls 1.4m
2
 
ROCSafe Hybrid 
Perfusion System 
(Terumo)
402
 
Capiox RX15 
1.5m
2 
SARNS
TM
 with 
XCoating
TM
 
Polymer-based 
Xcoating
TM
 
(Poly 2-
methoxyethylacrylate) 
665mls 1.9m
2 
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1.6.3 Modulating intracellular signalling 
Given that ROS, p38 MAP kinase and NF-κB pathways are activated by experimental stress, 
surgery and cardiopulmonary bypass, they can be targeted for modulation of systemic 
inflammation.  A review of some classes of immunomodulatory agents with particular focus 
on sulforaphane is given in the following section. 
1.6.3.1 Antioxidants 
Epidemiological evidence supports the use of anti-oxidants in the treatment and prevention of 
cardiovascular disease466 with divergent results from clinical trial evidence, in part due to 
population selection467.  Clinical trials with large numbers of participants have not yet 
revealed benefits in antioxidant use and improved mortality or adverse event profiles in 
individuals at risk of cardiovascular disease468.  In CABG, surgery is associated with a 
consumptive decrease in homocysteine an important component of glutathione anti-oxidant 
protection330.  The use of N-acetylcysteine as a ROS scavenger reduced tissue oxidative 
stress331 and attenuated pro-apoptotic pathways in myocardium332.  In addition, short-term 
treatments with statins have been shown to improve the redox-status of saphenous vein grafts 
in patients requiring coronary artery bypass surgery414.  There may also be a beneficial 
synergistic effect of statin therapy when combined with angiotensin converting enzyme (ACE) 
inhibition415.   
1.6.3.2 Signalling cascade molecular inhibitors 
Small molecular inhibitors of p38 MAP kinase target the ATP binding site in a competitive 
fashion423.  However, non-specific off-target inhibition of other molecular kinases has been 
reported424.  With p38 MAP kinase inhibitors, there is the additional challenge of targeting 
individual isoforms which possess differential effects within specific tissues337.  Clinical trials 
of p38 MAP kinase inhibitors have been promising but have been stopped due to adverse side 
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effects (occurring due to the non-selective inhibition, or due to the inherent multi-signalling 
importance of p38 MAP kinase)425.  Additionally, p38 MAP kinase suppression has been 
observed to escape from prolonged inhibition426.  Despite these considerations, a specific 
p38α/β inhibitor (SB-681323) has been used to target the inflammatory cascade activation 
seen after percutaneous coronary intervention with reduction in high sensitivity C-reactive 
protein post-procedure, with a modulatory effect additionally observed with pre-treatment416.  
No selective p38 MAP kinase inhibitor has yet reached clinical trials in the context of cardiac  
surgery.   
 
Experimentally, steroids suppress p38 MAP kinase activation by enhancing the activity of 
MKP-1417.  Targeting of p38 MAP kinase activation using specific blockers, following 
ischaemia-reperfusion, afforded protection from apoptosis and reduced infarct tissue size in 
an animal model of MI429.  Inhibition of p38 MAP kinase activation during CPB with 
SB203580 affected the contractile response of the mesenteric microcirculation in porcine 
models resulting in relative vasodilation428 and attenuated pro-inflammatory cytokine 
expression in rat lung tissues469.  Experimental use of NF-κB decoy peptides has shown 
promise in reducing macrophage migration into vein grafts430.  However, in vivo applications 
requires far more precision of delivery and targeted specificity to avoid enhancing the 
potentially deleterious effects of NF-κB activity286. 
1.6.3.3 Signalling effects of common drugs used in cardiothoracic surgery 
Aprotinin is a naturally-occurring proteolytic enzyme isolated from bovine lung and 
pancreatic tissue470.  Mechanistically as a broad-spectrum serine protease inhibitor, aprotinin 
can inhibit trypsin, chymotrypsin, plasmin and kallikrein144, a component of the contact 
activation system and limits fibrinolysis.  Aprotinin can decrease neutrophil and macrophage 
activation and chemotaxis and reduces oxidative stress.  Following CPB, aprotinin preserves 
cellular junctions and attenuates oedema in myocardial tissues in association with a 
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suppression of p38 MAP kinase in porcine experimental models419.  Aprotinin has been 
shown to suppress the induction of MAP kinases via the induction of HO-1 and a ROS-
protective effect in smooth muscle cells from rat aortae420.  In human broncho-alveolar fluid 
from patients undergoing surgery with conventional CPB, levels of IL-8 and neutrophil 
accumulation are attenuated421 along with suppression of nitric oxide422 in with aprotinin 
dosing.   
 
In contrast to specific molecular inhibitors described, salicylates/NSAIDs413 and 
glucocorticoids418 have been used as anti-inflammatory agents clinically, modulating NF-κB 
signalling but also suffering from the same off target non-specificity.  Aspirin is known to 
enhance the phosphorylation of p38 MAP kinase to regulate COX-2 expression471.  Aspirin 
also regulates the thrombotic function of platelets via a p38 MAP kinase mediated pathway472.  
Immune-modulatory effects have also been reported in statins473, ACE inhibitors474, anti-
diabetic medication475, analgesics476 and a comprehensive review is beyond the scope of this 
thesis.  Given this, any study in patients has the added dimension of the effects of 
polypharmacy as well as whatever intervention is undertaken on the patient. 
1.6.4 Sulforaphane  
Sulforaphane (1-isothiocyanato-4-methylsulhinylbutane) is an organosulfur compound which 
has been associated with a variety of protective biological effects.  These include anti-
microbial and anti-cancer properties in addition to anti-inflammatory effects, which are the 
focus of this thesis. An outline of the biological relevance of sulforaphane to cardiac surgery 
is given below.  
1.6.4.1 Biochemical properties 
Sulforaphane is found naturally in cruciferous vegetables belonging to the Brassicaceae 
family.  These vegetables include broccoli, cauliflower, bok choy and cabbage.  Sulforaphane 
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is produced during dietary consumption of the precursor glucoraphanin which is particularly 
abundant in broccoli sprouts411,412.  Chemically derived from glucose and amino acids, 
sulforaphane belongs to a class of organic compounds known as the glucosinolates.  It has the 
molecular formula C6H11NOS2 and has a molar mass of 177.29g.   
 
The enzyme myrosinase (thioglucoside glucohydrolase) is responsible for the conversion of 
the precursor glucoraphanin into the active form of sulforaphane.  Myrosinase is inherently 
present within plants and also present in the bacterial flora of the human intestine477.  This 
enzyme is found in the highest quantities in Daikon (Japanese white radish).  Myrosinase 
belongs to a family of plant defence enzymes against herbivores - some glucosinolate 
hydrolysed metabolites can be toxic478.  The chewing action whilst eating food enhances the 
release of myrosinase (Figure 1.9). 
 
The primary site of absorption of sulforaphane occurs within the jejunum479.  Due to 
sulforaphane’s lipophilic profile and small molecular size, it is passively absorbed via 
enterocytes in the liver from the entero-portal system480.  Sulforaphane is conjugated in the 
liver with glutathione by the action of glutathione-s-transferase and excreted in the urine481.  
Investigators have reported that high cellular accumulation of sulforaphane occurs in 
mammalian cells noting cellular concentrations of 4.4-13.3mM following 30 minutes 
incubation with 0.028-0.28mM sulforaphane, suggesting a plasma-tissue difference of 47-145 
fold accumulation482.  When fed to rats, sulforaphane is detected in all tissues with 
concentrations highest in gut, prostate, kidney and lung317. 
1.6.4.2 Experimental studies using sulforaphane 
Sulforaphane modulates phase I metabolism via the inhibition of the cytochrome P450 
enzyme system, or via the regulation of the mRNA expression of these enzymes483.    
Sulforaphane also modulates phase II drug metabolism enzymes and antioxidant enzyme 
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systems via the antioxidant response element (ARE)-mediated gene expression.  The 
mechanism of sulforaphane mediated regulation of the ARE-mediated genes is via the 
transcription factor nuclear factor E2-related factor 2 (Nrf2)318,322,374,484-486.  In the resting 
unstimulated state, kelch-like ECH-associated protein 1 (Keap1) suppresses Nrf2 by targeting 
it for ubiquitination within the cytosol of the cell487.  The keap1-Nrf2 interactions can be 
disrupted by a variety of stimuli including dietary antioxidants (e.g. sulforaphane) and shear 
stress374.  Sulforaphane reacts with the thiol groups of the Keap1 protein and enhances the 
dissociation of Nrf2 from this complex. This then results in the stabilisation of Nrf2 and its 
translocation into the nucleus of the cell to manifest its effects.  Following nuclear 
translocation, Nrf2 forms a heterodimer with Maf proteins487.  This leads to enhancement of 
binding of the Nrf2/Maf complex to the ARE-enhancer in the promoter region of the 
protective phase II / antioxidant genes. A number of antioxidant defence genes can be 
activated following Nrf2 nuclear translocation; these include haem-oxygenase 1 (HO-1), 
NADPH, GPx and Trx488.  The importance of this on ROS regulation and inflammatory 
activation has been discussed in 1.5.1 (page 56).  These have the effect of reducing activation 
of p38 MAP kinase320,321,489-491 as well as on NF-κB286.    
 
Pre-clinical studies from our group and others have demonstrated that sulforaphane 
suppresses inflammation by inhibiting activation of p38 MAP kinase and NF-κB374,486,492-496. 
Genetic polymorphisms in Nrf2 has been reported to be associated with increased risk of 
developing acute lung injury following trauma, in patients497.  Pre-treatment of endothelial 
cells with sulforaphane at 1µmol/L for 4 hours elevated Nrf2 expression at protein level but 
not enhance Nrf2 transcripts with suppression of VCAM-1 expression via a p38 mechanism374.  
This effect occurs at two levels; by targeting MKP-1 to reduce MKK3/6 signalling and thus 
attenuate p38 phosphorylation and also by altering redox status of cells and upstream MAP 
kinase kinase kinases (ASK1) are inhibited by Nrf2-inducible thioredoxin498. 
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A potential alternative mechanism includes the removal of activated cells from injured tissues 
via cell cycle arrest and apoptosis.  Overexpression of Bax, down-regulation of Bcl-2 along 
with modified caspase signalling are reported with sulforaphane-induced apoptosis in colon 
cancer cells499.  Sulforaphane can induce cell-cycle arrest in the G2/M phase with decrease in 
cyclin B1 and accumulation of cyclin dependent kinases500.  Thus it is feasible that 
sulforaphane may also target leukocytes for apoptosis but this has not yet been tested. 
 
It can take hours before alterations in gene expression become functionally evident at the 
protein level.  In this regard, the kinetics of the biological effects of sulforaphane may be 
different to the kinetics of sulforaphane bioavailability.  In the literature, early pre- and co-
treatment with sulforaphane appears to have relatively fast biological effects within 1-2 hours.  
For example, following iv administration of 25mg/kg sulforaphane into wild-type male 
Sprague-Dawley rats, maximal induction of NQO1 mRNA expression in lymphocytes was 
observed at 1.6 hours; GPx at 0.72 hours; and HO-1 at 0.56 hours501.  One-hour pretreatment 
of aortic endothelial cells with sulforaphane (1-4 µM)  suppressed TNFα-indued MCP-1 and 
VCAM-1 pro-inflammatory gene transcription as well as protein levels with suppression of 
p38 MAP kinase phosphorylation but no effect on NF-κB493.  Co-treatment of raw 
macrophages with Sulforaphane (5 µM) and LPS (500 ng/ml) revealed down-regulation of 
inducible iNOS and Cox-2 within 2 hours494.  Similarly, Sulforaphane (10-20 µM) pre-
treatment for 45 minutes in macrophages exhibited reduced NF-κB activation following LPS 
stress494.  Together, these observations suggest that Nrf2 is a fast-acting transcription factor 
(not requiring synthesis but moreover, stabilisation and nuclear translocation) or that the anti-
inflammatory effects observed with short/early treatments occur independently of genes 
activated via the Nrf2/ARE pathway.  Further studies are required to distinguish between 
these possibilities. 
????
?
 
Figure 1.9 The biochemical conversion and interactions of sulforaphane 
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1.6.4.3 Clinical Studies 
Epidemiological evidence revealed that consumption of broccoli and related vegetables is 
associated with reduced risk of coronary heart disease mortality502-504.  In humans, 
consumption of a single portion of broccoli sprouts generated sulforaphane concentrations in 
plasma that reached a peak value at 1-1.5 hours after feeding and declined with first-order 
kinetics411,412,505.  A single portion of broccoli cress generated sulforaphane concentrations in 
plasma that reached approximately 1µM at 1 hour after feeding and were sufficient to dampen 
inflammatory responses411,412,505.  Although sulforaphane is rapidly cleared from plasma, 
consumption of broccoli can induce antioxidant enzymes for at least 24h in leukocytes of 
healthy volunteers505.  Oral consumption of broccoli sprout homogenates containing 
sulforaphane have shown increased levels of antioxidant enzymes in human upper airways 
from nasal lavage505.  There are numerous studies currently open to recruitment utilising 
sulforaphane for the treatment of breast cancer, prostate cancer, asthma, schizophrenia and 
cystic fibrosis506.  The studies presented in chapter 5 (page 199); explores the effect of 
sulforaphane pre-treatment on leukocyte pro-inflammatory activation in the context of a 
large-animal model of cardiopulmonary bypass and in human volunteers. 
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1.7 HYPOTHESES 
The inflammatory response following cardiopulmonary bypass is well characterised as are the 
deleterious consequences.  Despite this, the precise molecular signalling mechanisms 
regulating this process are uncertain.  In this thesis, the following hypotheses were addressed: 
 
i. Cardiopulmonary bypass leads to the rapid induction of reactive oxygen species in 
leukocytes which is associated with early activation of pro-inflammatory signalling (e.g. 
p38 MAP kinase and NF-κB activation) associated with leukocyte transmigration.   
 
ii. Both miniaturised cardiopulmonary bypass are associated with reduced reactive oxygen 
species / pro-inflammatory activation in leukocytes and attenuated systemic 
inflammation compared to conventional cardiopulmonary bypass.   
 
iii. Pre-treatment with sulforaphane may attenuate intracellular pro-inflammatory 
signalling in response to surgery with cardiopulmonary bypass. 
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1.8 AIMS OF THE PROJECT 
This project was conducted in the following stages: 
 
i. A preliminary phase of technical development and validation of assays for ROS, p38 
MAP kinase activation and NF-κB activation in leukocytes was completed.   
 
ii. These assays and the cantharidin blister assay were then used to determine the 
influence of cardiac surgery on inflammatory signalling in leukocytes and to compare 
the effects of miniaturised cardiopulmonary bypass with conventional cardiopulmonary 
bypass systems.  
 
iii. Finally, studies of cultured cells, animal models and humans were undertaken to 
determine whether sulforaphane attenuated the pro-inflammatory signalling responses 
following exposure to cardiopulmonary bypass. 
 
A flow chart detailing the overall sequence of the various components studied is given in 
Figure 1.10.  The precise details of experiments are covered in the respective sections of this 
thesis. 
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Figure 1.10 Flow-chart schematic of experimental approaches considered in this thesis 
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CHAPTER 2. MATERIALS AND METHODS 
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2.1 MATERIALS 
2.1.1 Reagents 
Buffers for intracellular staining were obtained from BD Biosciences.  The ROS-sensitive 
probe 3’-(p-aminophenyl) fluorescein (APF) and 2’7’-di-chlorodihydrofluorescein diacetate 
(DCF) were obtained from Molecular Probes.  Cantharidin (Cantharone™) was obtained from 
Dormer Laboratories Inc (Rexdale, Ontario, Canada).  p38 MAP kinase blocking peptide was 
obtained from Cell Signalling.  p65 blocking peptide was obtained from SAB Signalway.  
D,L-Sulforaphane was obtained from Toronto Research Chemicals Inc.  All other reagents 
were obtained from Sigma-Aldrich unless otherwise indicated. 
2.1.2 Antibodies 
Specific primary conjugated and secondary conjugated antibodies were purchased or obtained 
as gifts and are listed in Table 2.1. 
2.1.3 Gel Electrophoresis and Western Immunoblotting 
TBS-T (10× stock solution) was prepared by dissolving 24.2g Trizma® base with 80.0g 
sodium chloride and 5ml Tween-20 made up to 1L with de-ionised water with adjustment of 
pH to 7.0 by the addition of hydrochloric acid.  Transfer buffer was prepared by dissolving 
50ml NuPAGE transfer buffer (20×) (Invitrogen) with 200ml methanol (Fisher Scientific) and 
750ml de-ionised water and 1ml NuPAGE antioxidant (Invitrogen).  Stripping buffer was 
prepared by dissolving 15g glycine with 1g SDS and 10ml Tween 20 adjusted to a pH of 2.2 
with hydrochloric acid made up to 1L with ultrapure water. 
2.1.4 PCR primer sequences 
Primer sequences are given in Table 2.2 and were purchased from Sigma-Aldrich. 
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Table 2.1 Antibodies used 
 
 
Target Antigen Target Host 
Conjugated 
Fluorophore 
Isotype Source Storage Applications 
CD32 Human Mouse FITC IgG1 Serotec -20˚C 
Flow 
cytometry 
CD14 Human Mouse Pacific Blue IgG2a 
Caltag 
Medsystems 
4˚C 
Flow 
cytometry 
CD3 Human Mouse PE-Cy7 IgG1 
Beckman 
Coulter 
4˚C 
Flow 
cytometry 
CD14 Human Mouse Pacific Blue IgG2a, κ BioLegend 4˚C 
Flow 
cytometry 
CD3 Human Mouse APC IgG1, κ BioLegend 4˚C 
Flow 
cytometry 
Phospho-p38 
MAPK 
(pT180/pY182) 
Human Mouse PE-Cy7 IgG1, κ 
BD 
Biosciences 
4˚C 
Flow 
cytometry 
Phospho-NF-κB 
p65 (pS529) 
Human Mouse PE IgG2b, κ 
BD 
Biosciences 
4˚C 
Flow 
cytometry 
IgG1 Isotype 
control 
Human Mouse PE-Cy7 IgG1, κ BioLegend 4˚C 
Flow 
cytometry 
IgG2b Isotype 
control 
Human Mouse PE IgG2b, κ BioLegend 4˚C 
Flow 
cytometry 
Phospho-p38 
MAPK 
(pT180/pY182) 
Human Mouse -  
New 
England 
Biolabs 
-20 ˚C 
Western 
Blotting 
p38 MAPK Human Rabbit -  
New 
England 
Biolabs 
-20 ˚C 
Western 
Blotting 
Phospho-NF-κB 
p65 (pS536) 
Human Rabbit  -  
New 
England 
Biolabs 
-20 ˚C 
Western 
Blotting 
NF-κB p65 (C-20) 
Human, 
pig 
Rabbit  - IgG 
New 
England 
Biolabs 
-20 ˚C 
Western 
Blotting 
α-Tubulin 
Human, 
Pig 
Mouse - IgG1 
Sigma-
Aldrich 
-20 ˚C 
Western 
Blotting 
Anti-rabbit IgG 
HRP 
Rabbit Goat  -  Dako 4˚C 
Western 
Blotting 
Anti-mouse IgG 
HRP 
Mouse Goat -  Dako 4˚C 
Western 
Blotting 
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Table 2.2 Primer sequences utilised 
Target gene Species Sequence 
IL-6 (F) Pig 5’-GCTTCCAATCTGGGTTCAAT 
IL-6 (R) Pig 5’-CTAATCTGCACAGCCTCGAC 
IL-8 (F) Pig 5’-GACCAGAGCCAGGAAGAGAC 
IL-8 (R) Pig 5’-ACAGAGAGCTGCAGAAAGCA 
TNFα (F) Pig 5’-GACAGATGGGCTGTACCTCA 
TNFα (R) Pig 5’-GAGGTTGACCTTGGTCTGGT 
Cyclophilin (F) Pig 5’-ATTTGATGATGAGAATTTTATC 
Cyclophilin (R) Pig 5’-ATGCCCTCTTTCACTTTG 
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2.2 METHODS 
2.2.1 Isolation of peripheral blood mononuclear cells 
Heparinised blood was gently layered onto histopaque at an approximate ratio of 2:1 or less, 
prior to centrifugation at 300g for 30 minutes (Figure 2.1).  Following centrifugation, the 
peripheral blood mononuclear cell (PBMC) layer was carefully transferred into a clean 15ml 
tube and gently mixed with isotonic PBS.  These cells were then washed twice by 
centrifugation and re-suspension in PBS (as above), re-suspended in PBS and counted using a 
haemocytometer, prior to experimentation at a concentration of 1×106/ml. 
????
?
 
Figure 2.1 Isolation of blood leukocyte populations via density-gradient centrifugation 
After careful layering of whole blood onto Histopaque-1077 (left panel) and centrifugation at 300 × g 
for 30 minutes at room temperature, erythrocytes and granulocytes relocated to the bottom of the 
tube (right panel).  PBMCs were located at the interface between Histopaque-1077 and the plasma 
(right panel). 
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2.2.2 Cantharidin skin blister assay to study leucocyte extravasation 
Cantharidin was pre-diluted 1:6 with acetone and (25μL) carefully applied on to 10mm radius 
discs of filter paper on the non-dominant forearm to achieve a working concentration of 0.1% 
(Figure 2.2).  This was covered with a 20mm × 20mm square of paraffin paper and protected 
with mefix and mepore dressings to provide a protective and waterproof covering.  At desired 
time points following typical blister formation the epithelial surfaces of the vesicles were 
breeched and fluid gently aspirated using siliconised tips. 
 
Following aspiration of the vesicle, 10μl of neat blister fluid was diluted 1/25 in 240μl PBS 
and gently mixed.  The diluted blister fluid was then loaded into a cytospin apparatus (Figure 
2.3) and centrifuged at 300 × g for 5 minutes onto a glass slide.  The preparation was allowed 
to air-dry prior to staining using the Diff-Quick kit consisting of a fixative (triarylmethane), 
an eosinophilic stain (xanthine dye) and a basophilic stain (thiazine dye) to facilitate 
leukocyte subpopulation determination.  A glass cover slip was applied prior to bright-field 
imaging. 
 
The microscopic appearance of a blister is shown in Figure 2.4A, and an example of 
histological data from blister fluid is shown in .Figure 2.4B. 
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Figure 2.2 Creation of Cantharidin skin blisters on the volar aspect of the forearm 
Cantharidin was applied directly onto 8mm filter paper discs applied directly onto the skin.  These 
discs were then covered by nescofilm.  Mefix dressings were applied above these to secure both the 
disc and nescofilm.  Tegaderm was applied as the top-most layer to provide water-proofing. 
Filter paper disc
Cantharadin
Nescofilm covering
Mefix dressing
Tegaderm cover
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Figure 2.3 Analysis of leukocytes in blister fluid by centrifugation and staining 
Slides were assembled onto a clip, covered by filter paper and a fluid loading chamber and secured 
(left panel).  Blister fluid was then introduced into the chamber.  The assembly was then centrifuged 
for 5 minutes at 300g.  Slides were then carefully removed from the assembly and air-dried (centre 
panel).  Once dry, the slides were then stained using the Diff-Quik kit for leukocyte identification, 
prior to protection with a coverslip and analysis by light microscopy (right panel). 
Slide clip
Slide Filter paper
Fluid loading chamber
30 mins / 300g 
centrifugation
Diff-Quik
Staining
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Figure 2.4 Typical macro and microscopic appearance of cantharidin blisters 
Skin blister formation occurs within the area of direct skin application of cantharidin here shown with 
a 5 pence coin for size comparison (A).  Following centrifugation of blister fluid onto a glass slide, and 
Diff-Quick staining (B), neutrophils are characterised by blue nuclei, pink cytoplasm and violet 
granules; eosinophils are characterised by blue nuclei, blue cytoplasm and red granules; basophils are 
characterised by purple/dark blue nuclei and violet granules and monocytes possessing a 
characteristic violet nucleus and light blue cytoplasm.  A representative image is shown from a 
healthy individual. 
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2.2.3 Detection of reactive oxygen species (ROS) 
Intracellular ROS levels were measured using the redox-sensitive fluorescent dyes APF and 
DCF (Figure 2.5).  These dyes are activated by distinct albeit overlapping sets of ROS species 
(Table 2.3).  To load cells with APF or DCF, 500μl of suspended PBMC or (1:10) diluted 
blood were combined with each dye (final concentration of 10μM) and incubated for 30 
minutes at 37˚C prior to quantification of fluorescence by flow cytometry (see below). 
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Figure 2.5 Chemical basis for ROS detection assays 
(A) APF is non-fluorescent until it reacts with the hydroxyl radical, peroxynitrite anion or hypochlorite 
anion.  Upon oxidation, the ROS dyes exhibit bright green fluorescence detectable by flow cytometry.  
(B) DCF is non-fluorescent until the acetate groups are removed by intracellular esterases and 
oxidation occurs within a cell driven by a wide variety of ROS including peroxyl and hydroxyl radicals 
and the peroxynitrite anion.   
 
 
 
ROS
ROS
Aminophenyl fluorescein (APF) APF (fluorescent form)
Dichloro fluorescein (DCF)
DCF (flourescent form)
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B
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Table 2.3 Specificity of APF and DCF activation by various reactive oxygen species 
APF and DCF have distinct but overlapping specificities towards ROS.  ROS were generated 
experimentally and fluorescence was measured using excitation/emission wavelengths of 490/515nm 
for APF and 500/520nm for DCF.  Average fluorescence values are shown for various ROS species.  
APF resists auto-oxidation with a greater sensitivity for neutrophil/granulocyte ROS signalling.  These 
data were generated and published by an external laboratory
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ROS detection Method 
 
ROS APF DCF 
Sp
ec
ie
s 
•OH 1200 7400 
ONOO
-
 560 6600 
-
OCl 3600 86 
1
O2 9 26 
•O2
-
 6 67 
H2O2 <1 190 
NO <1 150 
ROO• 2 710 
Auto-
oxidation 
<1 2000 
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2.2.4 Intracellular staining for phosphorylated p38 MAP kinase and NF-κB  
Whole blood was sampled into a vacutainer containing anticoagulant (citrate).  500μl of this 
blood was combined with pre-warmed (1:5 de-ionised water) BD Lyse/Fix Buffer (containing 
phosphatase inhibitors) and incubated in a water bath for 10 minutes at 37˚C.  Leukocytes 
were purified by centrifugation (300  g for 5 minutes) and washed once with PBS.  Cells were 
re-suspended in 0.5 ml BD Perm Buffer III pre-chilled (to -20˚C), vortexed, and incubated on 
ice for 30 minutes.  Following this, cells were then washed twice with PBS and re-suspended 
in 0.5ml BD Stain Buffer (FBS) prior to incubation for 30 minutes (at room temperature) with 
PE-Cy7- or PE- conjugated antibodies that recognised either Ser529 phosphorylated RelA 
(p65; NF-κB) or Thr180/Tyr182 phosphorylated p38 MAP kinase or isotype-matched 
controls, with subsequent washing and analysis by flow cytometry (Figure 2.6). 
2.2.5 Flow cytometric data collection and analysis  
Samples were analysed using a CyanADP flow cytometer (Beckton Dickinson).  
Fluorescence of APF, DCF or fluorophore-conjugated antibodies to p38 MAP kinase, p65 
NF-κB, anti-CD32, anti-CD14 and anti-CD3 was excited using a 488nm laser.  Prior to 
analysis on the Cyan ADP flow cytometer, the laser was allowed at least 15 minutes to warm 
up and stabilise.  Chroma-beads were used to check the laser’s alignment (Figure 2.7).  At 
least 10,000 cells were studied in each sample.  Data files were then analysed using Summit 
4.3 software to determine the fluorescent intensities of individual cells within the sample 
(Figure 2.6).   
 
 
?????
?
  
?
Figure 2.6 Flow cytometry measurement and channels utilised in intracellular detection 
assays 
Leukocytes were either loaded with a ROS-sensitive fluorescent dye (APF or DCF) or permeabilised 
and stained with a directly conjugated fluorescent antibody (or the relevant matched isotype controls 
for the target molecule).  Samples were then re-suspended in PBS for analysis.  (A) The fluidics of the 
flow cytometer channels a column of cells into single file prior to excitation with a blue 488nm laser.  
As they pass through the beam the light deflection gives values of forward (FS) and side scatter (SS) 
indicating cell size and intracellular granularity.  ROS induction was evaluated within the FITC (FL1 
filter) channel with phospho-p38 and phospho-p65 induction being detected in the PE-Cy7 (FL4 filter) 
and PE (FL2 filter) channels respectively.  Following data acquisition, samples were (B) sorted by 
forward scatter and pulse width profiles to select out singlets, eliminating clumped cells.  The 
remaining cells were (C) analysed using forward and side scatter to differentiate between granulocyte, 
monocyte and lymphocyte cell subpopulations.  Quantification of fluorescence was then determined 
for each subpopulation and (D) recorded as the mean fluorescent intensity between un-stimulated 
and stimulated specimens.  In some experiments, cells were co-stained with specific markers to allow 
gating of specific populations. 
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Figure 2.7 Temporal stability of the 488nm blue laser 
Multi-coloured fluorescent beads were run through the flow cytometer prior to sample analysis and 
at interim intervals to determine the temporal variability in laser intensity and/or detection sensitivity.  
There was less than 5% drift. 
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2.2.6 Culture of porcine aortic endothelial cells 
Pig aortic endothelial cells (PAEC) were obtained by collagenase digestion of pig aortas 
(Landrace Cross; 4-6 months old; approximately 80 kg weight) and then cultured in M199 
(Sigma-Aldrich) supplemented with 10% foetal calf serum, 5 mM L-Glutamine, 5 µg/ml 
endothelial cell growth factor, 100 U/ml penicillin, 100 µg/ml streptomycin, 50 µg/ml 
gentamycin and 2.5 µg/ml amphotericin. Cells were cultured using gelatin-coated flasks/6-
well plates and used at passage 2-3. 
2.2.7 RNA extraction from leukocytes 
RNA was extracted from blood using the RNA blood mini Kit (Qiagen®) according to 
manufacturer’s instructions.  Blood cells were lysed in two separate procedures: erythrocyte 
lysis and leukocyte lysis.  Erythrocytes are more susceptible to hypotonic shock than 
leukocytes.  Thus in the presence of a hypotonic buffer, erythrocytes were lysed.  Intact 
leukocytes were then recovered using centrifugation and lysed under highly denaturing 
conditions which immediately inactivate RNAases, allowing for isolation of intact RNA.   
2.2.8 RNA extraction from tissues 
Tissues (1-2g) were disrupted/shredded in an eppendorf tube containing 1ml TRIZOL reagent 
(a mono-phasic solution of phenol and guanidine isothiocyante) to isolate total RNA.  This 
was performed at room temperature with precautions taken to minimise the risk of RNAase 
contamination.  The integrity of RNA was maintained during the process of sample 
homogenisation/disruption by TRIZOL reagent which additionally disrupts cells and 
dissolves cell components.  Chloroform (0.2ml) was added to each sample-containing 
microfuge tube to allow for the separation of the solution into an aqueous phase (containing 
RNA) and an organic phase/interphase (containing DNA and proteins), once subject to 
centrifugation at 12,000g for 15 minutes at 2-8°C.  The aqueous phase was isolated and 
transferred to a fresh microfuge tube.  RNA was precipitated with the addition of 0.5mL 
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isopropyl alcohol.  This formed a gel-like pellet on the side and bottom of the tube.  The 
pellet was washed with 75% ethanol before allowing the pellet to air dry.  The RNA pellet 
was then re-dissolved in molecular grade RNAase-free water followed by quantification by 
spectrophotometry and subsequent analysis. 
2.2.9 Reverse Transcription PCR 
Following RNA extraction from tissues, yields were quantified using spectrophometric / 
nano-drop assays.  Purity was determined by the ratio of absorbance at 260nm and 280nm 
(A260/280) ultraviolet light wavelengths.  For each reaction, 0.5µg RNA template was used to 
generate cDNA.  RNA template was added to a mixture containing Quanta Biosciences 
qScript™ cDNA SuperMix (a reaction buffer containing MgCl2, dNTPs, recombinant RNase 
inhibitor protein, primers - random and oligoDTs - and qScript reverse transcriptase). 
Mixtures were then incubated as follows: 5 min at 25°C (annealing); 30 min at 42°C 
(extension); 5 min at 85°C (inactivation of reverse transcriptase).  After completion of cDNA 
synthesis, samples were stored at -20°C, prior to amplification. 
2.2.10 Quantitative Real-Time PCR 
Following reverse transcription of extracted RNA, cDNA at 1:5 dilution was used for PCR 
amplification of target genes; and 1:20 dilution for housekeeping genes (e.g. cyclophilin-D).  
Reaction mixtures were set up on ice.  Forward and reverse primers specific for the target 
genes were diluted to 10µM in RNase/DNase-free dH2O.  A reaction mastermix for each 
primer set was prepared containing the following reagents; 12.5 µl PerfectA SuperMix; 0.5 µl 
forward primer; 0.5 µl reverse primer and 6.5 µl RNase/DNase-free dH2O per reaction.  All 
samples were analysed in triplicate, in addition to a ‘no-template’ control.  Samples were then 
analysed on the CFX96 Real-Time PCR detection system (BioRad Hercules, CA) using the 
following protocol: 95°C for 2-3 minutes (initial denaturation); 35-40 cycles of 95°C for 10-
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15 seconds (denaturation); 55-65°C for 30-45 seconds (annealing); 68-72°C for 30 seconds 
(extension). 
2.2.11 Protein extraction 
Total protein extracts were obtained using the commercially available kits (Active Motif).  
Tissue samples were disrupted in ice-cold Complete Lysis Buffer (containing DTT, lysis 
buffer and protease inhibitor cocktail as per the manufacturer’s recommendations) and 
incubated for 30 minutes on ice.  Specimens were then centrifuged at 10,000 × g for 10 
minutes at 4°C to obtain the supernatant containing the whole-cell lysate.  Specimens were 
then aliquoted and stored at -80°C prior to analysis. 
2.2.12 Immunoblotting 
Protein samples were quantified by spectrophotometric methods prior to analysis.  NuPAGE 
LDS loading buffer (Invitrogen) was added to samples containing equivalent amounts of 
protein which were then denatured by incubation at 98°C for 5 minutes.  Samples were then 
loaded onto NuPAGE Novex 4-12% Bis-Tris gels (Invitrogen) at 10ug/well concentrations 
alongside a pre-stained standard (Spectra™ Broad Range Protein ladder, Thermo scientific) 
and electrophoresed for approximately 60 minutes at 150 volts in NuPAGE MOPS SDS 
running buffer (Invitrogen).  Separated proteins were then transferred to a Polyvinyl 
Difluoride (PVDF) membrane (Millipore) using transfer buffer and applying a potential 
difference of 30 volts for 90 minutes.  Once transfer was completed, membranes were 
incubated in 25ml of blocking buffer for 60 minutes at room temperature on a rocking 
platform followed by washing three times for 5 minutes using TBS-T.  Membranes were then 
incubated in the antibody of interest (1:1000) diluted in 25ml of a suitable blocking buffer, 
placed on a rocking platform for 1 hour at room temperature.  After three consecutive washes 
with TBS-T, membranes were incubated in 25ml of diluted secondary antibody (1:30,000) for 
60 minutes and then washed a further three times with TBS-T.  Proteins were then detected 
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using Western Lightening Enhanced Chemi-luminescence Substrate (ECL) (Perkin Elmer) for 
1 minute and exposing the membranes to autographic films (Kodak).  Films were then 
developed using the Compact X4 automatic X-ray film developer (X-ograph). 
2.2.13 Plasma sulforaphane assay 
Sulforaphane levels were measured in plasma samples by liquid chromatography mass 
spectrometry (LC-MS).  HPLC was performed with a Water 2690 Separation Module system 
(Milford, MA, USA) equipped with a phenomenex Gemini 3μ C18 110A column (150 × 2 
mm) using a isocratic elution (acetonitrile / 0.1% formic acid in water = 50:50).  The flow rate 
of the mobile phase and the column oven temperature were set at 0.2 ml/min and 30˚C, 
respectively.  The HPLC system was coupled to an API 2000 triple-quadrupole mass 
spectrometer equipped with a turbo ion spray ionization source (AB MDS Sciex, Toronto, 
Canada).  The MS-MS detection was achieved using a positive ion multiple reaction 
monitoring (MRM) mode with an m/z transitions of 177.9 → 114.0 for sulforaphane, and 
256.1 → 167.0 for diphenhydramine. 
2.2.14 Histological processing 
Formalin-preserved tissues were carefully trimmed using, double edged razor blades, and 
placed into embedding cassettes.  The embedding schedule involved : 70% ethanol (two 
changes, 1 hour each); 80% ethanol (one change, 1 hour); 95% ethanol (one change, 1 hour); 
100% ethanol (three changes, 1 hour each); xylene (three changes, 1.5 hours each); paraffin 
wax (58-60°C, two changes, 2 hours each) followed by embedding of tissues into paraffin 
blocks.  The paraffin blocks were then cut at 5 µm sections and mounted onto slides.  
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2.2.15 Haematoxylin and Eosin staining 
Tissue specimens were de-paraffinised and rehydrated in xylene (3 changes, 3 minutes each), 
100% ethanol (3 changes, 3 minutes each), 95% ethanol (3 minutes), 80% ethanol (3 minutes) 
and deionized water.  Excess water was then blotted prior to haematoxylin staining for 8 
minutes.  Specimens were then washed in running tap water for 5 minutes and allowed to 
differentiate in 1% acid alcohol for 30 seconds.  Specimens were then washed in tap water for 
1 minute prior to bluing in 0.2% ammonia and then washed again.  Following a rinse in 95% 
ethanol, the eosin counterstain was applied for 30 seconds.  Specimens were then rinsed in 
95% ethanol (3 changes, 5 minutes each), 100% ethanol (3 changes, 5 minutes each) and 
xylene (3 changes, 15 minutes each).  Results were then mounted with a xylene based 
medium. 
2.2.16 Conduct of large animal study 
Female Landrace pigs, mean 53.6kg (range 49.6 - 61.2kg) were purchased from a farm 
supplier and acclimatised for 3 days within the animal facility.  Animals were identified by 
tattoo markings and ear notchings and weighed on the day of transfer to the facility.  They 
were managed on a low-calorie, cruciferous vegetable-free diet for the preceding 1 week on 
the farm.  All animals were housed under specific-pathogen free conditions and studied 
according to UK Home Office regulations and after appropriate local ethical review.  Animals 
alternately received control or sulforaphane injections in pairs.  The study was part-blinded.  I 
performed the surgery with an assistant who was blinded to the allocation.  The perfusion 
team were blinded to treatment allocation.  The study involved live (ROS) assays and assays 
of p38 MAP kinase and p65 NF-κB phosphorylation that could be processed at the end of the 
study.  An assistant researcher (blinded to treatment allocation) performed the live ROS 
assays.  I performed the p38 MAP and NF-κB kinase assays at the end of the surgical 
procedure as well as the protein blots and genetic transcription analysis.  The histological 
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analysis was undertaken by an expert experimental histopathologist who was blinded to 
treatment allocation. 
2.2.16.1 Statistical considerations 
Given the considerations of sulforaphane activity in-vitro and in-vivo and based on the 
assumption of being able to detect a 50% difference between sulforaphane-pretreated and 
control test groups, using an alpha value (p value) of 0.05 and a power of 0.85, a minimum of 
5.344 pigs per group were required for the study. 
2.2.16.2 Anaesthesia and surgical preparation 
On the day before surgery, animals were fasted for 12 hours prior to the use of general 
anaesthesia.  They were allowed access to water without restriction during this time.  Animals 
were then allowed out of the farm pen and manually restrained in the holding pen by technical 
support staff.  An intramuscular sedative was given using a combination of Ketamine 
(20mg/kg) / Xylazine (2mg/kg).  Adequately sedated animals were then loaded into a 
transport trolley and moved to the surgical facility.  Facemask induction was performed with 
5% isoflurane gas to induce anaesthesia and oxygen flow rates of between 8-10 litres/min.  
Pigs were then transferred to the operating table, positioned prone followed by the insertion of 
indwelling venous cannulae into an accessible ear vein, secured with tape.  A basal blood 
sample was taken for analysis.  An extension line was connected before injection of 10ml of 
saline or 2mg/kg sulforaphane in 10ml of saline into the animal.  Topical anaesthetic 
(lignocaine) was sprayed onto the hypopharynx prior to intubation using animal size 8-10 
endotracheal tubes.  Adequacy of intubation was confirmed by the presence of ventilatory 
sounds in the lungs; the absence of air in the stomach and end-tidal CO2 capnography.  
Animals were then connected to the ventilator with FiO2 adjustments that achieve an oxygen 
saturation tension of >90% and tidal volumes of 5-10ml/kg/minute.  Anaesthesia was 
maintained with an isoflurane/O2 mixture driven by medical air.  Animals were then 
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repositioned supine with attachment of diathermy, rectal temperature probe,  ECG electrodes 
with continuous monitoring and connection to the defibrillator using external paddles.  All 
areas outside of the anaesthetic and surgical field were blanketed to maintain temperature 
homeostasis; with the assistance of a heated operating table.  
2.2.16.3 Surgical access 
Surgery was performed using strict aseptic technique.  The operative field was cleaned with 
hibiscrub wash and waterproof drapes applied, exposing the neck and the sternum.  The CPB 
circuit was primed with Hartmann’s solution (2000ml) and heparin (5000IU).  Lines were 
divided and clamped in preparation for extracorporeal circulation. Continuous arterial blood 
pressure monitoring was instituted via an indwelling arterial line in the external carotid artery 
following surgical neck dissection.  The first arterial blood aspirate was used to determine the 
basal arterial blood gas (ABG).  Central venous monitoring was instituted via an indwelling 
jugular vein line.  The first venous blood aspirate was used to determine the basal activated 
clotting time (ACT).  A skin incision from the supra-sternal notch to xiphisternum was 
created using a 10-blade scalpel.  Dissection down to the sternum was performed using hand-
held diathermy at 50J with release of the supra-sternal ligament, with close attention to 
haemostasis throughout.  Retro-sternal adhesions were released with a finger sweep prior to 
division of the sternum using a pair of heavy Mayo’s scissors (in some cases sternotomy was 
completed using a Gigli saw).  Intravenous heparin was given following the completion of 
sternotomy (300IU/kg).  The aorta and right atrium were then dissected and exposed using 
hand-held diathermy at 50J.  The aortic cannulation site was prepared using 2/O ethibond 
double purse-string sutures (1 × 1 cm) with two snuggers on opposing sides secured with 
Dunhill clips.  Aortic cannulation was performed when the ACT  >400 seconds.  The aortic 
pipe was inserted into the aorta, with the direction of flow orientated towards the arch and 
descending aorta. The right atrium was cannulated using a two-stage venous cannula, 
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directing the distal end towards the inferior vena cava. Cardiopulmonary bypass was 
subsequently maintained for two hours.  Lung ventilation was discontinued during this period.  
2.2.16.4 Details of Cardiopulmonary bypass 
Normothermic (porcine 38-39˚C) non-pulsatile CPB was maintained using a Stöckert 
multiflow roller pump (Sorin Group GmbH, Munich, Germany) generating forward flow of 
between 2-4l/min with line pressures <300mmHg.  Gas exchange was achieved via hollow 
fibre-membrane oxygenator apparatus (Dideco).  Mean arterial pressures between 50-
65mmHg were achieved with incremental doses of metaraminol, as required.  The adequacy 
of cardiopulmonary bypass was checked by blood gas analysis at 30 minute intervals.  
Animals remained on cardiopulmonary bypass for 2 hours. 
2.2.16.5 Termination of study and organ procurement 
Tissues (kidney, lung, heart in order) were harvested prior to termination, under anaesthesia.  
Firstly, the abdomen was incised using a 10-blade scalpel from the lower portion of the 
median sternotomy incision to above the pubic symphysis.  Cutaneous bleeding was 
controlled with handheld diathermy at 50J and incision through the linea alba was made to 
expose the parietal peritoneum.  This was carefully opened between a pair of Dunhill clips 
ensuring the bowel contents were not breached.  The omentum along with the small and large 
bowel were eviscerated en-masse and displaced laterally to expose the left kidney.  Gerota’s 
fascia was opened over the surface of the kidney and the hilum was carefully dissected to 
expose the ureter and vascular structures.  The renal hilum was then clamped between two 
pairs of Roberts forceps and cleanly divided with a 10-blade scalpel.  The superior pole of the 
kidney was then detached (approximately 3cm), and divided in half.  One half was placed into 
a sterile 50ml falcon tube and snap frozen in liquid nitrogen and stored at -80°C until required 
for protein and RNA extraction (as described above).  Alternatively, the other half of tissue 
was placed into a 50ml falcon tube containing 10% neutral buffered formalin and stored at 
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4°C  for histological processing (as described below).   Next, the anterior edge of visible the 
middle lobe of the right lung was gently grasped with a Duvall clip and an approximate 5 × 5 
cm wedge of tissue was carefully excised using a 10-blade scalpel.  This was then cut in half 
and prepared in the same way as previously for protein/RNA extraction and histological 
processing.  Finally, the apex of the heart was gently grasped using a Debakey clamp and the 
ventricular apex (approximately 3cm of tissue) was cleanly divided using a 10-blade scalpel.  
This was then divided in half and processed as above. Once completed, the experiment was 
terminated using a schedule 1 method (>150mg/kg iv phenobarbital delivered either through 
the CPB machine or central access site).  Death was confirmed via absence of brainstem 
reflexes – e.g. absence of response to corneal reflex.   
2.2.17 Conduct of human broccoli consumption clinical trial 
Prior to commencing the study, a favourable ethical opinion was obtained locally (REC 
reference 11/H0707/10).  Six healthy individuals were studied on two separate occasions, in 
random order.  Leukocyte activity in study participants was measured following the 
consumption of 200g of homogenized broccosprouts (from Discover Fresh, the Netherlands - 
a patented variety containing a precisely known amount of sulforaphane; 1200μmol/200g) or 
following the consumption of 200g alfalfa sprouts (from Sky Sprouts, Totnes, UK - non-
sulforaphane containing control diet).  The dose of 200g broccosprouts was chosen because it 
was tolerated well in humans and led to maximal induction of antioxidant enzymes (in 
previous studies)505.  
 
We know that sulforaphane reaches peak plasma levels 1.5 hours after oral ingestion412, has a 
plasma half-life of approximately 1.77 hours411 and is cleared from the plasma via urinary 
excretion in 24 hours.  A generous wash-out period of two weeks between each arm of the 
study was included in the trial design.  During the study, participants were asked to refrain 
from eating green vegetables, spices and condiments for 72h prior to study on both occasions.    
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Blood was sampled prior to consumption of Broccosprout homogenate (BSH) or Alfalfa 
sprout homogenate (ASH), and then repeated at varying times (1 to 24h afterwards).  The 
resistance of leukocytes to inflammatory activation was assessed by treating blood samples 
with TNFα, ex-vivo, and measuring the activity of NF-κB and p38 MAP kinase by 
intracellular staining and flow cytometry.  Alternatively, the resistance of leukocytes to ROS-
associated inflammatory activation was assessed by treated blood samples with PMA 
200ng/ml ex-vivo and flow cytometry. 
2.2.17.1 Preparation of broccoli or alfalfa sprout homogenates 
Broccoli sprouts from a single production lot were used three days following germination 
(Discover Fresh, the Netherlands).  Sprouts were processed in a designated food product 
preparation area immediately upon arrival and prior to the expiration date. Proper hand-
washing procedures and vinyl gloves were used to prevent contamination during processing.  
Sprouts were combined with sterile water in 1:1.2, w:w proportions. This mixture was then 
homogenized in 1l aliquots in a clean blender to eliminate the variable of chewing by subjects.  
The aliquots of homogenate were then pooled and mixed with daikon sprouts. This was 
accomplished by adding 2% daikon (compared to broccoli sprout mixture based on fresh 
weight) and homogenizing the preparation in the blender once again.  The daikon/broccoli 
sprout mixture was then incubated at 37°C for 2 h. This process adds excess myrosinase to 
maximally convert the free glucosinolates of the broccoli sprouts to sulforaphane, the 
biologically active compound.   After incubation, the isothiocyanate mixture was aliquoted 
into 50 ml sterile Falcon tubes (equivalent to 70g dry weight per aliquot – single dose) and 
stored at −20°C using dedicated freezer storage space.   The broccoli sprout homogenates 
were thawed at 4°C 12–24 h prior to dosing and were not administered if thawed for greater 
than 24 h.  Alfalfa sprout homogenates were prepared using the same procedures, substituting 
locally purchased organic alfalfa sprouts (Sky Sprouts, Totnes, Devon) for Broccosprouts, as 
above. 
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2.2.17.2 Inclusion/Exclusion criteria 
Participants were considered eligible for the trial if they met the following inclusion criteria: 
age 18+ years; male or female and able to commit for the duration of the trial.  Participants 
were considered ineligible if any of the following circumstances applied: pregnancy; 
practising vegetarian; history of allergy; current smoker or smoking cessation within the last 3 
months; current use of inhaled, topical or systemic corticosteroids or within the last 2 weeks; 
current use of non-steroidal anti-inflammatory use or within the last 1 week; current use of 
nutritional or multivitamin supplements or current participation in any other randomised 
controlled trial. 
2.2.17.3 Participant allocation and sample size determination 
Participants were randomised by trials unit personnel not otherwise involved in the study.  
Randomisation was blocked (one block of six volunteers) and, because the preparations were 
concealed, the study personnel were blind to the allocations until the end of the study.  Based 
on the following assumptions, a sample size of 6 was required to detect a difference of 1 
standard deviation in reactive oxygen species (ROS) between broccoli and alfalfa conditions 
at a 5% significance level (2-sided) with 90% power.  The assumptions were: cross-over trial 
design, i.e. one sample inference test; 1 baseline measurement of the outcome ROS; 5 post-
intervention measurements of the outcome ROS; correlation between baseline and post-
intervention ROS measurements = 0.50; correlation between post-intervention ROS 
measurements = 0.70. 
2.2.17.4 Statistical Analysis 
Outcome measurements were analysed in a mixed regression model to take into account the 
repeated measurements over time.  The baseline measurements were fitted as a covariate.  
The sample size calculation was powered to detect a main effect difference between broccoli 
and alfalfa conditions but the interaction of condition and time of measurement were also 
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estimated and retained in the model if found to be statistically significant at the level of 
p<0.05. 
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CHAPTER 3. VALIDATION OF ASSAYS OF 
LEUKOCYTE INFLAMMATORY ACTIVATION 
 123 
 
3.1 INTRODUCTION 
The induction of ROS and phosphorylation of p38 MAP kinase and NF-κB are important 
processes in inflammatory activation of leukocytes.  A key aim of this thesis was to determine 
the kinetics of activation of these signalling pathways in response to cardiac surgery with the 
use of CPB.  This was achieved by serial sampling of peripheral blood from patients 
undergoing CABG with CPB (Chapter 4) or from pigs exposed to experimental CPB (Chapter 
5). Thus the work relied on accurate quantitation of ROS and active forms of p38 MAP kinase 
or NF-κB (RelA) in specific leukocyte populations from whole blood samples. 
 
Specifically, the following assays were developed using commercially-available staining kits 
and measurement of fluorescence by flow cytometry: 
 
1. Quantitation of ROS levels in leukocytes using fluorescent ROS-sensitive dyes (DCF 
or APF). 
2. Quantitation of levels of Thr180/Tyr182 phosphorylated p38 MAP kinase by 
intracellular staining using antibodies directly conjugated to PE-Cy7. 
3. Quantitation of levels of Ser529 phosphorylated NF-κB (RelA) by intracellular 
staining using antibodies directly conjugated to PE. 
 
In this chapter, a series of studies to validate these assays prior to their use in clinical or 
animal studies was undertaken. The intention was to measure these species in specific 
leukocyte populations, namely lymphocytes, monocytes and granulocytes.  Previous studies 
have achieved this by co-staining leukocyte sub-populations using antibodies that recognise 
specific markers.  For example, staining of CD3, CD14 and CD32 can discriminate between 
lymphocytes (CD3+, CD14-, CD32-), monocytes (CD3-, CD14+, CD32+) and granulocytes 
(CD3-, CD14-, CD32+).  The identity of leukocyte sub-populations can also be inferred by 
flow cytometry via their distinctive profiles of forward scatter (FSC; proportional to size) and 
side scatter (SSC; proportional to granularity). 
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3.2 HYPOTHESIS AND AIMS 
The hypotheses tested in the following chapter were: 
 
i. Intracellular staining using specific antibodies can be used to measure the levels of 
phosphorylated p38 MAP kinase or phosphorylated NF-κB (RelA) in leukocyte 
populations from whole blood samples 
ii. DCF and APF can be used to measure levels of ROS in leukocyte populations from 
whole blood samples. 
 
The aims of the studies presented in this chapter were to: 
 
i. Examine whether FSC and SSC profiles can be used to identify lymphocytes, 
monocytes and granulocyte populations in whole blood samples 
ii. Assess the specificity of intracellular staining for phosphorylated p38 MAP kinase or 
NF-κB (RelA) using isotype-matched control antibodies and blocking peptides, 
iii. Determine whether DCF or APF can be activated by experimental conditions that are 
known to induce ROS. 
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3.3 RESULTS 
3.3.1 Identification of leukocyte sub-populations using FSC and SSC profiles 
A key aim of this study was to measure inflammatory signalling in specific leukocyte 
populations in multiple blood samples (generated via clinical trials and animal studies). 
Although leukocyte population identity can be achieved by co-staining using specific 
antibodies (e.g. CD3, CD14, CD32), this approach was judged unsuitable for the analysis of 
large numbers of samples because it is time consuming and expensive. Because of these 
constraints, the possibility of identifying leukocyte sub-populations based on their size and 
granularity was considered, an approach that does not require additional staining procedures.  
 
To validate this approach, leukocytes were stained for cell surface markers (CD3, CD14 or 
CD32) and expression was assessed by flow cytometry (Fig 3.1 A-C).  Back-gating of 
fluorescence data onto FSC and SSC profiles revealed three populations that possessed 
distinct size and granularity (Figure 3.1D). The population that stained CD3+ (CD14-, CD32-) 
was nominated lymphocytes (Figure 3.1B, D), while the population that stained CD14+, 
CD32+ (CD3-) was nominated monocytes (Figure 3.1A, C, D). A highly granular population 
stained positive for CD32 (but negative for CD3 and CD14) and was nominated granulocytes 
(Figure 3.1C, D). 
 
?????
?
  
Figure 3.1 Leukocyte subpopulations identified via forward and side scatter profiles 
Freshly-isolated peripheral blood samples were incubated with either (A) Pacific blue-conjugated anti-
CD14, (B) PE-Cy7 conjugated anti-CD3 or (C) FITC-conjugated anti-CD32 antibodies (middle panel).  
Alternatively, they were left unstained (left panel).  Fluorescence of cells was measured by flow 
cytometry.  Dots plots are presented to compare fluorescence with forward scatter. Positively-stained 
cells exhibited higher fluorescence than that obtained in the absence of staining (observed above the 
dotted line in centre panels). Positive cells were back-gated into forward and side scatter (FSC/SSC) 
profiles to assess their size and granularity (right panels). (D) Forward and side scatter profiles were 
combined for lymphocytes, monocytes and granulocytes (indicated). 
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To measure p38 MAP kinase and NF-B phosphorylation by intracellular staining, whole 
blood samples were treated with a buffer that simultaneously lysed the red blood cells and 
permeabilised the leukocytes (see Methods 2.2.4). Interestingly, the application of this buffer 
(BD Perm III buffer) to whole blood samples for 15 min significantly altered the FSC and 
SSC profiles of human leukocytes (Figure 3.2A). Specifically, although populations 
corresponding to lymphocytes and granulocytes could be observed, monocytes could not be 
distinguished by FSC/SSC profiles (Figure 3.2A, compare unpermeabilised with 
permeabilised). 
 
Staining of fixed/permeabilised cells using anti-CD3 antibodies and back-gating confirmed 
the FSC and SSC profile of the lymphocyte population (Figure 3.2B, left panel). However, 
parallel studies revealed that the FSC/SSC profile of CD14-positive permeabilised cells 
overlapped with the profile for granulocytes (Figure 3.2B, right panel). Indeed, the process of 
fixation and permeabilisation led to increased SSC in CD14-positive cells (Figure 3.1A with 
Figure 3.2B).  In conclusion, we could not discriminate between monocytes and lymphocytes 
in fixed/permeabilised cells. 
 
These data informed the gating strategy and interpretation of future experiments using clinical 
and porcine samples. Specifically, we analysed three populations of cells (lymphocytes, 
monocytes and granulocytes) for studies of ROS using APF or DCF dyes which were 
conducted using non-fixed, non-permeabilised cells (Figure 3.2A, left panel).  By contrast, we 
analysed two populations (mononuclear cells and granulocytes) for studies of p38 MAP 
kinase and NF-B phosphorylation which were carried out using fixed, permeabilised cells 
(Figure 3.2A, right panels). 
?????
?
 
Figure 3.2 Permeabilisation of leukocytes alters scatter profiles 
Whole blood was treated with BD Perm III buffer on ice for 15 min (fixed and permeabilised) or 
remained untreated (freshly isolated).  Samples were then analysed by flow cytometry with 
assessment of the forward and side scatter flow characteristics, after sorting for singlets.  Dot plots 
are presented to compare forward scatter and side scatter profiles. The identity of particular cell 
populations is indicated (A).  Whole blood treated with BD Perm III buffer on ice for 15 min were 
incubated with either PE-Cy7 conjugated anti-CD3 (left panel) or with Pacific blue-conjugated anti-
CD14 (right panel) antibodies.  Fluorescence was measured by flow cytometry after gating out red 
blood cells and debris.  Positive cells were back-gated into forward and side scatter (FSC/SSC) profiles 
to assess size and granularity and dot plots are presented (B).  
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3.3.2 Determining specificity of intracellular staining 
The specificity of antibody binding was confirmed using blocking peptides and by using 
isotype-matched control antibodies.  Blood samples were analysed at the basal state or 
following treatment with TNFα or LPS because these stimuli are known to activate NF-κB 
and p38 MAP kinase in multiple cells types. 
 
In the first instance, binding of PE-Cy7-conjugated antibodies that were raised against either a 
peptide corresponding to phosphorylated p38 MAP kinase or against an irrelevant peptide 
(control) was compared.  This comparison is valuable because fluorescence generated with 
control antibodies reflects autofluorescence and/or non-specific binding of antibodies per se 
(e.g. via the Fc portion).  Samples were treated with LPS or remained untreated as a control 
prior to staining.  Analysis of granulocytes (identified by FSC/SSC profiles) revealed that 
fluorescence generated by anti-phosphorylated p38 MAP kinase antibodies was higher than 
fluorescence from isotype-matched control antibodies in LPS-treated cells but not in untreated 
cells (Figure 3.3A, left and centre panels).  These data demonstrate that the anti-
phosphorylated p38 MAP kinase antibodies bind to a molecule that is induced by LPS in 
granulocytes.  We concluded that this molecule corresponds to phosphorylated p38 MAP 
kinase, because a specific blocking peptide for phosphorylated p38 MAP kinase significantly 
reduced binding of anti-phosphorylated p38 MAP kinase antibodies (Figure 3.3B, compare 
sample 1 and sample 2) whereas control peptides had little effect (Figure 3.3B, compare 
samples 1-2 with samples 3-4) and MFI measured with control peptides was similar to that 
measured in the absence of any peptide or negative irrelevant controls (Figure 3.3, compare 
samples 1-2 with samples 5-6).   The antibody is highly specific, as complete blockade of 
detectable fluorescence occurred with the blocking peptides; the PE-Cy7 MFI in Figure 3.3B 
sample 1 represent the arbitrary lower limit of fluorescence set by the flow cytometry 
protocols, and no inducible signal was observed with LPS stimulation shown in Figure 3.3B 
sample 2.  In the absence of a specific p38-blocking peptide, constitutive levels of p38 MAP 
 130 
 
kinase are indicated in Figure 3.3B sample 3 and sample 5, and inducible levels are shown in 
Figure 3.3B sample 4 and sample 6.  
 
Parallel studies demonstrated that binding of anti-phosphorylated NF-κB to permeabilised 
mononuclear cells was enhanced by treatment of leukocytes with TNFα (Figure 3.3C, 
compare samples 13 and 14).  In the presence of varying concentration of specific blocking 
peptides (0-100 µg/µl) for phosphorylated NF-κB, antibody binding was reduced whereas 
control peptides had little effect (Figure 3.3C, compare samples 1-6 with samples 7-12). 
Collectively, these data suggest that anti-phosphorylated p38 MAP kinase or anti-
phosphorylated NF-κB antibodies react specifically with their respective targets. 
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Figure 3.3 Confirmation of antibody binding specificity 
Peripheral blood samples were incubated with LPS (100ng/ml for 30min; centre panel) or remained 
untreated as a control (A, left panel).  They were then treated with BD Perm III buffer on ice for 15 
minutes to fix and permeabilise leukocytes prior to incubation with PE-Cy7-conjugated antibodies that 
were raised against phosphorylated p38 MAP kinase (p38) or an irrelevant antigen (Control). 
Fluorescence of samples was quantified by flow cytometry and histograms are presented. The mean 
fluorescence intensities (PE-Cy7 MFI) of cells incubated with anti-phosphorylated p38 MAP kinase 
antibodies are presented (A, inset). The level of p38 MAP kinase phosphorylation was calculated by 
subtracting fluorescence generated using control antibodies from fluorescence generated using anti-
phosphorylated p38 MAP kinase antibodies (A, right panel) in granulocytes.  Statistical calculations 
indicated are Student’s t-test. 
 
Anti-phosphorylated p38 MAP kinase antibodies were pre-incubated with a specific p38 MAP kinase 
blocking peptide or a non-specific irrelevant peptide for 1 hour on ice (or remained untreated)(B). 
Anti-phosphorylated NF-B antibodies were pre-incubated with a specific NF-B blocking peptide or a 
non-specific irrelevant peptide at varying concentrations for 1 hour on ice (or remained untreated)(C). 
These preparations were used for intracellular staining of leukocytes exposed to LPS (B) or TNF (C) 
for 30 min.  Fluorescence of samples was quantified by flow cytometry and mean values generated 
from multiple cells for p38 MAP kinase phosphorylation (PE-Cy7 MFI) (B) or NF-B phosphorylation 
(PE MFI) (C) in mononuclear cells.  Statistical calculations indicated are Student’s t-test. 
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3.3.3 p38 MAP kinase and NF-κB were phosphorylated in peripheral blood leukocytes 
by inflammatory stimuli  
The following experiments examined whether the anti-phosphorylated p38 MAP kinase or 
anti-phosphorylated NF-κB antibodies could be used to monitor activation in leukocytes 
exposed to a variety of stress stimuli.  Intracellular staining followed by flow cytometry 
revealed that phosphorylation of p38 MAP kinase and NF-κB were elevated by incubation of 
samples at room temperature with arsenite in mononuclear cells (Figure 3.4A and B, lower 
panels).   By contrast, PMA enhanced p38 MAP kinase phosphorylation in granulocytes and 
mononuclear cells but did not influence NF-κB phosphorylation whereas TNFα stimulation 
induced NF-κB and not p38 MAP kinase in both granulocytes and mononuclear cell 
populations (Figure 3.4B, compare A and B).  Taken together, these data suggest that 
intracellular staining followed by flow cytometry can be used to monitor the activity of p38 
MAP kinase and NF-κB in leukocytes in whole blood samples. 
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Figure 3.4 p38 MAP kinase and NF-κB phosphorylation was induced with experimental 
stress in mononuclear cells 
Whole blood from healthy volunteers was treated with 200ng/ml PMA, 250µM sodium arsenite, 
20ng/ml TNFα for 30 minutes (or remained unstimulated ).  Levels of phosphorylated p38 MAP kinase 
(A) or NF-κB (B) were assessed by intracellular staining followed by flow cytometry.  Mean 
fluorescence values generated from multiple cells are presented for granulocytes and mononuclear 
cells (identified by their FSC/SSC profiles).  The level of p38 MAP kinase or NF-B phosphorylation was 
calculated by subtracting fluorescence generated using control antibodies from fluorescence 
generated using anti-phosphorylated p38 MAP kinase or anti-phosphorylated NF-B antibodies.  
Mean MFI values were calculated from 6 independent experiments and are presented with standard 
error of the mean.  (*p<0.05; **p<0.01; ***p<0.005 Student’s t-test, compared to control). 
 
 
Control PMA TNFα Arsenite Control PMA TNFα Arsenite
Control PMA TNFα Arsenite Control PMA TNFα Arsenite
Control PMA TNF Arsenite
0
2
4
6
8
10
N
F-

B
 A
ct
iv
it
y
Control PMA TNF Arsenite
0
5
10
15
20
p
3
8
 M
A
P
 K
in
as
e 
ac
ti
vi
ty
Control PMA TNF Arsenite
0
10
20
30
40
50
N
F-

B
 A
ct
iv
it
y
*
**
***
**
A B
**
Control PMA TNF Arsenite
0
50
100
150
200
250
p
3
8
 M
A
P
 K
in
as
e 
ac
ti
vi
ty
*
p38 phosphorylation in granulocytes
P
E-
C
y7
 M
FI
 (
A
U
)
P
E-
C
y7
 M
FI
 (
A
U
)
P
E 
M
FI
 (
A
U
)
P
E 
M
FI
 (
A
U
)
p38 phosphorylation in mononuclear cells
p65 phosphorylation in granulocytes
p65 phosphorylation in mononuclear cells
 134 
 
3.3.4 ROS were induced in peripheral blood leukocytes by inflammatory stimuli 
To validate the ROS assays, preliminary experiments were conducted using whole blood or 
purified peripheral blood mononuclear cells (PBMC) from healthy volunteers.  Samples were 
loaded with APF or DCF and fluorescence was quantified by flow cytometry.  Basal ROS 
levels were measured in mononuclear cells that were either purified from peripheral blood or 
remained unpurified (whole blood) prior to labelling.  They were greatly enhanced in purified 
PBMC compared to whole blood (Figure 3.5, compare left and right panels and note the 
different scales used on the y-axes).  It is plausible that prolonged incubation at room 
temperature or mechanical stimulation during PBMC purification led to enhanced ROS levels. 
Regardless of the mechanism, whole blood samples were selected for use in all future 
experiments in order to minimise activation during sample preparation which could 
potentially mask biological effects. 
 
Furthermore, an evaluation of whether APF or DCF could be used to monitor ROS induction 
in granulocytes, monocytes or lymphocytes exposed to a stress stimulus was undertaken. 
Treatment with PMA enhanced the fluorescence of both DCF and APF in granulocytes and 
monocytes (Figure 3.5B) and the most significant changes were observed using APF 
(compare left and right panels).  APF was therefore selected to measure basal and inducible 
ROS in leukocytes in subsequent experiments. 
 
 135 
 
Total ROS detection in PBMC (n=1)
Unstained Dichloroflourescein Aminophenylfluorescein
0
20
40
60
1500
2000
2500
3000
F
IT
C
 M
e
a
n
 F
lu
o
re
sc
e
n
t 
In
te
n
si
ty
0 50 200 0 50 200 0 50 200PMA (ng/ml)
Total ROS detection in Whole blood (n=1)
Unstained Dichloroflourescein Aminophenylfluorescein
0
50
100
150
200
0 50 200 0 50 200 0 50 200PMA (ng/ml)
F
IT
C
 M
e
a
n
 F
lu
o
re
sc
e
n
t 
In
te
n
si
ty
 
  
Figure 3.5 PMA induced ROS in peripheral blood leukocytes from healthy volunteers 
Whole blood samples (right panel) or isolated PBMC (A, left panel) from healthy volunteers were 
loaded with APF or DCF (or remained untreated as a control). Samples were then either stimulated 
with PMA (50ng/ml or 200ng/ml) or remained unstimulated as a control.  Fluorescence of 
mononuclear cells was quantified by flow cytometry after gating using FSC/SSC data and mean values 
generated from multiple cells are presented.  Whole blood samples from healthy volunteers were 
loaded with DCF (B, left panel) or APF (B, right panel). Samples were then either stimulated with PMA 
(200ng/ml) or remained unstimulated as a control. Mean fluorescence intensity (MFI) values 
generated from multiple cells are presented for granulocytes, monocytes and lymphocytes (identified 
by their FSC/SSC profiles). Mean MFI values were pooled from studies of 4 individuals and are 
presented together with individual MFI data. (*p<0.05; **p<0.01 Student’s t-test) 
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3.4 CONCLUSIONS 
 
1. FSC and SSC profiles could be utilised to distinguish lymphocytes, monocytes and 
granulocytes in freshly-isolated peripheral blood samples in flow-cytometric analyses. 
 
2. Fixation and permeabilization of leukocytes alters the FSC/SSC profile of monocytes, 
thus causing partial overlap with the profile of granulocyte population. 
 
3. Nevertheless, granulocytes and mononuclear cells can be distinguished by their FSC/SSC 
profiles in fixed and permeabilised peripheral blood samples. 
 
4. Isotype-matched irrelevant antibodies and blocking peptides confirmed the specificity of 
antibodies against phosphorylated p38 MAP kinase or phosphorylated p65-NF-B. 
 
5. Intracellular staining and flow cytometry detected enhanced p38 MAP kinase and NF-B 
phosphorylation in whole blood samples exposed to stressful stimuli. 
 
6. DCF and APF dyes and flow cytometry detected enhanced ROS in whole blood samples 
exposed to stressful stimuli. 
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3.5 DISCUSSION 
Although the ROS-sensitive dyes and intracellular staining antibodies used in this study have 
been tested extensively in previous studies, it was felt that they should be validated in our 
hands prior to their use in clinical and animal studies.  This exercise was useful since we 
observed an unexpected interaction between sample preparation and the identification of 
leukocyte sub-populations using FSC and SSC profiles. Specifically, fixation and/or 
permeabilization enhanced the apparent granularity of monocytes.  The consequence is that 
only two populations could be discriminated by FSC/SSC profiling of cells following 
intracellular staining, namely mononuclear cells and granulocytes.  This is important because 
it influenced the interpretation of our data which could not be used to interrogate monocytes 
following intracellular staining.  By contrast, ROS levels could be measured in monocytes, 
lymphocytes and granulocytes because this assay did not require cell fixation and 
permeabilisation. 
 
The earliest experiments conducted utilised PBMCs.  However, it was concluded that purified 
PBMCs were unsuitable for monitoring of ROS and p38 MAP kinase or NF-κB 
phosphorylation for the following reasons; (1) for the detection of ROS, elevated levels of 
intracellular ROS were detected in isolated PBMCs by comparison to whole blood, indicating 
that PBMC analysis may overestimate ROS levels in vivo.  (2) Although phosphorylation of 
MAP kinases and phosphorylation of NF-κB were not determined in PBMCs, altered 
phosphorylation states are expected since MAP kinases are exquisitely sensitive to 
mechanical force343,508,509.  (3) The inherent time constraints of handling and processing were 
unsuitable because a rapid assay was required for the planned studies.  (4) PBMC isolation 
requires approximately 50mls of blood to yield a sufficient number of cells for experimental 
work.  This may be reasonable for pilot studies in healthy volunteers but it is difficult to 
justify this volume of blood, at multiple time points (as per the anticipated design of the 
cardiopulmonary bypass study), in patients who have undergone major surgery that is 
 138 
 
inherently associated with bleeding.  The flow cytometric assays requiring <5mls of whole 
blood were adopted for this reason. 
 
TNFα, LPS, PMA and arsenite were selected for study as these stimuli are known to be strong 
activators of leukocytes.  The pathways and signalling molecules downstream from these 
stimuli have previously been described in 1.5.1, 1.5.2 and 1.5.3.  The purpose of these studies 
was not to elucidate the mechanisms and inflammatory cascades limited to these particular 
stimuli but to establish the assays as a reliable tool for detection of our markers of interest.  
Thus we used several stimuli in parallel to test the suitability of the assays for analysis of 
whole blood samples.  It should be stressed that the experimental set up was not designed to 
look at kinetics of activation nor the relative influence of ROS on p38 MAP kinase and NF-
κB (and their cross-talk).  These questions cannot be answered on the basis of the 
experimental data generated in this chapter.  What the data do show, is that different kinetics 
of activation of ROS, p38 MAP kinase and NF-κB are associated with PMA treatment, and 
that LPS, TNFα and arsenite have different effects on the signalling p38 MAP kinase and NF-
κB cascades. 
 
A limitation of the assays used is that they do not generate absolute quantitate data on levels 
of p38 MAP kinase nor NF-κB phosphorylated forms or ROS.  Instead, they can provide 
information on the relative abundance of these molecules in cells exposed to different 
conditions.  Because of this limitation, it was not possible to determine the sensitivity of the 
assay at a formal level.  Thus the ability of these assays to detect activation of p38 MAP 
kinase, NF-κB or ROS induction in samples from patients or large animals undergoing bypass 
was determined empirically (see chapters 4 and 5). 
 
The technical validation work presented in this chapter were important because they led to the 
development of tools and protocols to analyse ROS induction and p38 MAP kinase and NF-
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B activation in leukocytes from patients (Chapter 4) and health human volunteers, or pigs 
exposed to CPB (Chapter 5).  
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CHAPTER 4. INFLAMMATORY SIGNALLING 
MODULATION BY CARDIOPULMONARY  
BYPASS OPTIMISATION 
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4.1 INTRODUCTION 
Coronary artery bypass graft surgery, for ischaemic heart disease, performed with the use of 
conventional CPB systems can lead to the generation of molecular triggers that promote 
inflammation.  These signals orchestrate the inflammatory response to surgery by influencing 
pro-inflammatory signalling within and between blood and tissue cellular compartments.  
Therefore, from a therapeutic perspective, the optimisation of CPB (in the form of the 
currently available miniaturised CPB system) may result in attenuated pro-inflammatory 
leukocyte signalling.  This reduction in pro-inflammatory signalling, in turn, may lead to a 
reduction in the margination of activated leukocytes into organs after cardiac surgery, and 
consequently a lower incidence organ dysfunction with corresponding improvements in 
clinical outcome measures. 
 
Although it is well recognised that CPB can induce systemic inflammation as discussed in 
1.4.1 (page 36), the regulatory signalling pathways that are activated by CPB have not been 
precisely defined.  Moreover, the mechanism underlying the inflammatory effects of CPB 
miniaturisation has not been characterised at a molecular level.  
 
In the work presented in this chapter, preliminary studies of ROS, p38 MAP kinase and p65 
NF-κB activation were conducted prior to their full assessment within a randomised clinical 
study. 
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4.2 HYPOTHESIS 
The hypotheses tested in this chapter were: 
 
i. Cardiopulmonary bypass leads to the rapid induction of reactive oxygen species in 
leukocytes which is associated with early activation of pro-inflammatory signalling (e.g. 
p38 MAP kinase and NF-κB activation) associated with leukocyte transmigration.   
 
ii. Miniaturised cardiopulmonary bypass leads to reduced pro-inflammatory activation in 
leukocytes and an attenuated systemic inflammatory response compared to conventional 
cardiopulmonary bypass.   
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4.3 RESULTS: PRELIMINARY STUDIES 
4.3.1 The effect of cardiopulmonary bypass on reactive oxygen species induction 
Preliminary pilot studies were performed to determine whether surgery with CPB activates 
pro-inflammatory intracellular signalling pathways.  Initially, ROS levels in leukocytes were 
studied in three patients undergoing heart surgery (CABG, aortic valve replacement, aortic 
root replacement) with conventional CPB support.  Given that these are rapid signalling 
molecules with short half-lives (discussed in 1.5.1, page 56) and that CPB was considered the 
initiating event in pro-inflammatory activation, blood was sampled at baseline (on the 
morning of surgery); then at the start of CPB support followed by further blood sampling at 
30 minutes, 1 hour, 5 hour and 24 hour timepoints relative to the initiation of CPB.  Two 
different ROS sensitive probes were utilised (APF and DCF) to assess the induction of ROS.  
Ex-vivo phorbol ester (PMA 200ng/ml for 30 minutes) was also applied to leukocytes within 
this experimental setting.  As these were preliminary sets of experiments, it was uncertain if 
changes in ROS were detectable in leukocytes from patients and this element of ex-vivo stress 
was included in the study to amplify and enhance the intrinsic ROS response within the cells 
of interest to us.  This approach also allowed for the assessment of the leukocyte priming 
phenomenon post exposure to CPB. 
 
Firstly, the DCF redox-sensitive dye was used to determine broad ROS changes in leukocytes 
with analysis by flow cytometry.  The two-way analysis of variance in the granulocyte 
fraction identified via flow cytometry (Figure 4.1A) revealed the main effect of CPB 
exposure was significant, F(5,20) = 3.442, p<0.05; as was the effect of ex-vivo PMA stimulus 
F(1,4) = 8.369, p<0.05.  Post-hoc evaluation performed with the Dunnett multiple 
comparisons test to compare differing time points to baseline controls.  These statistical 
evaluations indicated that there was a significant increase in mean PMA-enhanced ROS levels 
at the start of CPB (mean 3684 ± 2110 FITC MFI units, p<0.01) and at 30 minutes (mean 
3150 ± 1998 FITC MFI units, p<0.05), compared to baseline (mean 1104 ± 463 FITC MFI 
units).  By contrast, in PMA-unstimulated leukocytes subject to CPB, the change of means 
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from baseline (333 ± 235 FITC MFI units) to the start of CPB (1215 ± 617 FITC MFI units) 
was not statistically significant.   There was a trend towards ROS levels returning to baseline 
levels at 5 hours (PMA-unstimulated, 471 ± 178 FITC MFI units) from the start of CPB in the 
granulocyte fraction.   
 
Two-way analysis of variance in the monocyte fraction (Figure 4.1B) revealed no effect from 
CPB exposure nor an effect from PMA-stimulation at the 0.05 alpha level.  The trends in 
PMA-unenhanced ROS were similar to those seen in granulocytes: baseline mean 378 ± 489 
FITC MFI units vs start of CPB mean 1875 ± 1867 FITC MFI units vs 5 hours post CPB 
mean 409 ± 80 FITC MFI units. 
 
In the lymphocyte fraction determined by flow cytometry (Figure 4.1C) two-way analysis of 
variance in fluorescence revealed the main effect of CPB exposure was significant, F(5,20) = 
2.797, p<0.05; but the effect of ex-vivo PMA stimulus was not significant; F(1,4) = 0.2006, 
p<0.67.  This is evident in the graph when we compare the scale of fluorescent intensity in 
unstimulated and stimulated leukocytes throughout the duration of surgery and into the post-
operative recovery period.  PMA-enhanced ROS levels increased significantly at the start of 
CPB (mean 1023 ± 1157 FITC MFI units, p<0.05) and persisting up till 30 minutes (mean 
1109 ± 796 FITC MFI units, p<0.05) of CPB exposure, compared to baseline levels (mean 
287 ± 356 FITC MFI units). 
 
In keeping with the patterns observed in the granulocyte and monocyte fraction data, the 
changes between baseline (mean 253 ± 294 FITC MFI units) and the start of CPB (mean 922 
± 680 FITC MFI units) and at 5 hours post-CPB (mean 380 ± 105 FITC MFI units) in 
untreated cells were not statistically significantly different. 
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Figure 4.1 DCF-spectrum ROS activation during cardiac surgery 
Surgery with conventional cardiopulmonary bypass was studied.  Blood was sampled prior to surgery 
on the morning of the operation (baseline), at the start of CPB and 30 minutes, 1 hour, 5 hours and 24 
hours post initiation of CPB.  Samples were loaded with the DCF ROS-sensitive probe and treated with 
PMA (200ng/ml) for 30 minutes (or remained untreated as controls) prior to analysis by flow 
cytometry.  Fluorescence was assessed by flow cytometry for (A) granulocyte (B) monocyte and (C) 
lymphocyte subpopulations by forward and side scatter profiles.  Fluorescence values were pooled 
from data generated using 3 patients and mean values ± SEM are shown.  (* p<0.05; ** p<0.01; two-
way ANOVA with Dunnett’s post-hoc multiple comparisons test post-hoc multiple comparisons test).  
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In parallel, the APF ROS-sensitive probe was used to evaluate leukocyte changes in the 
context of cardiac surgery with cardiopulmonary bypass.  Two-way analysis of variance in 
fluorescence in the granulocyte fraction (Figure 4.2A) revealed the main effect of PMA-
stimulus was highly significant, F(1,4) = 192.9, p<0.0005; whereas the main effect of CPB 
exposure was not; F(5,20) = 0.1653, p<0.97.  Post-hoc evaluation using the Bonferroni 
multiple comparisons test between groups showed highly significant PMA-inducible ROS 
activation at all timepoints (e.g. baseline comparison PMA-unstimulated 36.4±16.1 vs PMA-
enhanced 7708 ± 1994 FITC MFI units, p<0.0001).  In unstimulated cells, APF-detectable 
ROS at the start of CPB (mean 54.1 ± 33.8 FITC MFI units) were not statistically different 
from baseline levels (mean 36.2 ± 16.1 FITC MFI units) nor at 5 hours (mean 56.3 ± 17.3 
FITC MFI units) in the granulocyte fraction.  Mean fluorescence levels were similar for all 
granulocyte samples treated with PMA, irrespective of CPB time (Figure 4.2).  This could be 
because PMA-enhanced levels of ROS approach the maximum detection threshold of the 
flow cytometry settings (Figure 4.2A, compare scales of -PMA and +PMA; note the 
maximum threshold for flow cytometry is arbitrarily set at 10,000 MFI units). 
 
Two-way analysis of variance in fluorescence in the monocyte fraction (Figure 4.2B) revealed 
the main effect of PMA-stimulus was significant, F(1,4) = 15.43, p<0.05; as was the effect of 
CPB exposure F(5,20) = 22.17, p<0.0001.  Highly significant PMA-enhanced ROS activation 
was detected at 1 hour (mean 1617 ± 1169 FITC MFI units, p<0.01), 5 hours (mean 4092 ± 
1221 FITC MFI units, p<0.0001) persisting up to 24 hours (mean 4494 ± 757 FITC MFI units, 
p<0.0001) post-CPB compared to baseline levels (mean 1514 ± 1169 FITC MFI units).  
Levels of ROS at the start of CPB (mean 59.4 ± 38.8 FITC MFI units), 1 hour (69.1 ± 41.2 
FITC MFI units) and 5 hours (mean 69.3 ± 14.2 FITC MFI units) were not statistically 
significantly different compared to baseline (mean 47.1 ± 42.8 FITC MFI units) in 
unstimulated specimens. 
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In the lymphocyte fraction determined by flow cytometry (Figure 4.2C), two-way analysis of 
variance revealed a significant effect with PMA-stimulus, F(1,4) = 130.5, p<0.0005; as was 
the effect of CPB exposure F(5,20) = 7.615, p<0.0005.  PMA-enhanced ROS activation was 
enhanced at 5 hours (mean 622.5 ± 187.3 FITC MFI units, p<0.005) and at 24 hours (mean 
716.1 ± 304.5 FITC MFI units, p<0.001), compared to baseline (mean 88.2 ± 56.8 FITC MFI 
units)..  However, there were no significant changes in ROS levels in unstimulated 
lymphocytes over time 
 
Taken together, these data suggest that PMA-enhanced ROS increased following anaesthesia, 
sternotomy, surgical access, heparinsation, cannulation - all before the initiation of CPB - and 
remained elevated for between 1-5 hours.   The pattern of PMA-unenhanced ROS mirrors that 
of PMA-enhanced values at early timepoints (up to 1 hour) relative to the use of CPB.  The 
ROS data suggests that following CPB, leukocytes may be primed towards exhibiting an 
enhanced ROS response to an external PMA stimulus at late timepoints (5 hours and 24 hours, 
most evident in Figure 4.2B and C).  
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Figure 4.2 APF-spectrum ROS activation during cardiac surgery 
Surgery with conventional cardiopulmonary bypass was studied.  Blood was sampled prior to surgery 
on the morning of the operation (baseline), at the start of CPB and 30 minutes, 1 hour, 5 hours and 24 
hours post initiation of CPB.  Samples were loaded with the APF ROS-sensitive probe and treated with 
PMA (200ng/ml) for 30 minutes (or remained untreated as controls) prior to analysis by flow 
cytometry.  Fluorescence was assessed by flow cytometry for (A) granulocyte (B) monocyte and (C) 
lymphocyte subpopulations by forward and side scatter profiles.  Fluorescence values were pooled 
from data generated using 3 patients and mean values ± SEM are shown.  (** p<0.01; ***p<0.005; # 
p<0.001; two-way ANOVA with (A) Bonferroni multiple comparisons test between goups or (B and C) 
Dunnett post-hoc multiple comparisons test within groups). 
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4.3.2 Cardiopulmonary bypass alters p38 MAP kinase and NF-κB signalling in 
circulating leukocytes 
Further pilot experiments were conducted in three patients undergoing surgery (aortic valve, 
mitral valve surgery, combined valve surgery) to assess the influence of CPB on p38 MAP 
kinase and p65 NF-κB phosphorylation in leukocytes.  These assays were performed on 
fixed/permeabilised cells (in contrast to the live ROS assays) and afforded the opportunity to 
perform tests at shorter time intervals between sampling (i.e. 15 minutes rather than 30 
minutes in the ROS experiments).  Given the observation of enhanced ROS between baseline 
and the start of CPB, an extra blood sampling time point was taken at the post-anaesthetic 
induction stage.  The rationale for this was to provide a window for evaluation of the changes 
from anaesthesia / monitoring and the surgical process that follows, prior to the initiation of 
CPB.  Blood specimens for these experiments were therefore taken at baseline (on the 
morning of surgery); post anaesthesia; at the start of CPB and then at 15 minutes, 30 minutes, 
45 minutes, 60 minutes and 1 hour and 6 hours post-CPB.  CPB was considered the main 
driving event for inflammation and the timings of the experiments were designed around this 
index ‘stimulus event’.  Given the kinetics of activation of p38 MAP kinase as discussed in 
1.5.2 (page 60) and NF-κB 1.5.3 (page 64), the majority of blood sampling timings occurred 
within the first hour, relative to CPB exposure.  Whole blood specimens were not subject to 
an ex-vivo stress, as the assay did not rely on ‘loading’ of a detecting probe (whose effect 
may or may not need amplifying), but instead detected the intrinsic phosphorylation levels of 
p38 MAP kinase and NF-κB within leukocytes. 
 
To begin, levels of p38 MAP kinase activity in granulocytes were detected by flow cytometry 
(Figure 4.3A).  A one-way ANOVA was conducted to compare the effect of CPB exposure on 
p38 MAP kinase phosphorylation at multiple timepoints.  There was a significant effect of 
CPB exposure over time with p38 MAP kinase phosphorylation levels, F(6,12) = 4.376, 
p<0.01.  Post-hoc analysis showed post induction p38 MAP kinase phosphorylation (mean 
384.6 ± 162.3 PE-Cy7 MFI units) was not different compared to baseline (mean 347.7 ± 
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171.7 PE-Cy7 MFI units).  These correspond to anaesthesia and monitoring events in the 
surgical process.   Statistically significant peak levels of p38 MAP kinase were measured at 
the start of CPB (mean 557.8 ± 221.2 PE-Cy7 MFI units, p<0.05), corresponding to surgical 
access/trauma and these levels declined and reached a sub-baseline level at 2 hours post-CPB 
(mean 102.7 ± 9.0 PE-Cy7 MFI units, p<0.05), compared to baseline.  In mononuclear cells, 
these trends were repeated between baseline (mean 14.2 ± 3.4 PE-Cy7 MFI units), peaking at 
the start of CPB (mean 30.13 ± 24.4 PE-Cy7 MFI units) and reaching sub-baseline trough 
levels 2 hours (mean 4.7 ± 2.5 PE-Cy7 MFI units) post-CPB but these differences were not 
statistically significant (Figure 4.3B). 
 
There was a significant effect of CPB exposure over time with levels of phosphorylated p65 
NF-κB levels in granulocytes, F(6,12) = 8.092, p<0.005.  In contrast to p38 MAP kinase, 
levels of phosphorylated p65 NF-κB were maximally induced at 2 hours following CPB 
(mean 10.28 ± 2.88 PE MFI units, p<0.05) compared to baseline (mean 4.41 ± 2.37 PE MFI 
units).  These levels then subsequently declined to sub-baseline levels at 6h (mean 1.60 ± 1.31 
PE MFI units, p<0.01) post-CPB (Figure 4.3C).  During the period of exposure to CPB, there 
was a downward trend for levels of phosphorylated p65 NF-κB but these data did not reach 
statistical significance compared to baseline. 
 
When considering the mononuclear cell fraction, there was a significant effect of CPB 
exposure over time with levels of phosphorylated p65 NF-κB levels, F(6,12) = 7.244, 
p<0.005.  Peak activation occurred at 2 hours (mean 3.70 ± 1.47 PE MFI units, p<0.05) 
followed by a decline of p65 NF-κB at 6 hours (0.62 ± 0.43 PE MFI units, p<0.01) with 
reference to baseline levels (mean 1.14 ± 0.43 PE MFI units).  This is in keeping with the 
patterns observed in the granulocyte fraction. 
 
Thus we concluded that surgery with CPB was associated with activation of p38 MAP kinase 
and NF-κB in leukocytes with differing kinetic profiles. 
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Figure 4.3 p38 MAP kinase and NF-κB induction with cardiac surgery 
Surgery with conventional cardiopulmonary bypass was studied.  Blood was sampled prior to surgery 
on the morning of the operation (baseline), post anaesthetic induction (PI) at the start of CPB and 15 
minutes, 30 minutes, 45 minutes, 60 minutes and 6 hours post initiation of CPB.  Leukocytes were 
immediately fixed and permeabilised prior to staining with anti-phospho Thr180/Tyr182 p38 MAP 
kinase (A) granulocytes, (B) mononuclear cells or anti-phospho Ser529 NF-κB antibodies (C) 
granulocytes (D) mononuclear cells. Fluorescence was assessed by flow cytometry and adjusted by 
subtracting values generated using fluorescent isotype-matched antibodies.  Fluorescence values 
were pooled from data generated using 3 patients and mean values ± SEM are shown. (* p<0.05; ** 
p<0.01; repeat measures one-way ANOVA with Bonferroni’s post-hoc multiple comparisons test). 
 
B a s e l i n e P I S t a r t 1 5 3 0 4 5 1 h 2 h 6 h
0
2 0 0
4 0 0
6 0 0
8 0 0
p 3 8  M A P  k in a s e  in d u c t io n
in  g r a n u lo c y te s
P
E
-C
y
7
 M
F
I 
(A
U
)
B a s e l i n e P I S t a r t 1 5 3 0 4 5 1 h 2 h 6 h
0
1 0
2 0
3 0
4 0
5 0
p 3 8  M A P  k in a s e  in d u c t io n
in  m o n o n u c le a r  c e lls
P
E
-C
y
7
 M
F
I 
(A
U
)
B a s e l i n e P I S t a r t 1 5 3 0 4 5 1 h 2 h 6 h
0
1
2
3
4
5
6
7
8
9
1 0
1 1
1 2
1 3
1 4
1 5
p 6 5  N F - B  in d u c tio n
in  g r a n u lo c y te s
P
E
 M
F
I 
(A
U
)
B a s e l i n e P I S t a r t 1 5 3 0 4 5 1 h 2 h 6 h
0
1
2
3
4
5
p 6 5  N F - B  in d u c tio n
in  m o n o n u c le a r  c e lls
P
E
 M
F
I 
(A
U
)
*
* **
* **
C D
A B
Timepoint Timepoint
Timepoint Timepoint
*
 152 
 
4.4 RESULTS: CLINICAL STUDY 
Although other studies have shown that CPB can induce systemic inflammation, the pro-
inflammatory signalling pathways that are activated by CPB have not been defined. Moreover, 
the mechanism underlying the anti-inflammatory effects of CPB miniaturisation has not been 
characterised at a molecular level. To address the question of whether optimising 
cardiopulmonary bypass systems can attenuate pro-inflammatory signalling in human 
leukocytes, a randomised clinical trial was performed using the Sorin ECCO miniaturised 
bypass system.   
 
Building on the earlier work in this chapter, pro-inflammatory signalling pathways in 
leukocytes were assessed at multiple time points relative to the initiation of CPB.  Primary 
outcome measures were defined as activation of p38 MAP kinase (which is known to promote 
inflammation by activating downstream AP-1 superfamily transcription factors and by 
stabilising inflammatory transcripts), and activation of p65 Rel A sub-unit NF-κB 
transcription factor (which activates multiple inflammatory genes).  In addition, the effects of 
ROS signalling, (which is known to modulate both p38 MAP kinase and NF-κB activities), 
was evaluated.  Secondary outcome measures included assessment of the number of 
leukocytes within cantharidin skin blisters (as a marker of leukocyte margination), circulating 
white cell counts, serum C-reactive protein levels (as secondary markers of inflammation) and 
serum troponin and creatinine levels (as markers of myocardial injury and of renal 
dysfunction).   
 
This study was conducted in patients undergoing surgical revascularisation for coronary 
artery disease, which is frequently carried out at the Hammersmith institution. In order to 
determine the kinetics of inflammatory signalling pathway activation with cardiopulmonary 
bypass, this study compared conventional CPB (cCPB) and miniaturised CPB (mCPB) in a 
clinical setting.   
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4.4.1 Study design and settings 
A single centre, open, parallel-group RCT was performed (ISRCTN30610605).  A favourable 
local ethics opinion was obtained prior to commencement of the clinical trial (REC reference 
08/H0708/67).  The study took place within the Department of Cardiothoracic surgery of the 
Hammersmith Hospital, Imperial College NHS Healthcare Trust in London, UK.  The 
randomised patients were enrolled between August 2010 and January 2012.  Informed written 
consent was obtained from the research participants.   
4.4.1.1 Participants 
Patients referred for primary isolated, non-emergent CABG to a single surgeon with extensive 
experience with the use of both cCPB and mCPB systems were considered for inclusion.  
Excluded were patients under 18 years of age; emergency surgery requiring an operation 
within 24h; combined valve replacement procedures in addition to CABG; repeat surgery 
requiring re-sternotomy; poor left ventricular function with an ejection fraction of <30% on 
echocardiogram; recent cerebro-vascular accident within 3 months preoperatively or more 
than 75% carotid artery obstruction on ultrasound; pre-existing renal impairment with serum 
creatinine in excess of 177 μmol/L; pre-existing coagulopathy; pre-existing liver dysfunction 
or the recent (within 5 days) use of antiplatelet agents (aspirin/clopidogrel).   
4.4.1.2 Intervention and comparator 
Anaesthetic technique was standardized for all patients. Thiopentone (1–3 mg/kg) was used 
for induction with 3–5 mg/kg fentanyl, and volatile agents were delivered in 50% air–O2 
mixture for maintenance. Propofol (3mg/kg/h) was given as an infusion during CPB and 
neuromuscular blockade was achieved by 0.1–0.15 mg/kg pancuronium.  Initial 
anticoagulation was accomplished with 3 mg/kg body weight of intravenous heparin and was 
supplemented as required in order to maintain an active clotting time of 480 s or above. All 
operations were performed using cCPB or mCPB with ascending aortic cannulation, two 
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stage venous cannulation, and moderate systemic hypothermia (32°C) with parallel blood cell 
salvage (Electa, Sorin group, Milan, Italy).  Coronary artery anastomoses were constructed 
using intermittent cross-clamp fibrillation (ICCF) in the randomised CPB groups.  ICCF was 
introduced after cross clamping of the aorta in order to perform coronary grafting. This was 
followed by de-clamping the aorta and reperfusion of the heart. The same procedure was then 
repeated for each of the subsequent grafts.  No cardioplegia was utilised. 
 
mCPB was conducted using the Sorin Dideco Extracorporeal Circulation Optimized (ECCO) 
system as described previously435.  During the use of mCPB, the patients’ systemic vascular 
resistance was used to perform a retrograde autologous prime of the arterial line and the 
arterial line filter.  In this way, the patient’s own arterial blood pressure was used to displace 
the circulating prime into the soft-shell reservoir.  This displaced prime was then removed via 
suction to the cell salvage device.  An autologous antegrade prime was then carried out by 
kinetically draining blood from the right atrium and displacing the prime volume into the soft 
shell reservoir.  mCPB was then initiated with a flow of 1.7-2.4/min/m2. The cCPB circuit 
utilised a Stockert roller pump, membrane oxygenator, venous reservoir and non-heparin 
bonded circuit with cardiotomy suction.  The details of these two systems are summarised in 
Table 4.1. 
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Table 4.1 Characteristics of Cardiopulmonary bypass systems 
 cCPB system mCPB system 
Target ACT >400s >400s 
Venous cannula 
34 Fr 2 stage (Medtronic) 
1/2 inch tubing 
29Fr Optiflow (Sorin) 
3/8 inch tubing 
Reservoir Sorin Evo Soft Shell reservoir 
Pump 
Roller pump (Stockert, 
Germany) 
Centrifugal pump (Stockert, 
Germany) 
Heat exchanger  / Oxygenator Avant (Sorin) Eos (Sorin) 
Flows (target cardiac index) 
1.8-2.4L/min/m
2
 cooled to 
32°C 
1.8-2.4L/min/m
2
 cooled to 
32°C 
Prime volume 1400mls Hartmann’s 
300mls Hartmann’s with 
retrograde autologous prime 
Safety features  
Venous air removal device 
(VARD) 
Operative field blood Cardiotomy suction Cell salvage 
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4.4.1.3 Timing of measurements 
Sampling times are summarised in Figure 4.4. Participants underwent baseline blister 
formation on the day before surgery.  Baseline blood samples and blister fluid were harvested 
on the following day, the morning of the operation. Patients received high-flow oxygen prior 
to anaesthetic induction and endotracheal intubation.  Central venous cannulation of the right 
internal jugular vein and arterial access from the right radial artery was performed and a 
second ‘post-induction’ (PI) blood specimen was subsequently taken.  Blood was then 
sampled on commencement of CPB (0 h time point) and then at 30 min, 1h, 2h and a final 5h 
specimen relative to the initiation of CPB.  Blister fluid was harvested 5h following the start 
of CPB. 
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Figure 4.4 Summary of blood and blister fluid sampling times 
Blood and cantharidin-induced skin blister fluid were sampled in patients exposed to cCPB or mCPB. 
Blister fluid was harvested pre-operatively and on the day of surgery.  Blood was sampled before 
surgery and at multiple time points after CPB. A time-line is presented to summarise sampling times 
(calculated relative to the time of CPB induction which is indicated as t=0h). 
Blood sampling:
Blister fluid harvest:
Time (hours): 0 1 2 3 4-1-2-24
CPB initiation
post-inductionbaseline
5
Figure 1
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4.4.1.4 Outcome measures 
Primary outcome measures were blood parameters of cellular stress, specifically reactive 
oxygen species levels and phosphorylation of p38 MAP kinase and NF-κB (RelA). Secondary 
outcomes included leukocyte counts in cantharidin-induced skin blisters, circulating white 
cell counts, serum C-reactive protein levels (secondary markers of inflammation) and serum 
troponin and creatinine levels. 
4.4.1.5 Randomisation 
Participants were randomised using the Clinical Trials Evaluation Unit (CTEU) portal system 
established by staff not otherwise involved in the study.  Random allocations were blocked 
and generated in advance of the study by computer.  The random allocations were concealed 
at the time of recruitment.  Randomisation was carried out by one of the investigators after the 
patient’s eligibility had been checked and written informed consent had been obtained.  No 
member of the clinical or research team was blinded to the treatment allocation.  Participants 
were blinded to the allocation.   
4.4.1.6 Statistical determinants and analysis 
We chose to study 13 patients per group.  Based on the data from a previous study195, a 
sample size of 13 in each group would have 99% power to detect a difference in means of 
1448 × 105 cells between any two groups assuming that the common standard deviation is 1 × 
105 using the Wilcoxon (Mann-Whitney) rank-sum test analysis with a 0.05 two-sided 
significance level.  Statistical advice was provided by Joseph Eliahoo, Statistical Advisory 
Service, Imperial College London. 
 
Statistical analyses of the data were carried out according to a pre-specified statistical analysis 
plan (SAP) after all subjects had completed the study and after the database had been locked. 
Continuously scaled outcomes are described as means and SD for each treatment group, at all 
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time points if measured more than once. A natural logarithm transformation was applied 
before analysis if outcome data were positively skewed, in which case findings are reported 
on the natural logarithm scale.  
 
The effects of mCPB compared to cCPB were estimated by fitting mixed regression models 
(using STATA v.11.2) to take into account the repeated measurements. The following 
predictors were included: main effect of time, fitted categorically, and main effect of the 
intervention (mCPB vs. cCPB).  Interactions between treatment group and time were also 
fitted and, if statistically significant at the 5% level, differences between groups with 95% 
confidence intervals (CI) are described for each time point separately; otherwise an overall 
treatment difference (with 95% CI) is reported. All data analyses were performed on an 
intention-to-treat basis irrespective of the final actual treatment modality received.  The 
statistical analysis with regression models was conducted by the trial statisticians Dr 
Francesca Fiorentino and Professor Barnaby Reeves of the local clinical trials unit. 
4.4.2 Patient recruitment 
A total of 50 patients were considered for inclusion into the study.  Of these, 7 declined to 
take part in the study and a further 17 were not enrolled due to them meeting one, or more, of 
the exclusion criteria.  The commonest reason for exclusion was pre-existing renal 
impairment, as defined by a creatinine of >177µmol/l (n=8), followed by concomitant anti-
platelet therapy with aspirin or clopidogrel (n=5).  The remaining 26 were randomised by 
computer allocation, using the clinical trials evaluation unit electronic portal, to undergo 
surgery with either mCPB (n=13) or cCPB (n=13).   
4.4.3 Protocol violations 
All patients allocated to cCPB had surgery performed as allocated with the use of cCPB 
circuits as described previously.  Of the participants allocated to undergo surgery using 
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mCPB, one participant underwent surgery with the use of cCPB (because the perfusionist 
available was not fully-trained in the running of mCPB).  The remaining 12 mCPB allocations 
underwent surgery with the allocated CPB circuit as planned. The sequence of allocations to 
the study are outlined in the CONSORT diagram illustrated in Figure 4.5. 
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Figure 2
Isolated, first time CABG: Anderson
Eligible (n=50)
Excluded (n=17)
• On Aspirin/clopidogrel (n=5)
• Creatinine >177umol/l (n=8)
• Poor LV function (n=2)
• Enrolled in another study (n=2)
Declined participation (n=7)
Randomised (n=26)
mCPB
Allocation (n=13)
cCPB
Allocation (n=13)
Undergo mCPB
(n=12)
Undergo cCPB
(n=1)
Undergo cCPB
(n=13)
Lost to follow up
(n=0)
Lost to follow up
(n=0)
Lost to follow up
(n=0)
mCPB +ICCF 
ITT Analysis (n=13)
cCPB +ICCF 
ITT Analysis (n=13)
 
Figure 4.5 Overview of participant selection 
Trial participants were recruited and then assessed for various exclusion criteria (indicated). Of those 
included in the study, computer randomisation allocated participants to either mCPB (investigative 
group) or cCPB (control group) with coronary surgery performed with intermittent cross-clamp 
fibrillation (ICCF). One patient in the mCPB group received cCPB as indicated. Statistical analysis was 
based on intention to treat (ITT). 
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4.4.4 Baseline characteristics and peri-operative details 
Patient characteristics are summarised in Table 4.2.  Statistical comparisons of baseline group 
characteristics are not presented in keeping with CONSORT recommendations. Participant 
ages were comparable between cCPB (mean 66.3 ± 8.1 years) and mCPB (mean 68.4 ± 6.8 
years) groups.  The male:female ratio was higher in the cCPB (10:3) than the mCPB (8:5) 
group.  The mean body mass index was similar for both groups 29.7 ± 4.5 kg/m2 for the 
mCPB group and 29.3 ± 4.1 kg/m2 for the cCPB group. The mean logistic EuroSCORE for 
mCPB and cCPB was 3.35 ± 2.36% and 3.74 ± 3.14% respectively.  There tended to be more 
diabetic patients in the cCPB group (38 % type I, 15% type II) compared to the mCPB group 
(8 % type I, 8% type II).  All other parameters in terms of previous myocardial infarction, left 
ventricular function, smoking status, hypertension, renal disease, lung disease, extracardiac 
arterial pathology and neurological dysfunction were comparable between groups. 
 
Peri- and post- operative data are given in Table 4.3.  The median duration of CPB was 71 
min (IQR 62 – 84) in the mCPB group and 74 min (IQR 67 – 91) in the cCPB group. Median 
aortic cross-clamp times were 30 min (IQR 24-33) and 34 min (IQR 29-38) in the mCPB and 
cCPB groups respectively. The mean number of coronary artery bypass grafts performed in 
the randomised group was 3.2 for both mCPB and cCPB groups. The mean number of red 
cells transfused was 1.07 ± 1.38 units in the mCPB group and 1.15 ± 1.57 units in the cCPB 
group in the first 24 hours following surgery. Mean platelet transfusions were 0.15 ± 0.37 
pools in the mCPB group and 0.38 ± 0.51 pools in the cCPB group. FFP requirements were 
0.54 ± 1.05 pools in the mCPB group and 0.46 ± 1.13 pools in the cCPB group in the early 
post-operative period. The median hospital stay was 8 days for both the mCPB and the cCPB 
group (IQR [5,11] for the mCPB group and IQR[7,13] for the cCPB group).   There were no 
perioperative incidences of gross neurological dysfunction nor return to theatre for bleeding 
in any patient groups.  The cCPB group had 3 instances of surgical site wound infections and 
1 instance of the requirement for renal support therapy post-operatively. 
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Table 4.2 Pre-operative patient characteristics  
Values are expressed as mean with standard deviation or number with percentage in parentheses as 
indicated. 
Variable mCPB (n=13) cCPB (n=13) 
Female (n) 5 (38.4%) 3 (23.1%) 
Age (years) 68.4 ± 6.8 66.3  ± 8.1 
Body Mass Index (kg/m2) 29.74  ± 4.53 29.31 ± 4.11 
Logistic euroSCORE (%) 3.35 ± 2.36 3.74 ± 3.14 
Coronary vessel disease 
Single vessel disease 
Two vessel disease 
Three vessel disease 
 
0 
1 (8%) 
12 (92%) 
 
1 (8%) 
1 (8%) 
11 (84%) 
Angina Status 
Asymptomatic 
CCSI 
CCS II 
CCS III 
CCS IV 
 
1 (8%) 
0 
10 (77%) 
1 (8%) 
1 (8%) 
 
1 (8%) 
0 
7 (54%) 
3 (23%) 
2 (15%) 
Previous MI 3 (23%) 4 (31%) 
Ejection fraction 
Good >50% 
Fair 30-50% 
Poor <30% 
 
11 (85%) 
2 (15%) 
0 
 
12 (92%) 
1 (8%) 
0 
Diabetes 
Not diabetic 
Diet controlled 
Oral Therapy 
Insulin 
 
11 (85%) 
0 
1 (8%) 
1 (8%) 
 
6 (46%) 
0 
5 (38%) 
2 (15%) 
Smoking status 
Never smoked 
Current smoker 
Ex-smoker 
 
6 (46%) 
1 (8%) 
6 (46%) 
 
6 (46%) 
0 
7 (54%) 
Hypertension 
Treated for BP>140/90 
 
12 (92%) 
 
12 (92%) 
Chronic lung disease 
No 
Yes 
 
11 (85%) 
2 (15%) 
 
12 (92%) 
1 (8%) 
Extracardiac arteriopathy 
No 
Yes 
 
12 (92%) 
1 (8%) 
 
12 (92%) 
1 (8%) 
Pre-operative cardiac rhythm 
Sinus rhythm 
Atrial fibrillation/flutter 
 
11 (84%) 
1 (8%) 
 
12 (92%) 
1 (8%) 
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Table 4.3 Operative and post-operative patient parameters 
Values are expressed as medians with inter-quartile range (IQR) or means with standard deviation or 
number with percentage in parentheses, as indicated.  
 
Variable mCPB (n=13) cCPB (n=13) 
Cardiopulmonary bypass time (min) 71 (IQR 62-84) 74 (IQR 67-91) 
Total cross clamp time (min) 30 (IQR 24-33) 34 (IQR 29-38) 
Number of coronary artery grafts 3.23 ± 0.62 3.23 ± 0.93 
Time in ITU (days) 0.86 (IQR 0.80-1.33) 1.00 (IQR 0.80-1.10) 
Hospital stay (days) 8 (IQR 5-11) 8 (IQR 7-13) 
Transfusions in first 24 hours 
Packed red cells (units) 
Platelets (pools) 
Fresh frozen plasma (pools) 
 
1.07 ± 1.38 
0.15 ± 0.37 
0.54 ± 1.05 
 
1.15 ± 1.57 
0.38 ± 0.51 
0.46 ± 1.13 
Post-operative neurological dysfunction 
No 
 
13 (100%) 
 
13 (100%) 
Haemofiltration post-operatively 
No 
 
13 (100%) 
 
12 (92%) 
Infective complications 
None 
Harvest site infection 
Sternal wound infection 
 
13 (100%) 
0 
0 
 
10 (77%) 
1 (8%) 
2 (15%) 
Return to theatre 
No re-operation 
Return for bleeding 
 
13 (100%) 
0 
 
13 (100%) 
0 
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4.4.5 Primary outcome: leukocyte pro-inflammatory activation profiles 
In the 26 patients studied, given the number of observations, data distributions from flow 
cytometry measures of ROS, p38 and p65 in leukocytes from whole blood samples were 
found to be positively skewed.  The data were transformed into natural logarithms to 
(statistically) improve the nornality of the data distribution.  This normalised data was then 
evaluated using mixed-effects regression statistical models and presented in Table 4.4 for 
between-group comparisons.   
 
There were 6/546 missing data points for ROS; 2/364 for p38 MAP kinase and 2/364 for p65 
NF-κB  over the duration of the study (due to technical failure of the flow cytometer).  
Consequently, ANOVA could not be performed and multiple assessments could not be made 
on the basis of conventional post-hoc tests.  Instead, focused pair-wise tests were applied to 
the data (using the Wilcoxon rank test, given the non-Gaussian distribution of the data) 
between timepoints of interest and presented for within-group comparisons.  The mixed 
effects statistical analytical models were selected because of their advantage in dealing with 
missing values and have particular applicability over longitudinal studies such as the one 
presented here.  
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Table 4.4 Treatment effects of mCPB vs cCPB for primary and secondary endpoints 
a
FITC Mean Fluorescent Intensity (MFL) / arbitrary units (AU); 
b
PE-Cy7 MFI/AU; 
c
PE MFI/AU;
 d
cell 
counts per blister (×10
5
).  Other units otherwise indicated. 
 
Endpoint 
Difference between 
mCPB and cCPB  
(log units) 
95% Confidence 
Interval 
p value 
P
ri
m
ar
y 
ROS in granulocytes
a
 -0.0531 -0.2740 to 0.1678 0.638 
ROS in monocytes
a
 0.0102 -0.3251 to 0.3456 0.9520 
ROS in lymphocytes
a
 
30 mins post-CPB induction 
60 mins post-CPB induction 
120 mins post-CPB induction 
300 mins post-CPB induction 
 
0.3192 
-0.0122 
-0.0428 
0.1460 
 
0.1114 to 0.5270 
-0.2200 to 0.1957 
-0.2506 to 0.1650 
-0.0618 to 0.3538 
 
0.003 
0.909 
0.686 
0.168 
p38 in granulocytes
b
 -0.4688 -0.8923, -0.0453 0.03 
p38 in mononuclear cells
b
 0.4932 -0.4004, 1.3868 0.279 
p65 in granulocytes
c
 0.0517 -0.2426, 0.3459 0.731 
p65 in mononuclear cells
c
 0.1712 -0.2885, 0.6308 0.465 
Se
co
n
d
ar
y 
Cantharidin blister 
polymorphonuclear cell count
d
 
0.6998 -0.3449,  1.7445 0.173 
Cantharidin blister mononuclear 
cell count
d
 
0.3294 -0.3926,  1.0514 0.342 
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4.4.5.1 Cardiopulmonary bypass and the induction of ROS 
APF-spectrum ROS induction was first evaluated in patients undergoing surgery.  Compared 
to baseline, ROS were induced maximally at 30 minutes after CPB induction in the cCPB 
group (mean 12.88 ± 4.619 FITC MFI units vs 17.20 ± 7.68 FITC MFI units, p=0.052).  In 
the mCPB group, peak levels were recorded at the 30 minute post-CPB time point (mean  
17.97 ± 20.06 FITC MFI units), but these were not significantly different to baseline.  The 
data from the mCPB group exhibited a higher level of variation and multi-effects regression 
modelling revealed no difference between either cCPB or mCPB  for ROS induction in 
granulocytes; mean difference -0.0531 log units, 95% CI (-0.2740 to 0.1678), p = 0.638 
(Table 4.4, Figure 4.6A). 
 
There were no differences between either cCPB or mCPB groups for their pattern of 
induction of ROS in monocytes; mean difference 0.0102 log units, CI (-0.3251 to 0.3456),  p 
= 0.9520.  In this leukocyte subpopulation, peak levels of ROS were observed at 30 minutes 
post-CPB  for both cCPB (mean 15.51 ± 9.86 FITC MFI units) and mCPB (mean 16.68 ± 
23.15 FITC MFI units) groups, although the changes were not statistically significant 
compared with baseline levels (Table 4.4, Figure 4.6B).  
 
In lymphocytes, ROS levels were significantly higher, between groups, in patients exposed to 
cCPB (mean 5.78 ± 3.44 FITC MFI units) compared to mCPB (mean 3.74 ± 1.81 FITC MFI 
units) at 30 min; mean difference= 0.32 log units, 95% CI (0.1114, 0.5270), p=0.003.  This is 
exemplified by the change in ROS in the cCPB group between baseline and 30 minutes  
(mean 3.38 ± 0.91 vs 3.74 ± 1.81 FITC MFI units, p<0.05) that does not occur in the mCPB 
group  (Table 4.4, Figure 4.6C). 
 
 168 
 
Taken together, these data suggest that ROS pro-inflammatory signalling is induced 
maximally at 30 minutes of CPB and that mCPB differentially alters this induction in the 
lymphocyte population. 
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Figure 4.6 Effects of CPB on ROS induction in leukocytes 
CABG was performed with cCPB or mCPB. Peripheral blood samples were collected prior to surgery, 
post-induction, immediately prior to CPB (0 h) and at varying times following CPB initiation.  Samples 
were incubated with a ROS-sensitive dye, APF, prior to analysis by flow cytometry to quantify 
fluorescence in granulocytes or mononuclear cells (after gating of cells by size and granularity). 
Fluorescence levels were pooled and mean values ± SEM are shown.   (* p<0.05 Wilcoxon matched-
pairs signed rank test within-group, or statistical result from mixed-effect regression modelling are 
indicated between-groups). 
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4.4.5.2 Influence of optimisation of cardiopulmonary bypass on p38 MAP kinase 
phosphorylation 
Intracellular staining and flow cytometry revealed that phosphorylated p38 MAP kinase levels 
in the cCPB group at baseline (mean 118.44 ± 77.26 PE-Cy7 MFI units) reached a maximal 
level at the start of CPB (mean 135.98 ± 78.55 PE-Cy7 MFI units).  These changes did not 
reach statistical significance.  In keeping with the pilot data shown in the earlier part of this 
chapter, maximal levels of phosphorylated p38 MAP kinase significantly declined over the 
duration of CPB exposure to sub-baseline levels at 2 hours (mean 97.88 ± 74.58 PE-Cy7 MFI 
units, p<0.05).  In the mCPB group, p38 MAP kinase phosphorylation between baseline 
(mean  101.89  ±  74.19 PE-Cy7 MFI units) and the start of CPB (mean 122.05 ± 113.79 PE-
Cy7 MFI units) were not significantly different.  The decline in phosphorylated levelsof p38 
MAP kinase were more pronounced with mCPB exposure at 2 hours, significantly falling to 
sub-baseline levels (mean 60.55 ± 52.67 PE-Cy7 MFI units, p<0.005).  In comparing between 
the two CPB groups, at all timepoints from the start of CPB support to 2 hours, 
phosphorylated forms of  p38 MAP kinase were lower in the mCPB group.  These were 
significant differences on assessment by mixed-effects regression modelling; mean 
difference= 0.47 log units, 95% CI (0.89 to -0.05), p=0.03 (Table 4.4, Figure 4.7A). 
 
In mononuclear cells, the phosphorylated forms of p38 MAP kinase were not significantly 
different within groups nor between groups; mean difference 0.4932 log units, 95% CI (-
0.4004, 1.3868), p = 0.279 (Table 4.4, Figure 4.7B). 
 
Together, these data suggest that mCPB differentially alters pro-inflammatory p38 MAP 
kinase activation over time favouring earlier attenuation of this response preferentially within 
the granulocyte cell population. 
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Figure 4.7 Effects of CPB on p38 MAP kinase activation in leukocytes 
CABG was performed with cCPB or mCPB.  Peripheral blood samples were collected prior to surgery, 
post-induction, immediately prior to CPB (0h) and at varying times following CPB initiation.  
Leukocytes were fixed and permeabilised prior to intracellular staining using PE-Cy7-conjugated 
antibodies that recognise Thr180/Tyr182 phosphorylated p38 MAP kinase or with isotype-matched 
irrelevant antibodies as a control.  Fluorescence of (A) granulocytes or (B) mononuclear cells was 
quantified by flow cytometry (after gating of cells by size and granularity).  Fluorescence levels, 
calculated after subtracting values from isotype-control antibodies, were pooled and mean values ± 
SEM are shown.  (* p<0.05; ***p<0.001 Wilcoxon matched-pairs signed rank test within-group, or 
statistical result from mixed-effect regression modelling are indicated between-groups). 
B a s e l i n e P I S ta r t 3 0 m 1 h 2 h 5 h B a s e l i n e P I S ta r t 3 0 m 1 h 2 h 5 h
0
5 0
1 0 0
1 5 0
2 0 0
T im e p o in t  re la t iv e  to  C P B
P
E
-C
y
7
 M
F
I 
(A
U
)
C o n v e n tio n a l-C P B M in i-C P B
p38 MAPK phosphorylation in granulocytesA
B p38 MAPK phosphorylation in mononuclear cells
B a s e l i n e P I 0 3 0 6 0 1 2 0 3 0 0 B a s e l i n e P I 0 3 0 6 0 1 2 0 3 0 0
0
1 0
2 0
3 0
4 0
T im e p o in t  re la t iv e  to  C P B
P
E
-C
y
7
 M
F
I 
(A
U
)
C o n v e n tio n a l-C P B M in i-C P B
*
*
***
 172 
 
4.4.5.3 Influence of optimisation of cardiopulmonary bypass on NF-κB phosphorylation 
Phosphorylation of NF-κB p65 subunits in granulocytes did not significantly differ between 
groups; mean difference 0.0517 log units, 95% CI (-0.2426, 0.3459), p = 0.731 (Table 4.4, 
Figure 4.8A).  Similarly, phosphorylated forms of NF-κB p65 subunits in mononuclear cells 
also did not significantly differ between CPB groups; mean difference 0.1712 log units, 95% 
CI (-0.2885, 0.6308), p = 0.465 (Table 4.4, Figure 4.8B).   
 
However, within groups, there was significant attenuation in phosphorylated levels of 
granulocyte fraction p65 NF-κB between baseline and 5 hours for both cCPB (mean 3.21 ± 
1.98 PE MFI units vs mean 1.71 ± 1.73 PE MFI units, p<0.005) and mCPB (mean 3.00 ± 1.09 
PE MFI units vs mean 2.08 ± 1.22 PE MFI units, p<0.05) groups (Figure 4.7A). 
 
Within groups, there was significant attenuation in phosphorylated levels p65 NF-κB in the 
mononuclear cell fraction between baseline and 5 hours also for both cCPB (mean 1.57 ± 1.53 
PE MFI units vs mean 0.55 ± 0.47 PE MFI units, p<0.005) and mCPB (mean 1.10 ± 0.73 PE 
MFI units vs mean 0.52 ± 0.68 PE MFI units, p<0.005) groups (Figure 4.7B). 
 
These data suggest that altering the components of the cardiopulmonary bypass circuit does 
not alter the inflammatory activation profile of phosphorylated forms of p65 NF-κB in the 
context of cardiac surgery.  A consistent message that does emerge is phosphorylated forms 
of p65 NF-κB declines over the passage of time, following anaesthesia, surgical trauma and 
cardiopulmonary bypass. 
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Figure 4.8 Effects of CPB on leukocyte NF-κB phosphorylation 
CABG was performed with cCPB or mCPB. Peripheral blood samples were collected prior to surgery, 
post-induction, immediately prior to CPB (0h) and at varying times following CPB initiation.  
Leukocytes were fixed and permeabilised prior to intracellular staining using PE-conjugated 
antibodies that recognise Ser529 phosphorylated RelA or with isotype-matched irrelevant antibodies 
as a control. Fluorescence of (A) granulocytes or (B) mononuclear cells was quantified by flow 
cytometry (after gating of cells by size and granularity). Fluorescence levels, calculated after 
subtracting values from isotype-control antibodies, were pooled and mean values ± SEM are shown.  
(*p<0.05; *** p<0.005 Wilcoxon matched-pairs signed rank test within-group). 
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4.4.6 Secondary outcomes 
4.4.6.1 Leukocyte migration into skin blisters 
Leukocyte migration into cantharidin-induced blisters was assessed by studying blister fluid 
which was sampled pre-operatively and at 5 h post-operatively.  Representative images of 
blister fluid under light microscopy are shown in Figure 4.9 Cardiac surgery with CPB 
promoted leukocyte migration into skin blisters.  An additional representative image from off-
pump surgery without CPB is presented to set the context for coronary surgery in the absence 
of CPB support. 
 
A 15 fold increase in PMN margination into blisters was observed post operatively in the 
mCPB group (mean 4.41 ± 4.28 × 105 cells/blister vs mean 65.50 ± 62.40 × 105 cells/blister, 
p<0.05 Wilcoxon matched-pairs signed rank test) and a 6 fold increase (mean 6.63 ± 6.87 × 
105 cells/blister vs mean 41.33 ± 37.85 × 105 cells/blister, p<0.005 Wilcoxon test) in patients 
exposed to cCPB (Figure 4.9).  There was no difference between groups on mixed regression 
analysis modelling: mean difference 0.6998 log units, 95% CI (-0.3449, 1.7445), p = 0.173 
(Table 4.4).  Mononuclear cell accumulation in blister fluid was also enhanced following 
surgery with CPB.  The cCPB group there was 7 fold increase in mononuclear cell 
margination into tissues (mean 2.77 ± 2.29 × 105 cells/blister vs mean 19.38 ± 12.74 × 105 
cells/blister, p<0.005 Wilcoxon test).  In the mCPB a 13 fold increase in tissue margination 
was observed (mean 1.84 ± 0.76 × 105 cells/blister vs mean 23.61 ± 9.61 × 105 cells/blister, 
p<0.05 Wilcoxon test).  However, there were no significant differences in leukocyte migration 
between the cCPB or mCPB groups.  In keeping with the granulocyte margination data, there 
was no difference between groups on mixed regression analysis modelling: mean difference 
0.3294 log units, 95% CI (-0.3926, 1.0514), p = 0.342 (Table 4.4). 
 
These data demonstrate that surgery leads to leukocyte activation and tissue extravasation.  
However, this test did not discriminate between cCPB or mCPB technologies. 
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Figure 4.9 Cardiac surgery with CPB promoted leukocyte migration into skin blisters 
CABG was performed with cCPB or mCPB.  An additional Off-pump coronary revascularisation (OPCAB) 
patient was studied, independently of the randomised trial, to highlight the effect of coronary surgery, 
but without CPB support.  Blister fluid samples were collected prior to surgery (Baseline) and at 5 h 
following CPB initiation (Post-CPB). Cells were collected, stained using Diffquick and visualised by 
microscopy. Representative images are shown.  
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4.4.6.2 Conventional clinical markers of inflammation  
White cell counts and CRP were measured in all patients in peripheral blood. Two-way 
analysis of variance of peri-operative white cell counts revealed that the main effect of timing 
of measurements between baseline and on days 1 and 4 was significant, F(2,48) = 12.04, 
p<0.0001; but the modality of CPB use (whether conventional or miniaturised) did not 
account for any differences observed F(1,24) = 0.0002, p = 0.99.  Post-hoc evaluation using 
the Dunnett multiple comparisons test showed a significant rise in white cell counts between 
baseline and day 1 (mean 7.5 ± 2.4 ×109/L vs 10.2 ± 2.0 ×109/L, p<0.005) returning to 
baseline levels on day 4, in the mCPB group.  Similarly, in the cCPB group, surgery with 
CPB exposure resulted in significant rises in white cell counts from baseline to day 1 (mean 
8.0 ± 1.7 ×109/L vs 9.5 ± 2.4 ×109/L, p<0.05), normalising by day 4 (Table 4.5). 
 
When considering the influence of surgery and CPB on CRP levels, two-way analysis of 
variance revealed the main effect of timing of measurements between baseline and on days 1 
and 4 was highly significant as expected, F(2,48) = 72.66, p<0.0001.  However, the modality 
of CPB use (whether conventional or miniaturised) did not account for any differences 
observed between the mCPB and cCPB groups: F(1,24) = 1.469, p = 0.24.  Post-hoc 
evaluation using the Dunnett multiple comparisons test showed rises in CRP between baseline 
and day 1 were not significant (mean 2.38 ± 2.28 mg/mL vs 48.39 ± 30.35 mg/mL, p = 0.07) 
but significant changes appeared on day 4 (baseline vs mean 162.44 ± 87.37 mg/mL, 
p<0.0001), in the mCPB group.  Similarly, in the cCPB group, surgery with CPB exposure 
resulted in significant rises in CRP from baseline to day 1 (mean 3.00 ± 2.53 ×109/L vs 55.52 
± 32.94 ×109/L, p<0.05), and even more pronounced on day 4 (baseline vs mean 195.44 ± 
84.12 ×109/L, p<0.0001)(Table 4.5). 
 
Together these data highlight the inflammatory nature of cardiac surgery with the use of CPB 
support but have little sensitivity in discriminating between mCPB or cCPB systems, 
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Time  
White cell counts (×10
9
/L) CRP (mg/mL) 
mCPB cCPB mCPB cCPB 
Baseline 7.5 ± 2.4 8.0 ± 1.7 2.38 ± 2.27 2.97 ± 2.54 
Day 1 10.2 ± 2.0 9.5 ± 2.4 48.39 ± 30.35 55.52 ± 32.93 
Day 4 8.9 ± 2.4 9.2 ± 2.2 162.44 ± 87.37 195.44 ± 84.12 
Table 4.5 White cell counts and CRP are enhanced by surgery with CPB 
CABG was performed with cCPB or mCPB. Peripheral blood samples were collected prior to surgery 
(Baseline) and at 1 or 4 days post-surgery. Samples were tested for numbers of white cells or CRP.  
Mean values ± SD are shown.  
 178 
 
4.4.6.3 Plasma markers of organ dysfunction 
In this study, we also monitored markers of renal dysfunction, cardiac injury and end-markers 
of blood loss.  There were no significant changes in serum creatinine levels between pre- and 
post- operative time points in the mCPB group.  A significant decline in measured creatinine 
levels occurred in the cCPB group between day 1 and day 4 post-CPB (mean 84.00 ± 28.78 
µmol/L vs mean 118.31 ± 76.09 µmol/L, p<0.05, Bonferroni multiple comparisons test 
following two-way analysis of variance).  Serum creatinine levels were significantly lower in 
the mCPB compared to the cCPB group (mean 75.62 ± 29.90 µmol/L vs mean 118.31 ± 76.09 
µmol/L, p<0.05) on the 4th post-operative day (Table 4.6). 
 
We also monitored markers of cardiac injury in the early phases (0 and 30 minutes) after the 
commencement of CPB.  In view of the known reports suggesting that different markers 
appear at different time points during reperfusion, we measured two markers of injury; 
cardiac Troponin T (cTnT) and Creatine Kinase isoenzyme MB (CK-MB).  cTnT is a cardio-
specific and highly sensitive marker for myocardial damage.  In studies using intermittent 
cross clamp fibrillation during CABG, it was shown that this biomarker peaks at 5-6 hours 
post-operatively178,510.  CK-MB mass is used to determine cardiac injury post infarction.  
Significantly elevated levels of markers of myocardial injury were observed in blood within 
30 min after institution of CPB (this period is likely to be associated with at least 2 grafts and 
two sessions of ischemia and reperfusion) irrespective of whether the biomarker was CK-MB 
or cTnT (Figure 4.104).  Whilst total CK-MB levels were similar for both interventions (mean 
3.5 ± 0.3 µg/ml vs. mean 3.3 ± 0.3µg/ml) total cTnT release was significantly lower in the 
mCPB group (mean 95.9 ± 14.4 µg/L vs. mean 58.8±7.6 µg/L, p=0.02).  Area under the curve 
to estimate total protein for cTnT and CK-MB release during CPB was calculated using the 
trapezium rule.  These findings are in keeping with the published literature on optimised 
bypass systems discussed in 1.6.2, page 76. 
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Blood transfusion requirement data are summarised in Table 4.3 and already discussed in 
section 4.4.4, page 162.  To complement these data, levels of haemoglobin pre-operatively 
and on the 1st and 4th post-operative days are presented in Table 4.6.  Two-way analysis of 
variance revealed the main effect of timing of measurements between baseline and on post-
operative days to be significant, F(2,48) = 64.72, p<0.0001.  The modality of CPB used 
during surgery in this parameter did not account for any differences observed: F(1,24) = 
0.4016, p = 0.53.  Post-hoc evaluation using the Dunnett multiple comparisons test showed 
falls in haemoglobin between baseline and day 1 (mean 13.4 ± 1.3 g/dL vs mean 9.6 ± 0.9 
g/dL, p<0.0001) and day 4 (baseline vs 10.1 ± mean 0.9 g/dL, p<0.0001)  were significant.  
Similarly, in the cCPB group, surgery with CPB exposure resulted in significant falls in 
haemoglobin count from baseline to day 1 (mean 13.3 ± 1.8 g/dL vs mean 10.1 ± 1.1 g/dL, 
p<0.0001) and day 4 (baseline vs mean 10.4 ± 1.6 g/dL, p<0.0001). 
 
Together, these data support the conclusion that cardiac surgery results in significant blood 
loss, myocardial injury and derangement in serum markers of kidney function.  Optimisation 
of cardiopulmonary bypass appears to confer a protective effect on biochemical markers of 
kidney function and is associated with a reduction in biochemical markers of myocardial 
injury. 
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Time  
Haemoglobin (g/dL) Creatinine (µmol/L) 
mCPB cCPB mCPB cCPB 
Baseline 13.4 ± 1.3 13.3 ± 1.8 88.69 ± 22.58 97.39 ± 28.75 
Day 1 9.6 ± 0.9 10.1 ± 1.1 70.39 ± 31.04 84.00 ± 28.78 
Day 4 10.1 ± 0.9 10.4 ± 1.6 75.66 ± 29.90 118.31 ± 76.09 
Table 4.6 Changes in haemoglobin and serum creatinine levels with CPB 
CABG was performed with cCPB or mCPB. Peripheral blood samples were collected prior to surgery 
(Baseline) and at 1 or 4 days post-surgery. Samples were tested for haemoglobin count or serum 
creatinine levels.  Mean values ± SD are shown.  
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Figure 4.10 Myocardial injury markers are elevated with the use of CPB 
Blood collections were made before surgery (on the morning of surgery and post intubation following 
anaesthesia) and immediately after starting CPB and then at 30, 60, 120 and 300 min after the 
initiation of CPB.  Immunoassay for the in-vitro quantitative determination of both proteins was used 
(Roche Diagnostics GmbH). 
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4.4.6.4 Flow cytometry profiles during cardiopulmonary bypass 
Representative flow cytometry histogram profiles from experiments are shown in Figure 4.11 
of cells for ROS, p38 MAP kinase and p65 NF-κB analysis.  There was a shift in the entire 
population for each leukocyte subset of interest at different timepoints in the surgical process.   
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Figure 4.11 Representative flow cytometry profiles for ROS, p38 MAP kinase and p65 NF-
κB 
Blood was sampled at various timepoints (indicated) in patients undergoing coronary surgery with 
CPB.  Samples were (A) loaded with APF to detect ROS or alternatively fixed and permeabilised prior 
to staining with antibodies for (B) p38 MAP kinase or (C) p65 NF-κB phosphorylation, followed by 
analysis by flow cytometry.   
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4.4.7 Adverse events 
No adverse events occurred as a direct result of exposure to CPB.  One patient in the mCPB 
group developed a pulmonary embolus in the post-operative period, requiring admission to 
the intensive care unit and prolonged ventilatory support until eventual recovery and 
successful discharge from hospital.  Three patients in the cCPB group developed post-
operative wound-related infections and were treated with long-term antibiotics.  There were 
no clinically evident wound-related infections in the mCPB group.  One patient in the cCPB 
group required renal support therapy in the post-operative period.  No patients required return 
to theatre for adverse peri-operative events. All participants in the study were ultimately 
discharged home.   
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4.5 CONCLUSIONS 
Comparison of inflammatory signalling between cCPB and mCPB groups revealed the 
following differences: 
 
1. ROS induction occurred following surgical trauma prior to the initiation of CPB and 
peaked at approximately 30 minutes into the CPB run.  ROS-signalling events were 
similar in the mCPB and cCPB groups for granulocytes, the predominant cell populations 
involved in the early phases of inflammation.  In the lymphocyte cell fraction, ROS 
activation was significantly higher in the cCPB group at the 30 minute time point 
following the initiation of CPB, compared to mCPB.  
 
2. Activation by phosphorylation of p38 MAP kinase occurred following surgical access and 
initiation of CPB.  Levels of p38 MAP kinase activity were significantly higher in the 
cCPB group compared to the mCPB group following the end of the bypass run.  
Attenuation of p38 MAP kinase levels was more pronounced in the mCPB group. 
 
3. NF-κB phosphorylation did not appear to be significantly influenced by surgery or CPB, 
with attenuation of levels of phosphorylation of p65 at the later time points in the study in 
both groups.  
 
4. Surgery and exposure to CPB was associated with accumulation of leukocytes in tissue.  
However, despite the different characteristics of p38 MAP kinase and ROS activation, 
there were no statistically significant differences in leukocyte migration into cantharidin 
blisters between either the two groups. 
 
5. Correspondingly, there were similar rises in inflammatory markers (CRP, WCC) at late 
timepoints in keeping with the intensely inflammatory nature of surgery. 
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6. Serum creatinine was significantly higher in the cCPB group than compared to the mCPB 
group on the 4th post-operative day following surgery. 
 
7. Troponin release was reduced in the mCPB group compared to the cCPB group 
 
Together, these data show for the first time that surgical access and CPB per se influences 
inflammatory signalling pathways. 
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4.6 DISCUSSION 
4.6.1 Molecular mechanisms and surgical factors influencing the systemic 
inflammatory response 
This study has assessed the intracellular signalling pathways that promote systemic 
inflammation in patients undergoing CABG with CPB.  Specifically, cardiac surgery leads to 
the activation by phosphorylation of p38 MAP kinase, in circulating leukocytes and induction 
of ROS.  In addition, induction of ROS and activation of p38 MAP kinase occurred prior to 
the commencement of CPB. This is an important observation because it suggests that factors 
associated with early surgical procedures (i.e. up to the point of cannulation of the great 
vessels) are sufficient to trigger pro-inflammatory pathways within leukocytes in patients 
undergoing cardiac surgery for coronary revascularisation. This process is likely to involve 
the release of DAMPs into the circulation207,511.  Further work is required to define the 
specific DAMPs that promote systemic inflammation in response to cardiac surgery.  
Although cardiac surgery with cCPB induced ROS and activated p38 MAP kinase in 
leukocytes, this process did not activate NF-κB via phosphorylation at Ser 529.  It is plausible 
that cardiac surgery activates NF-κB through other mechanisms, or at other phosphorylation 
sites, and further studies should be carried out to assess this. Alternatively, systemic 
inflammatory responses following cardiac surgery with CPB may be governed primarily by 
p38 MAP kinase signalling in the absence of NF-κB activation, at least in circulating 
leukocytes prior to their migration into tissues. The corollary is that p38 MAP kinase 
activation in granulocytes may be an important initiator of systemic inflammation and end-
organ damage in patients exposed to cCPB. This has obvious implications for the 
development of therapeutic strategies to target pro-inflammatory signalling pathways in 
patients undergoing cardiac surgery with CPB. 
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4.6.2 Timing of blood sampling in clinical studies 
The precise timing of sampling of blood during the clinical study was considered with great 
care.  Firstly, the over-arching aim of the study was to define the precise effects of CPB 
distinct from surgery and other aspects of the surgical process (such as weaning off support, 
protamine reversal etc.).  Therefore, all timings were conducted with reference to the 
initiation of CPB as our starting hypothesis was that CPB is the index initiating event of pro-
inflammatory activation.   
 
This central consideration informed the basis for the timings in the original preliminary ROS 
experiments.  In these early ROS experiments, a relatively late (24 hour) time point was 
studied.  This was of interest to determine if there are late ROS signalling events, and 
afforded the opportunity to evaluate the potential phenomenon of leukocyte priming.  
However, it is important to also consider the effect of other interventions and events that 
occur at the 24 hour time point that are inherently different to those of earlier periods.  
Namely, the patient has usually been recovered on ITU: mechanical ventilatory support has 
been weaned; the patient has been recovered from anaesthesia and been extubated.  During 
this period, there are varying levels of inotropic drugs used for support as well as a variable 
amount of blood transfusion.  Patients will have gone from a physiological state of starvation 
and stress and potential catabolism, in preparation for surgery, to the limited re-introduction 
of food whilst recovering.  Additionally, the introduction of some drugs (routinely aspirin, 
diuretics, b-blockers, laxatives) will have commenced.  Together, these events and 
interventions complicate the interpretation of the results, particularly those of a marker 
considered to be rapidly changing and short-lived.  It appears that a priming phenomenon may 
occur in the data presented.  However, an alternative interpretation of the data is that these 
post-operative events (of drugs, transfusion, recovery) actually trigger the enhanced ROS 
response to ex-vivo stress and no such priming actually is taking place.  For these 
confounding reasons, the later time point of 24 hours post CPB was not evaluated in patients 
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in the clinical trial.  It is also difficult to relate the changes observed at late timepoints back to 
the earlier period of CPB exposure and be confident about causality.   
 
In the subsequent experiments, a 5 hour time point was selected as this coincided with the 
blister assays.  This facilitated comparisons between ROS, p38 MAP kinase and p65 NF-κB 
changes within leukocytes in the circulation, and numbers of marginated (and therefore 
presumably activated) leukocytes within the tissue compartments. 
 
Shorter intervals between blood sampling were also considered, and indeed sampling was 
carried out at 15 minute intervals in the preliminary p38 MAP kinase and p65 NF-κB 
experiments in patient pilot studies.  This afforded the generation of valuable detailed 
information regarding the kinetics of activation.  However, the data did not reveal more 
meaningful changes than the 30 minute intervals settled upon in the final randomised clinical 
study.  An additional point to note is that having shorter (15 minute) intervals between blood 
sampling was not compatible with shorter interval ROS assays that were planned to run in 
parallel.  There is a very practical reason for this as sampling patient blood and performing 
the assays occurs by the bedside.  However, the specimens need to be transported back to the 
lab, and processed in time to return for the next assay.  The shortest practical interval to 
achieve this was 30 minutes. 
 
Consideration was given to timing of blood sampling to occur after the termination of bypass 
or after protamine reversal.  However, these proposed timepoints are variable and cannot be 
precisely controlled in these experiments (because experimentally we have no control over 
the duration of the operation).  The number of coronary artery grafts determines the duration 
of the cross clamp time which in turn determines the duration of CPB.  The inherent variation 
in these aspects of the operation makes interpretation of data difficult, particularly in trying to 
understand the kinetic profiles of activation, as the design of these experiments was targeted 
to address.  Re-analysis of the existing data in this context with respect to the pro-
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inflammatory markers is not meaningful given the timing of measurements have no relation to 
CPB duration or cross clamp time.  In an alternative experimental design, measuring the 
levels of ROS, p38 MAP kinase and NF-κB at the end of CPB (or alternative timepoints) 
could yield some mechanistic insight.  However, the activation profile that emerges from the 
studies presented here suggests that CPB is not the initiating event but instead a modulatory 
phenomenon in the inflammatory cascade.  This is exemplified by the fact that OPCAB 
surgery can result in SIRS manifestations, despite there being no cardiopulmonary bypass at 
all174,512. 
4.6.3 Molecular probe selection in the detection of ROS 
The ROS dyes presented in these studies have a differing spectrum of sensitivity and 
specificity for particular subtypes of ROS.  A summary of experimental data of ROS-
spectrum reactivity for the molecular probes is indicated in Table 2.3 (page 106).  The DCF 
dye is particularly sensitive at detecting •OH and ONOO- ROS species whereas the APF dye 
is highly sensitive for –OCl species as well as •OH events.  The differences observed in the 
pilot studies in patients may be reflective of this difference in ROS-spectrum sensitivity.  As 
well as this, the induction of ROS in the presence of the same phorbol ester stimulus was far 
greater in the APF group, nearing the detection thresholds of flow cytometry.  Importantly, 
the level of auto-oxidation of APF is significantly less than the level of auto-oxidation in DCF, 
and this may account for the apparently higher levels basal ROS seen with DCF in 
unstimulated conditions (mean 333 ± 235 FITC MFI units in DCF compared to 36.4 ± 16.1 
FITC MFI units in APF studies).  For the reasons of neutrophil hypochlorite radical  
specificity, of importance in inflammation, inducible-ROS sensitivity, negligible auto-
oxidation and technical ease of handling, APF was selected as the ROS probe of choice in the 
randomised clinical trial (and the large animal study presented in Chapter 5). 
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4.6.4 Comparisons within and between experimental data 
Selected summary data for ROS, p38 MAP kinase and p65 NF-κB levels are presented in 
Table 4.7, to facilitate comparison between the studies presented in this chapter and those 
presented in Chapter 3.  No formal statistical inferences were made between these data as this 
was not the purpose or design of the original experiments. 
 
The lowest levels of basal APF-spectrum, constitutive, ROS were observed in the patients in 
the randomised trial, even lower than those of healthy volunteers, with the highest levels in 
the pilot data group.  This pattern is also observed for the DCF-spectrum ROS (not measured 
in the randomised trial) that shows higher levels in clinical pilot data compared to controls.  
This may be a function of the differences in medical treatment between the three groups being 
considered.  The common cardiovascular preventative medications (aspirin513-515, statins414,516, 
ACE-inhibition517, beta receptor blockade518) for ischaemic heart disease all possess anti-
oxidant properties.  Therefore, the implication of long term treatment with these medications 
(in the run up to surgery) will alter the basal levels of ROS.  The nature of coronary artery 
disease for the randomised trial and other heart diseases (in the case of patients in the pilot 
clinical study, valvular pathology) is different with variation in pharmacological management.  
These differences may therefore be an important consideration for the variation observed 
between the clinical pilot data and the formal trial data.  In addition to the basal levels 
observed, the pilot clinical data demonstrates an enhanced effect of CPB on both DCF-
spectrum and APF-spectrum ROS.  In particular, the effects are more enhanced in the 
monocyte and lymphocyte fractions, as a proportion, implying a redox-sensitive mechanism 
for leukocyte priming and activation, where the effects are most marked at later timepoints 
after CPB exposure.  This may also reflect a priming effect of CPB in the context of an 
already enhanced basal level of ROS.  
 
Considering the profiles for phosphorylated p38 MAP kinase between experiments, this 
marker was lowest in samples from healthy volunteers and progressively increases with the 
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population of patients undergoing CABG in the randomised trial to a peak in the pilot series 
of patients who underwent more complex surgery (valve, combined surgery).  This concurs 
with the assertion of enhanced basal levels of pro-inflammatory markers with increased 
disease complexity and morbidity described in the literature349,416,426.  The pilot data is in 
agreement with the randomised trial in demonstrating that p38 MAP kinase is induced with 
surgery, but also prior to CPB exposure, and the pattern of attenuation also occurs at 2 hours.  
These observations imply some other additional molecular trigger (which includes DAMPs) 
may be the driver for the inflammatory response and CPB has a differentially modulatory 
effect.  The size of the p38 MAP kinase signalling changes are greatest with the pilot study 
group whereas the randomised data and volunteer data share similar degrees of response to 
stimuli / changes.  This implies that experimental models for p38 MAP kinase activation may 
replicate the stress conditions for coronary surgery, whereas more potent stimuli are required 
to reproduce the stress conditions for valve, or more complex surgery conditions in future 
studies. 
 
Levels of phosphorylated forms of NF-κB activity tended to be higher in both the pilot and 
the randomised clinical studies compared to those in the blood from healthy volunteers.  It is 
possible that activated forms of p65 NF-κB are already ‘high’ at the basal time point in 
patients, prior to surgery, because of existing co-morbidities and physiological stress.  For 
example, as angina and heart failure are known to enhance NF-κB in myocardium and 
leukocytes241,519-521 whereas basal NF-κB is ‘low’ in healthy volunteers.  Alternatively, age is 
an important factor influencing these manifestations as the disease process for atherosclerosis 
is one of chronic inflammation, NF-κB is at the hub of inflammatory ageing networks522.  
Blood in the clinical trials came from patients who were in their late 60s whereas the blood 
from volunteers was obtained from young adults in their mid-20s - early 30s.  Another 
contrasting observation is the reactivity of leukocytes between groups.  Both the pilot clinical 
data and the data from the randomised trial show an overall downtrend in the levels of 
phosphorylated forms of p65 NF-κB.  However, experimentally, we have seen that TNFα 
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phosphorylation of p65 NF-κB, in healthy volunteer blood to levels that far exceed those seen 
in the randomised trial.  One explanation is that chronic NF-κB activation in leukocytes of 
patients with cardiovascular diseases could lead to induction of negative regulations (e.g. 
IκBα, A20) that dampen subsequent NF-κB responses to inflammatory stimuli. 
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Table 4.7 Comparative levels of ROS, p38 MAP kinase an NF-κB between experiments 
Summary data was extracted from previous experiments and populated into this table.  Data for 
granulocytes (G), monocytes (M) or lymphocytes (L) is presented for ROS.  Data for granulocytes (G) 
and mononuclear cells (M) is presented for human studies of p38 MAP kinase or p65 NF-κB. Selected 
peak and basal levels are presented, in the respective MFI arbitrary units ± SD. 
 
Validation data in Chapter 3 
(healthy controls) 
Pilot Clinical data  
(patients) 
Randomised Clinical trial data  
(patients) 
R
O
S 
DCF Basal 
G: 213.2 ± 266.6 
M: 146.5 ± 115.8 
L: 134.5 ± 109.1 
 
DCF Peak 
G: 572.0 ± 136,6 (+PMA) 
M: 455.0 ± 105.5 (+PMA) 
L: 134.5.0 ± 109.1 (+PMA) 
 
 
APF Basal 
G: 40.31 ± 5.27 
M: 39.23 ± 7.50 
L: 12.79 ± 1.35 
 
APF Peak 
G: 7056 ± 1301 (+PMA) 
M: 2542 ± 1045 (+PMA) 
L: 156 ± 68 (+PMA) 
DCF Basal 
G: 333 ± 235 
M: 378 ± 489 
L:  253 ± 294 
 
DCF Peak 
G: 3683 ± 2110 (CPB 0 + PMA) 
M: 3139 ± 2851 (CPB 0 +PMA) 
L: 1108 ± 797 (CPB 30 + PMA) 
 
 
APF Basal 
G: 54.1 ± 33.8 
M: 47.1 ± 42.8 
L: 10.07 ± 5.12 
 
APF Peak 
G: 8041 ± 1550 (CPB 0 + PMA) 
M: 4494 ± 757 (CPB 24 + PMA) 
L: 716 ± 340 (CPB 24 + PMA) 
DCF Basal 
(no data) 
 
 
 
 
 
 
 
 
 
APF Basal 
G: 12.88 ± 4.69 
M: 9.56 ± 3.50 
L: 3.86 ± 1.18 
 
APF Peak 
G: 17.20 ± 7.68 (CPB 30m) 
M: 15.51 ± 9.86 (CPB 30m) 
L: 5.78 ± 3.44 (CPB 30m) 
p
3
8
 M
A
P
 k
in
as
e
 Basal 
G: 57.2 ± 33.1 
M: 1.9 ± 1.2 
 
Peak 
G: 194.9 ± 79.25 (PMA) 
M:15.83 ± 5.40 (Arsenite) 
Basal 
G: 347.7 ± 171.1 
M: 14.2 ± 3.4 
 
Peak 
G: 557.9 ± 221.2 (Start CPB) 
M: 30.13 ± 24.4 (Start of CPB) 
Basal 
G: 118. 4 ± 77.3 
M: 12.2 ± 13.9 
 
Peak 
G: 135.984 (Start of CPB) 
M: 14.48 (CPB 300) 
p
6
5
 N
F-
κB
 
Basal 
G: 2.46 ± 0.35 
M: 2.01 ± 1.23 
 
Peak 
G: 8.32 ± 1.11 (Arsenite) 
M: 36.15 ± 3.76 (Arsenite) 
Basal 
G: 4.41 ± 2.37 
M: 1.14 ± 0.43 
 
Peak 
G: 10.28 ± 2.88 (CPB 2h) 
M: 3.70 ± 1.47 (CPB 2h) 
Basal 
G: 2.99 ± 1.09 
M: 1.57 ± 1.53 
 
Peak 
B: 3.47 ± 1.78 (PI) 
M: 1.57 ± 1.53 (Baseline) 
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4.6.5 The effects of CPB miniaturisation on leukocyte activation and inflammation 
A majority of the studies investigating mCPB have used the early generation Minimized 
Extracorporeal Circulation (MECC) system manufactured by Jostra (Hirrlingen, Germany). 
The Hammersmith Unit has developed significant experience with the latest generation of 
mCPB systems, the ECCO circuit, which has proven to be safe and standardized404,405,435. 
Over 3 years, more than 600 patients have safely undergone cardiac surgery using the mCPB 
technique without any CPB-related adverse events. In a small retrospective study, blood 
transfusion requirements fell by 56% compared to cCPB523.  The ECCO mCPB system is a 
significant advance over previous technology because it includes a venous air removal device, 
whereas earlier mCPB systems carried the risk of air entering the circuit and air embolism.  
The ECCO circuit also requires significantly less priming volume and, therefore, would be 
expected to further reduce local haemodilution and reduce blood/non-endothelial surface 
contact. In addition, the ECCO system also has a tip to tip biocompatible coating using 
phosphorylcholine, which may attenuate the inflammatory response.  
  
Previous studies demonstrated that mCPB reduces blood loss and transfusion 
requirements443,452 and attenuates renal, myocardial and intestinal injury compared to cCPB. 
The beneficial effects of mCPB have been attributed to reduced inflammation since 
miniaturization of CPB lessens cytokine release and neutrophil activation in patients 
undergoing cardiac surgery114,402,403.  Here the effects of cCPB and mCPB on ROS, p38 MAP 
kinase and NF-B signalling molecules were compared.  p38 MAP kinase activation in 
granulocytes was significantly reduced in patients exposed to mCPB compared to cCPB.  By 
contrast, p38 MAP kinase activation in mononuclear cells, ROS induction and NF-B activity 
in both granulocytes and mononuclear cells was similar between both groups.  These data 
support the conclusion that miniaturisation of CPB had a highly specific inhibitory effect on 
p38 MAP kinase activation in granulocytes.  The observation that surgery with CPB 
promoted migration of leukocytes into cantharidin blisters confirms a previous finding195.  Of 
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note, mCPB and cCPB were associated with comparable numbers of leukocytes migrating 
into blisters and equivalent numbers of circulating white blood cells.  Collectively,  these 
studies suggests that the activation status of granulocytes (assessed by measuring p38 MAP 
kinase phosphorylation) correlates more tightly with systemic inflammation and renal injury 
than measures of leukocyte numbers.  Thus, measuring p38 MAP kinase activation status in 
granulocytes could provide a useful clinical diagnostic for the prediction of systemic 
inflammation and tissue injury in patients undergoing cardiac surgery.  
4.6.6 Limitations and considerations 
This RCT was conducted to assess the pro-inflammatory signalling profile in the leukocytes 
of patients exposed to CPB extracorporeal circulation circuits. Participants were randomly 
allocated to either mCPB or cCPB and were not aware of their allocation. The operating staff 
were not blinded to allocations which, in theory, may have introduced unconscious 
performance bias.  However, aortic cross-clamp and total CPB exposure times for both cCPB 
and mCPB were equivalent suggesting that surgical performance was similar in both 
randomised groups. Moreover, the randomised trial was designed around the operative 
practices of a single surgeon to eliminate variation in practice between different surgeons.  
Observers were not blinded as sampling was done undertaken directly from the patient during 
surgery. 
 
Another limitation is that we studied only a few of the myriad of factors that are activated in 
leukocytes in response to inflammatory signals.  For example, measuring TLR-receptor up-
regulation for the detection of DAMPs events; evaluating up-regulation of adhesion 
molecules cell surface markers; determining the activation of protective cellular pathways 
would give weight to the mechanistic insights required to understand the precise effects of 
CPB on inflammation.  Although these have been undertaken in isolated forms, there has not 
yet been one single unifying study with all of these considerations.  One approach to capture 
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some of this information at a broad level would be to assess leukocyte transcriptomes (e.g. 
using RNA sequencing) in patients undergoing surgery.  The studies presented also only 
consider leukocyte activation in isolation.  We understand the importance of endothelial cell 
activation, platelet activation and leukocyte-leukocyte interactions.  However, this is 
particularly difficult to study in vivo, particularly in humans.  
 
This trial was powered on leukocyte activation endpoints and the sample size was relatively 
small.  The study was underpowered for clinical observations, thus conclusions could not be 
drawn on the relative effects of cCPB or mCPB on end organ injury. Consequently, no formal 
assessment of organ dysfunction was made.  With hindsight, it may have been less than 
optimal to base the target sample size on cell counts rather than the primary outcomes, in 
particular choosing such a large target difference (1.5 standard deviations, even though this 
was based on pilot data).  Using the relevant correlations observed in the trial, we can now 
know that the trial was only able to detect a relatively large standardised difference in ROS 
levels in granulocytes (about 0.85 standard deviations) with 90% power and a 2-tailed 
significance level of 0.05. 
 
Miniaturised bypass is designed to attenuate the post-operative inflammatory response in 
patients undergoing cardiac surgery.  Studies, including this one, have been targeted at 
patients without significant co-morbidities and an ethical consideration always needs to be 
made when new technology is involved.  A criticism is that the patients are low-risk and may 
not be the best population to benefit from the protective effects of miniaturised bypass.  There 
is no literature on the use of miniaturised cardiopulmonary in complex surgical scenarios and 
prolonged bypass, and these groups of patients may be considered for future research. 
 
Although the current study has generated useful information, it is complicated by variation in 
patient demographics, pathophysiology of the primary disease, medical co-morbidities and 
inherent polypharmacy. Variation also arose operatively in the total duration of surgery and 
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exposure to CPB, reflecting primarily the number of coronary artery targets that required 
revascularisation.  To minimize these sources of variation, a large animal model of CPB was 
established in which healthy adult female pigs of, similar age, were exposed to CPB for a 
uniform duration. This study allowed assessment of the kinetics of leukocyte activation in 
response to CPB under well-controlled experimental conditions, presented in the next chapter.  
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CHAPTER 5. INFLAMMATORY SIGNALLING 
MODULATION BY SULFORAPHANE 
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5.1 INTRODUCTION 
In the preceding chapter, modulation of the inflammatory response to surgery was 
investigated. Technological optimisations of cardiopulmonary bypass systems were evaluated 
using the Sorin ECCO system in the context of coronary artery revascularisation.  With this 
approach, alterations in ROS induction and p38 MAP kinase activation were observed in 
leukocytes from patients.  Given that inflammation in response to cardiac surgery with CPB 
can be induced by a predictable and controlled stimulus (ie. the surgical access and 
cardiopulmonary bypass organ support itself), it may be possible to prevent or reduce 
inflammation by pretreatment with an anti-inflammatory compound. Here the potential anti-
inflammatory effects of sulforaphane were investigated.   The work that is described in this 
chapter deals with the use of sulforaphane, in a number of differing forms and modalities of 
delivery, as a means to influence the inflammatory signalling events within leukocytes.   
 
In the preliminary studies, detailed in the first parts of this chapter, ex-vivo experiments using 
whole blood sampled from healthy human volunteers with the use of purified sulforaphane 
were conducted.  This was done to evaluate the effects on leukocyte activation in the context 
of a variety of experimental chemical stressors.  Next, the hypothesis of whether pre-
treatment using sulforaphane would reduce inflammation and tissue injury in response to CPB 
was investigated.  Using a large animal model of conventional CPB, the influence of 
sulforaphane on leukocyte activity after exposure to the effects of extracorporeal circulation 
was determined.  Finally, the hypothesis of whether dietary consumption of sulforaphane-rich 
preparations would lead to suppressed leukocyte activity was examined in healthy human 
volunteers. 
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5.2 HYPOTHESIS 
The hypotheses tested in this chapter were: 
 
1.  Sulforaphane pre-treatment leads to attenuation of intracellular ROS induction, 
phosphorylated p38 MAP kinase or phosphorylated NF-κB in leukocyte populations 
following experimental stress. 
 
2.  Cardiopulmonary bypass leads to the rapid induction of reactive oxygen species in 
porcine leukocytes in association with early activation of pro-inflammatory signalling 
(e.g. p38 MAP kinase and NF-κB activation) and up-regulation of pro-inflammatory 
transcripts in tissues leading to end-organ injury. 
 
3.  Intravenous administration of sulforaphane 1h prior to cardiopulmonary bypass leads 
to biologically significant levels of sulforaphane in the plasma during the entire 
period of exposure to extracorporeal circulation in large animals. 
 
4.  Pre-treatment of large animals prior to exposure to cardiopulmonary bypass protects 
against pro-inflammatory signalling and attenuation of tissue injury.   
 
5.  Administration of the pre-cursor dietary form of sulforaphane attenuates leukocyte 
activation in human subjects.  
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5.3 RESULTS 
5.3.1 Influence of sulforaphane pre-treatment on ROS signalling in leukocytes 
The influence of sulforaphane on leukocyte activation was initially studied using peripheral 
blood samples from healthy human volunteers.  ROS activation was studied using the APF 
dye due to its relative selectivity for neutrophil-related ROS events (as show in previous 
chapters) and relative affinity for hypochlorite events.  Firstly, blood samples were pre-treated 
with purified sulforaphane (1µM or 10µM) or DMSO vehicle control for 1 hour.  Samples 
were then loaded with the APF dye for 30 minutes prior to the application of TNFα (20µg/ml) 
or PMA (200ng/ml) for 30 minutes.  Flow cytometry of cells loaded with APF revealed that 
ROS were induced by PMA treatment in granulocytes (baseline mean 53.0 ± 31.52 FITC MFI 
units vs mean 4133 ± 984 FITC MFI units, p<0.0001), monocytes (baseline mean 84.3 ± 38.9 
FITC MFI units vs mean 673 ± 286 FITC MFI units, p = 0.15) and lymphocytes (baseline 
mean 4.1 ± 0.30 FITC MFI units vs 17.1 ± 7.5 FITC MFI units, p<0.001)(Figure 5.15A-C, 
compare 7-9 with 1-3).  By contrast, TNFα did not enhance ROS levels in granulocytes 
(baseline mean 53.0 ± 31.5 FITC MFI units vs 329.1 ± 130 FITC MFI units), monocytes or 
lymphocyte subpopulations significantly (Figure 5.15A-C; compare 4-6 with 1-3).  Pre-
treatment of human leukocytes using sulforaphane suppressed the induction of ROS by PMA 
predominantly in the lymphocyte population at both 1µM (mean 11.8 FITC MFI units, p<0.05) 
and 10µM (mean 9.4 FITC MFI units, p<0.01) concentrations (Figure 5.15C; compare 8,9 
with 7).  Similar trends are observed in both the granulocyte and monocyte groups but these 
differences were not significant.  However, there were no effects with sulforaphane pre-
treatment in the TNFα-treated leukocytes.  Statistical inference was undertaken using two-
way analysis of variance considering the effect of stimulus and the effect of sulforaphane pre-
treatment.  Comparisons were performed using Bonferroni correction for multiple tests when 
effects were shown to be significant. 
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Figure 5.1 ROS induction in human leukocytes was attenuated by sulforaphane  
Whole blood from healthy volunteers (n=3) was pre-incubated with sulforaphane for 1 hour and then 
loaded with APF ROS probe for 30 minutes prior to treatment with PMA (200ng/ml) or TNFα (20µg/ml) 
for 30 minutes.  Samples were then processed and ROS levels were assessed by flow cytometry.   Data 
were pooled and presented as means ± SEM (*p<0.05; **p<0.01; #p<0.0001, Bonferroni multi 
comparisons test).   
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5.3.2 Effect of sulforaphane pre-treatment on p38 MAP kinase and NF-κB 
phosphorylation in leukocytes 
Given the effects of sulforaphane on ROS, we proceeded to evaluate the effects on the other 
pro-inflammatory markers.  The effects of sulforaphane pre-treatment on p38 MAP kinase 
and NF-κB activation were determined by intracellular staining for phosphorylated forms of 
these molecules followed by flow cytometry, with human blood pre-incubated with 
sulforaphane at 1-5µM concentrations of sulforaphane (or DMSO control) prior to TNFα 
(20ng/ml) for 30 minutes.   
 
Basal levels of phosphorylated in p38 MAP kinase in granulocytes were measured at 13.42 ± 
14.52 PE-Cy7 MFI units.  Following stimulation with TNFα, levels were measured at 33.38 ± 
34.59 PE-Cy7 MFI units and with sulforaphane pre-treatment at 5µM were measured as 19.92 
± 12.74 PE-Cy7 MFI units.  On an individual basis, the stimulus and pre-treatment effect 
appear clear, but on combined group statistical analysis, the data do not reach significance at 
the 0.05 α level, given the degree of variation, as evidenced by the standard deviations (Figure 
5.2A).  The trends are similar in the mononuclear cell fraction, but no statistically significant 
biological effect from stimulation nor pre-treatment is evident (Figure 5.2B).  In assessing the 
effect of sulforaphane on NF-κB signalling,  two-way analysis of variance showed a 
significant effect of pre-treatment; F(2,12) = 8.266, p<0.01, but not of stimulus.  At baseline, 
phosphorylated p65 NF-κB levels were 5.26 ± 4.24 PE MFI units.  The levels following 
TNFα stress (mean 8.53 ± 4.70 PE MFI units) were significantly reduced with sulforaphane 
pre-treatment at 1µM (mean 5.29 ± 2.99 PE MFI units, p<0.01) and 5µM (mean 5.75 ± 2.76 
PE MFI units, p<0.05) concentrations (Figure 5.2C).  The effects in mononuclear cells follow 
a similar trend but did not reach statistical significance (Figure 5.2D). 
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Figure 5.2 Sulforaphane pre-treatment suppressed NF-κB activation in response to TNFα 
Whole blood from healthy volunteers (n=4) was pre-incubated with varying concentrations of 
sulforaphane for 1 hour prior to experimental stress with TNFα for 30 minutes.  Samples were then 
fixed and permeabilised prior to intracellular staining for phosphorylated p38 MAP kinase (A and B) or 
p65/RelA (C and D) followed by flow cytometry.  Mean fluorescence intensity values were pooled and 
presented as means ± SEM.  (*p<0.05; **p<0.01, Bonferroni multi-comparisons test). 
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5.3.3 Antibody validation in porcine leukocytes 
Prior to in vivo studies using pigs, antibodies that target phosphorylated p38 MAP kinase or 
phosphorylated NF-κB (RelA/p65 subunit) in human cells were validated for use in porcine 
tissues.  Comparison of porcine and human protein sequences demonstrated a high degree of 
homology in protein sequences for p38 MAP kinase (Figure 5.3) and for p65/RelA NF-κB 
subunits with conservation at the phospho- acceptor sites of interest.  This is particularly 
important because peptides corresponding to these regions were used to generate antibodies 
that recognise phosphorylated p38 MAP kinase or phosphorylated p65 NF-κB.  Sequential 
analysis demonstrated 96% similarity between the human and porcine p38 MAP kinase 
protein sequence.  Similarly, p65 protein sequences showed 93% similarity between species.   
Moreover, staining of porcine leukocytes obtained from animals under sedation using anti 
phospho p38 MAP kinase antibodies was elevated by TNFα treatment (101.2 ± 25.3 PE-Cy7 
MFI units vs 172.3 ± 15.0 PE-Cy7 MFI units in granulocytes and 4.1 ± 8.7 PE-Cy7 MFI units 
vs 8.7 ± 1.9 PE-Cy7 MFI units in mononuclear cells)(Figure 5.5A).  Similarly, staining of 
leukocytes with anti phospho-p65 antibodies was elevated by TNFα treatment (1.01 ± 0.1 PE 
MFI units vs 5.6 ± 0.6 PE MFI units in granulocytes and 1.22 ± 0.2 PE MFI units vs 7.0 ± 1.5 
PE MFI units in the mononuclear cell fraction)(Figure 5.5B).  These data suggest these 
antibodies recognise modified p38 MAP kinase and NF-κB in porcine cells.  Representative 
forward and side scatter profiles from flow cytometry corresponding to porcine leukocyte size 
and granularity are shown in Figure 5.5C and D.  Unlike in humans, there was no discernible 
monocyte middle cell population in normal unpermeabilised cells (Figure 5.5C).  
Permeabilisation appeared to have affected forward and side scatter profiles in porcine 
leukocytes in keeping with observations seen in human cells (Figure 5.5D).  For experimental 
purposes, the cell population with enhanced side scatter were labelled as granulocytes, and the 
low-granular side scatter population were by default labelled as mononuclear cells. 
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Porcine        1 MSQERPTFYRQELNKTIWEVPERYQNLSPVGSGAYGSVCSAFDTKTGLRVAVKKLSRPFQ 
Human          1 MSQERPTFYRQELNKTIWEVPERYQNLSPVGSGAYGSVCAAFDTKTGLRVAVKKLSRPFQ 
                 *************************************** ******************** 
 
Porcine       61 SIIHAKRTYRELRLLKHMKHENVIGLLDVFTPARSLEEFSDVYLVTHLMGADLNNIVKCQ 
Human         61 SIIHAKRTYRELRLLKHMKHENVIGLLDVFTPARSLEEFNDVYLVTHLMGADLNNIVKCQ 
                 *************************************** ******************** 
 
Porcine      121 KLTDDHVQFLIYQILRGLKYIHSADIIHRDLKPSNLAVNEDCELKILDFGLARHTDDEMT 
Human        121 KLTDDHVQFLIYQILRGLKYIHSADIIHRDLKPSNLAVNEDCELKILDFGLARHTDDEMT 
                 ************************************************************ 
 
Porcine      181 GYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELLTGRTLFPGTDHINQLQQIMRLTG 
Human        181 GYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELLTGRTLFPGTDHIDQLKLILRLVG 
                 ************************************************* **  * ** * 
 
Porcine      241 TPPAYLINRMPSHEARNYIQSLTQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAA 
Human        241 TPGAELLKKISSESARNYIQSLTQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAA 
                 ** * *     *  ********************************************** 
 
Porcine      301 QALAHAYFAQYHDPDDEPVADPYDQSFESRDLLIDEWKSLTYDEVISFVPPPLDQEEMES 
Human        301 QALAHAYFAQYHDPDDEPVADPYDQSFESRDLLIDEWKSLTYDEVISFVPPPLDQEEMES 
                 ************************************************************ 
Figure 5.3 Protein sequence homology between porcine and human p38 MAP kinase 
Protein sequences for porcine (accession number XP_003356663) and human (accession number 
CAG38743) p38 MAP kinase were obtained from the National Centre for Biotechnology Information 
database portal.  Sequence homology between species was determined using the Sequence Analyser 
tool from the Swiss Institute of bioinformatics.  *denotes matching protein sequences.  Thr180 and 
Tyr182 phosphorylation sites of interest are highlighted in yellow. 
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Porcine        1 MDDLFPLIFPSEPAPASGPYVEIIEQPKQRGMRFRYKCEGRSAGSIPGERSTDTTKTHPT 
Human          1 MDELFPLIFPAEPAQASGPYVEIIEQPKQRGMRFRYKCEGRSAGSIPGERSTDTTKTHPT 
                 ** ******* *** ********************************************* 
 
Porcine       61 IKINGYTGPGTVRISLVTKDPPHRPHPHELVGKDCRDGFYEAELCPDRCIHSFQNLGIQC 
Human         61 IKINGYTGPGTVRISLVTKDPPHRPHPHELVGKDCRDGFYEAELCPDRCIHSFQNLGIQC 
                 ************************************************************ 
 
Porcine      121 VKKRDLEQAINQRIQTNNNPFQVPIEEQRGDYDLNAVRLCFQVTVRDPAGRPLRLPPVLS 
Human        121 VKKRDLEQAISQRIQTNNNPFQVPIEEQRGDYDLNAVRLCFQVTVRDPSGRPLRLPPVLS 
                 ********** ************************************* *********** 
 
Porcine      181 HPIFDNRAPNTAELKICRVNRNSGSCLGGDEIFLLCDKVQKEDIEVYFTGPGWEARGSFS 
Human        181 HPIFDNRAPNTAELKICRVNRNSGSCLGGDEIFLLCDKVQKEDIEVYFTGPGWEARGSFS 
                 ************************************************************ 
 
Porcine      241 QADVHRQVAIVFRTPPYADPSLQAPVRVSMQLRRPSDRELSEPMEFQYLPDTDDRHRIEE 
Human        241 QADVHRQVAIVFRTPPYADPSLQAPVRVSMQLRRPSDRELSEPMEFQYLPDTDDRHRIEE 
                 ************************************************************ 
 
Porcine      301 KRKRTYETFKSIMKKSPFNGPTDPRPATRRIAVPSRSSASVPKPAPQPYPFTPSLSTINF 
Human        301 KRKRTYETFKSIMKKSPFSGPTDPRPPPRRIAVPSRSSASVPKPAPQPYPFTSSLSTINY 
                 ****************** *******  ************************ ******  
 
Porcine      361 DEFTPMAFASGQIPGQTSALAPAPAPVLVQAPAPAPAPAMASALAQAPAPVPVLAPGLAQ 
Human        361 DEFPTMVFPSGQI-SQASALAPAPPQVLPQAPAPAPAPAMVSALAQAPAPVPVLAPGPPQ 
                 ***  * * ****  * *******  ** *********** ****************  * 
 
Porcine      421 AVAPPAPKTNQAGEGTLTEALLQLQFDTDEDLGALLGNNTDPTVFTDLASVDNSEFQQLL 
Human        420 AVAPPAPKPTQAGEGTLSEALLQLQFD-DEDLGALLGNSTDPAVFTDLASVDNSEFQQLL 
                 ********  ******* ********* ********** *** ***************** 
 
Porcine      481 NQGVSMPPHTAEPMLMEYPEAITRLVTGSQRPPDPAPTPLGASGLTNGLLSGDEDFSSIA 
Human        479 NQGIPVAPHTTEPMLMEYPEAITRLVTGAQRPPDPAPAPLGAPGLPNGLLSGDEDFSSIA 
                 ***    *** ***************** ******** **** ** ************** 
 
Porcine      541 DMDFSALLSQISS 
Human        539 DMDFSALLSQISS 
                 ************* 
Figure 5.4 Protein sequence homology between porcine and human p65 NF-κB 
Protein sequences for porcine (accession number NP_001107753) and human (accession number 
NP_068810) p65 obtained from the National Centre for Biotechnology Information database portal.  
Sequence homology between species was determined using the Sequence Analyser tool from the 
Swiss Institute of bioinformatics.  *denotes matching protein sequences.  Ser529 and Ser536 
phosphorylation sites of interest are highlighted in yellow. 
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Figure 5.5 Validation of anti-phospho-p38 and anti-phospho-p65 antibody staining using 
porcine cells by flow cytometric analysis 
Porcine blood samples were incubated with TNFα (10ng/µl for 30 minutes) or remained untreated as 
a control.  Leukocytes were fixed, permeabilised and stained using anti-phospho p38 antibodies (A) or 
anti-phospho p65 antibodies (B).  Fluorescence in distinct populations (identified by gating on forward 
and side scatter profiles) was measured by flow cytometry.  Representative images of 
unpermeabilised cells (C) and permeabilised cells (D) are shown for reference.  Mean values ± 
standard deviations were generated from data pooled from 3 independent experiments.  *p<0.05; 
**p<0.01, Student’s t-test. 
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5.3.4 Effect of sulforaphane pre-treatment in a large animal model of 
cardiopulmonary bypass 
The influence of sulforaphane on physiological responses to CPB was studied under well-
controlled experimental conditions by pre-treating pigs either with purified sulforaphane (i.v. 
2 mg/kg) or with saline as a control.  Animals were treated in accordance with the protocols 
described in 2.2.16, page 114.  In brief, adult female landrace pigs were prepared on a 
cruciferous vegetable-free diet for the preceding week.  Animals were anaesthetised and 
underwent sternotomy, cannulation and exposure to full cardiopulmonary bypass using a 
‘conventional’ cardiopulmonary bypass circuit described in 2.2.16.4 (page 117) conducted 
under porcine normothermia.  Blood was taken immediately after sedation (before surgical 
access, sternotomy etc.); at the initiation of cardiopulmonary bypass support and then at 1 and 
2 hours after the start of CPB.  Control or purified sulforaphane intervention injections were 
given immediately after the first blood specimen was taken.  Tissues were harvested as 
described in 2.2.16.5 (page 117).  Specimens were snap frozen and stored in -80°C conditions 
until the completion of all experiments and then studied en masse.  Animals were treated in 
according with Home Office regulations. 
 
The mean time from injection until the initiation of CPB was 106 ± 12 minutes in the control 
group and 107 ± 24 minutes in the sulforaphane intervention group.  In the first instance, 
plasma levels of sulforaphane were measured by LC-MS (Figure 5.6).  This demonstrated that 
plasma sulforaphane levels were significantly elevated immediately prior to the 
commencement of CPB (mean 353.25 ± 61.51 ng/ml)(CPB Start) and persisted for at least 2 h 
(mean 187.5 ± 40.73 ng/ml) in animals that were pre-treated with sulforaphane.  Sulforaphane 
was not detected in saline-treated animals, indicating that endogenous levels of this 
compound were negligible (Figure 5.7).   
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Figure 5.6 Plasma sulforaphane levels in experimental groups 
Animals were treated with sulforaphane or with vehicle alone as a control and were then subjected to 
CPB for 2 h. Plasma samples were collected prior to sulforaphane or control injection (baseline), 
immediately prior to CPB (cannulation) and at varying times following CPB initiation.  Sulforaphane 
levels were determined by LC-MS (ND, not detected).  Data were pooled from five animals and mean 
levels and standard error.  #p<0.0001, ANOVA followed by Dunnett’s test, compared to baseline. 
B a s e l i n e S ta r t 1  h o u r 2  h o u r s B a s e l i n e S ta r t 1  h o u r 2  h o u r s
0
1 0 0
2 0 0
3 0 0
4 0 0
5 0 0
S
u
lf
o
ra
p
h
a
n
e
 c
o
n
c
e
n
tr
a
ti
o
n
 (
n
g
/
m
l)
Saline Sulforaphane
ND ND ND ND ND ND
#
#
#
 212 
 
5.3.4.1 Sulforaphane effects on intracellular pro-inflammatory pathways in leukocytes 
during cardiopulmonary bypass 
The kinetics of leukocyte activation in response to CPB were determined by measuring p38 
MAP kinase phosphorylation, NF-B phosphorylation and ROS induction in leukocytes in 
pigs.  Blood samples were collected pre-operatively (baseline), following cannulation of the 
aorta and right atrium prior to the initiation of CPB (CPB start) and at 1-2 h following 
initiation of CPB.  Intracellular staining and flow cytometry demonstrated that CPB did not 
significantly induce phosphorylation of p38 MAP kinase in granulocytes (baseline 241.88 ± 
79.29 PE-Cy7 MFI units vs mean 210.26 ± 121.69 PE-Cy7 MFI units) at the start of CPB.  In 
keeping with the human data, levels of p38 MAP kinase were sub-baseline at 2 hours (mean 
187.08 ± 88.94 PE-Cy7 MFI units) but these changes were also not statistically significant 
(Figure 5.7A).  In mononuclear cells, the maximal levels of p38 MAP kinase were achieved at 
1 hour post-CPB (baseline mean 4.96 ± 3.56 PE-Cy7 MFI units vs mean 11.55 ± 13.4 PE-Cy7 
MFI units), but this did not reach statistical significance.  Sulforaphane pre-treatment initiated 
approximately 2 hours before the commencement of CPB showed a reduction in levels of p38 
MAP kinase at 1 hour (control mean 11.55 ± 13.4 PE-Cy7 MFI units vs sulforaphane mean 
1.40 ± 0.96 PE-Cy7 MFI units, p<0.05) between groups; and at 2 hours (control mean 9.51 ± 
12.36 PE-Cy7 MFI units vs sulforaphane mean 0.77 ± 0.83 PE-Cy7 MFI units, p<0.052)( 
Figure 5.7B). 
 
Compared to baseline (mean 2.46 ± 1.18 PE MFI units), the maximal levels of 
phosphorylated p65 NF-κB were measured at 1 hour post CPB (mean 3.46 ± 0.68 PE MFI 
units) in granulocytes.  This induction was not statistically significant.  The same pattern was 
observed in the mononuclear cell fraction (baseline mean 2.18 ± 0.72 PE MFI units vs mean 
3.171 ± 0.58 PE MFI units at CPB 1 hour).  Following pre-treatment with sulforaphane, 
granulocytes exhibited significantly lower levels of phosphorylated NF-B RelA at 1 hour 
(mean 3.46 ± 0.69 PE MFI units in controls vs 0.72 ± 0.25 PE MFI units, p <0.01) and 2 hour 
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time points (mean 3.03 ± 1.54 PE MFI units in controls vs 0.84 ± 0.46 PE MFI units, p <0.05) 
(Figure 5.7C).   In porcine mononuclear cells, baseline levels of p65 NF-κB were 2.16 ± 0.72 
PE MFI units.  The peak levels were recorded at 1 h following CPB (3.17 ± 0.58 PE MFI 
units), with this trend in elevation up until 2 hours of CPB.  Sulforaphane pre-treated animals 
exhibited significantly reduced levels of p65 at 1 hour post-CPB (mean 1.55 ± 0.29 PE MFI 
units, p<0.05) and 2 hours post-CPB timepoints (control means 2.96 ± 2.04 PE MFI units vs 
1.32 ± 0.31 PE MFI units, p<0.05)(Figure 5.7D). 
 
When considering ROS, compared to baseline (mean 9.92 ± 4.55 FITC MFI units), peak 
levels of ROS in granulocytes was recorded at 2 hours (12.25 ± 7.37 FITC MFI units) post-
CPB (Figure 5.8A).  The changes are small in magnitude and are not statistically significant.  
This is also seen in the mononuclear cell fraction, where induction changes are small 
(baseline mean 4.90 ± 5.98 FITC MFI units vs 6.41 ± 9.50 FITC MFI units at 2 hours post 
CPB) (Figure 5.8B).  There are no effects on ROS in sulforaphane treated animals. 
 
Together, these data show the signalling response to CPB in animals is distinct from that 
observed in the clinical CPB trial because p38 MAP kinase and NF-κB phosphorylation were 
not enhanced by surgery with CPB.  Despite this, sulforaphane appears to exert a biological 
effect at 1 and 2 hours following CPB by reducing p38 MAP kinase and NF-κB 
phosphorylation; having been delivered approximately 2 hours before the exposure to CPB. 
 
Levels of mRNA for TNFα, IL-6 and IL-8 were studied by quantitative SYBR-green PCR 
using gene specific primers as described (Table 2.2, page 97).  RNA was extracted using 
commercially-available kits and reverse transcribed using dedicated pipettes and reagents to 
avoid potential RNAase contamination.  Accurate quantification and quality assessment of the 
starting RNA sample was conducted by optical density assessment and samples used only if 
A260/280  approaching 2.0.  A water negative control was included in each run to exclude the 
possibility that fluorescent signal may arise from amplification of contaminating sequences.  
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Data were inspected after each run and it was ensured that amplification was logarithmic and 
a single PCR product with high temperature denaturing characteristics was produced (and 
low-temperature denaturing primer-dimers were absent). 
 
Analysis of mRNA levels of TNFα showed a significant increase from basal levels at 1 hour 
(mean 3.2 fold increase, p<0.001) and 2 hours (mean 2.2 fold increase, p<0.05) post-CPB 
exposure.  Sulforaphane pre-treatment significantly attenuated the level of mRNA transcripts 
at both timepoints 1 hour (mean 1.2 fold relative expression, p<0.01) and 2 hour (mean 0.94 
relative expression, p<0.05)(Figure 5.9A).  IL-8 transcripts were enhanced following CPB for 
1h (2.2 fold relative expression, p<0.01) and subsequently declined at 2 h post-CPB.  This 
induction was attenuated in the sulforaphane-treated group (1.1 relative expression, p<0.005) 
at the same 1 hour time point (Figure 5.9C). Interestingly, IL-6 mRNA levels in leukocytes 
were enhanced in pigs that were prepared for CPB (prior to the commencement of CPB; 
Figure 5.95B, compare ‘Baseline’ with ‘CPB Start’), indicating that this cytokine was induced 
by surgical procedures per se.  
 
Taken together, these data suggest that CPB exerts a pro-inflammatory effect on gene 
transcripts for TNFα and IL-8 in response to CPB.  Up-regulation of IL-6 transcripts appears 
before CPB and may represent the effects of other molecular triggers of inflammation 
independent of extracorporeal support.  The use of sulforaphane is associated attenuation of 
these gene transcripts in the large animal model. 
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Figure 5.7 p38 MAP kinase and NF-κB activation in leukocytes in response to CPB was 
suppressed by pre-treatment with sulforaphane 
Animals were treated with sulforaphane or with control and were then subjected to CPB for 2h. 
Peripheral blood samples were collected prior to sulforaphane or control injections (baseline), 
immediately prior to CPB (cannulation) and at varying times following CPB initiation.  Leukocytes were 
fixed and permeabilised prior to intracellular staining using PE-Cy7-conjugated antibodies that 
recognise Thr180/Tyr182 phosphorylated p38 MAP kinase or PE-conjugated antibodies that recognise 
Ser529 phosphorylated RelA or with isotype-matched irrelevant antibodies as a control.  Following 
lysis of red blood cells, fluorescence of granulocytes or mononuclear cells was quantified by flow 
cytometry (after gating of cells by size and granularity).  Mean fluorescence levels were calculated 
after subtracting values from isotype-control antibodies.  Mean values pooled from 5 animals per 
group are shown with SEM.  *p<0.05; **p<0.01 Fisher’s least significant difference multi-comparisons 
test. 
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Figure 5.8 Effect of CPB exposure on porcine ROS induction 
Animals were treated with sulforaphane or control and were then subjected to CPB for 2h. Peripheral 
blood samples were collected prior to sulforaphane or control injection (baseline), immediately prior 
to CPB (cannulation) and at varying times following CPB initiation.  Leukocytes were loaded with the 
APF ROS-sensitive probe.  Following lysis of red blood cells, fluorescence of granulocytes or 
mononuclear cells was quantified by flow cytometry (after gating of cells by size and granularity).  
Mean fluorescence levels were calculated.  Mean values pooled from 5 animals per group are shown 
with standard error. 
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Figure 5.9 Inflammatory cytokine induction in response to CPB was reduced by pre-
treatment with sulforaphane 
Animals were treated with sulforaphane or with control and were then subjected to CPB for 2h. 
Peripheral blood samples were collected prior to injections (baseline), immediately prior to CPB 
(cannulation) and at varying times following CPB initiation.  TNF, IL-8 and IL-6 transcript levels were 
quantified by real-time PCR.  Mean values pooled from 5 animals per group are shown with standard 
error.  *p<0.05; **p<0.01; ***p<0.005; #p<0.001, Bonferroni multi-comparisons test. 
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5.3.4.2 The effects of Sulforaphane on end-organ inflammation and injury following 
exposure to cardiopulmonary bypass 
Having assessed the intracellular signalling changes and the associated alterations in 
expression of pro-inflammatory transcripts within leukocytes in the circulation, the next phase 
of the experiments focused on the biological changes in end-organs and the relative influence 
of sulforaphane pre-treatment on these tissues.  To undertake this assessment,  firstly, 
histological analyses were performed to determine the effects of porcine CPB on renal, lung 
and myocardial microscopic tissue structure.   These were correlated with western blot 
analyses for protein expression of pro-inflammatory molecules and PCR analysis for the 
assessment of pro-inflammatory transcripts in tissue compartments.  Organs were harvested in 
a uniform fashion as described in 2.2.16.5 (page 117).  Tissues were stored at -80°C prior to 
thawing and study en masse at the completion of the experiments to ensure uniformity of 
handling and comparability of results. 
 
Histological assessments were performed by a consultant histopathologist blinded to the 
treatment allocation.  There was minor acute tubular necrosis (ATN) in renal samples from 
80% (4/5) control pigs undergoing CPB, evidenced by abnormal tubular flattening and debris 
within the tubular lumina (open arrows in Figure 5.10A, Saline; key features shown at higher 
magnification in the insets).  By contrast, ATN was not observed in kidneys from pigs pre-
treated with sulforaphane prior to CPB (p<0.05, Fisher’s exact test)(Figure 5.10A, right 
panel).  This indicates that sulforaphane pre-treatment may have a protective effect on 
kidneys from damage in response to surgery with CPB.  Gross histological changes in heart or 
lung were not observed suggesting that the architecture of these tissues was resistant to the 
duration of CPB exposed.  In 2/5 myocardial specimens within each group, there were noted 
to be emigrated neutrophils in the small blood vessel perivascular interstitial spaces (Figure 
5.11A).  In lung tissues, 9/10 specimens exhibited significant peri-bronchial lymphoid and 
interstitial hyper-cellularity with increased interstitial lymphoid or myeloid content (Figure 
5.12A).   Of note, the model did not involve cardioplegia or cross-clamp fibrillation and 
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therefore the heart was perfused throughout.  It is plausible that the absence of oedema in 
heart or lung relates to the absence of ischemia/reperfusion injury in this porcine model of 
CPB as we did not wean the animals off of extracorporeal circulatory support, nor did the 
model feature resumption of ventilation at any point.   
 
The potential influence of sulforaphane on p38 MAP kinase and NF-B phosphorylation in 
renal, lung and myocardial tissues was determined by Western blotting. To validate the 
technique we identified phosphorylated forms of p38 MAP kinase or RelA NF-B sub-units 
in cultured porcine aortic endothelial cells stimulated with PMA, which served as a positive 
control for antibody binding (Figure 5.10B, left panel).  Phosphorylated forms of p38 MAP 
kinase were not detected in renal (Figure 5.10B, right panel) or lung (Figure 5.12B) tissues 
from pigs exposed to CPB, whereas p38 MAP kinase phosphorylation was detected in the 
myocardium (Figure 5.11B).  Phosphorylated forms of p65 NF-κB  were active in all tissues 
(Figure 5.10B, Figure 5.11B, Figure 5.12B).  However, sulforaphane pre-treatment did not 
influence p38 MAP kinase or NF-B (RelA) activation by phosphorylation in tissues (Figure 
5.10B, Figure 5.11B, Figure 5.12B), indicating that its protective effects are not due to local 
suppression of either of these signalling pathways. Quantitative RT-PCR was carried out 
using the internal controls and procedures described above.  It demonstrated that sulforaphane 
reduced expression of IL-6 and TNF in lung (Figure 5.12C); and reduced IL-6, IL-8 and 
TNFα in myocardium (Figure 5.11C) but did not alter inflammatory transcripts in renal 
tissues (Figure 5.10C).  Thus we conclude that although sulforaphane can influence cytokine 
production in tissues, this effect does not account for its ability to reduce the early 
appearances of ATN in response to surgery with CPB.   Moreover, the cytokine expression 
does not correlate with differences in pro-inflammatory signalling molecular expression, nor 
gross macroscopic changes. 
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Figure 5.10 Renal effects of sulforaphane post-CPB 
Animals were treated with sulforaphane (animals 6-10) or with vehicle alone as a control (animals 1-5) 
and were then subjected to CPB for 2h.  Renal tissues were harvested. Tissue sections were stained 
with haematoxylin and eosin prior to histological assessment by an experienced pathologist who was 
blinded to the experimental design (A).  Representative images are shown. Arrows indicate abnormal 
tubular flattening and debris within the tubular lumina.  Renal tissue lysates were tested by western 
blotting using antibodies that recognise Thr180/Tyr182 phosphorylated p38 MAP kinase, total p38 
MAP kinase, Ser536 phosphorylated RelA or total RelA, and by using anti-α-tubulin antibodies to 
assess total protein levels (B). Lysates from phorbol myristyl acetate (PMA)-stimulated PAEC (known 
to contain phosphorylated p38 MAP kinase and RelA) were tested in parallel and served as a positive 
control for antibody binding. (C) IL-6, IL-8 and TNFα transcript levels were quantified by real-time PCR. 
Data were pooled from five animals and mean values ±SEM are shown. 
Saline Sulforaphane
pThr180/Tyr182 p38
α-Tubulin
p38
1 2 3 4 5 6 7 8 9 10
+ + + + + + + + + +
- - - - - + + + + +
Surgical Animals
0 0 0 0 0 0 0 0 0 0
pSer536 p65 NFκB
p65 NFκB
40 KDa
40 KDa
50 KDa
A B C
- - -
- - -
CPB
Sulforaphane
PAECs
0 25PMA (ng/ml) 100
70 KDa
70 KDa
A
B
C
0
2
4
6
8
R
el
at
iv
e 
m
R
N
A
0.0
0.5
1.0
1.5
2.0
R
el
at
iv
e 
m
R
N
A
0.0
0.5
1.0
1.5
2.0
R
el
at
iv
e 
m
R
N
A
ns
ns
ns
IL-6 IL-8 TNFα
Saline   Sulforaphane Saline   SulforaphaneSaline   Sulforaphane
?????
?
 
Figure 5.11 Myocardial effects of sulforaphane post-CPB 
Animals were treated with sulforaphane (animals 5-9) or with vehicle alone as a control (animals 1-4) 
and were then subjected to CPB for 2h.  Myocardium was harvested. Tissue sections were stained 
with haematoxylin and eosin prior to histological assessment by an experienced pathologist who was 
blinded to the experimental design (A).  Representative images are shown. Arrows demonstrate 
neutrophils in perivascular spaces.  Myocardial tissue lysates were tested by western blotting using 
antibodies that recognise Thr180/Tyr182 phosphorylated p38 MAP kinase, total p38 MAP kinase, 
Ser536 phosphorylated RelA or total RelA, and by using anti-α-tubulin antibodies to assess total 
protein levels (B). IL-6, IL-8 and TNFα transcript levels were quantified by real-time PCR (C). Data were 
pooled from five animals and mean values ±SEM are shown. ***p<0.005, Student’s t-test. 
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Figure 5.12 Pulmonary effects of sulforaphane post-CPB 
Animals were treated with sulforaphane (animals 6-10) or with vehicle alone as a control (animals 1-5) 
and were then subjected to CPB for 2h.  Lung tissue was harvested. Tissue sections were stained with 
haematoxylin and eosin prior to histological assessment by an experienced pathologist who was 
blinded to the experimental design (A).  Representative images are shown. Arrows demonstrate 
regions of hypercellularity.  Lung tissue lysates were tested by western blotting using antibodies that 
recognise Thr180/Tyr182 phosphorylated p38 MAP kinase, total p38 MAP kinase, Ser536 
phosphorylated RelA or total RelA, and by using anti-α-tubulin antibodies to assess total protein levels 
(B). IL-6, IL-8 and TNFα transcript levels were quantified by real-time PCR (C). Data were pooled from 
five animals and mean values ±SEM are shown. *p<0.05; ***p<0.005, Student’s t-test. 
 
A
B
C
pThr180/Tyr182 p38
α-Tubulin
p38
40 KDa
40 KDa
50 KDa
1 2 3 4 5 6 7 8 9 10
LUNG
pSer536 p65 NFκB70 KDa
p65 NFκB70 KDa
- - - - - + + + + +Sulforaphane
Saline Sulforaphane
Saline Sulforaphane
0.0
0.5
1.0
1.5
R
el
at
iv
e 
m
R
N
A
IL-6 IL-8 TNFα
Saline Sulforaphane
0.0
0.5
1.0
1.5
R
el
at
iv
e 
m
R
N
A
Saline Sulforaphane
0.0
0.5
1.0
1.5
R
el
at
iv
e 
m
R
N
A
***
*
 223 
 
5.3.5 Effect of homogenate consumption on leukocyte pro-inflammatory activity 
Building upon the findings in the earlier portion of this chapter, the final phase of 
investigation focussed on assessing the effects of a sulforaphane-rich diet in healthy human 
volunteers.  The hypothesis that the consumption of a single dose of a sulforaphane-rich 
preparation, in the form of a pre-blended homogenate (eliminating the variable of chewing, 
and action of myrosinase), leads to suppression of inflammatory activation of leukocytes for 
up to 24 hours was tested.   
5.3.5.1 Participants 
This study was conducted according to the methods outlined in 2.2.17, page 118.  Nine 
participants were recruited into the study.  Three participants withdrew from the study after 
administration of the first homogenate, all citing the unpalatable nature of the preparations 
and declined to continue.  Data from the remaining 6 participants is presented and broad 
characteristics are given in Table 5.1.   
 
There were a total of 4 female and 2 male participants with a mean age of 29.5 ± 1.6 years 
and a BMI 21.7 ± 0.9 kg/m2, reflecting the ‘healthy’ young nature of this population.  No 
adverse events were noted from the remaining participants, with specifically no gastro-
intestinal upsets nor any adverse clinically apparent immune reaction nor susceptibility to 
infections, reported in other studies.   The most frequent country of origin was the United 
Kingdom (n=3) with a spread of Northern European, Middle Eastern and Far Eastern ancestry.  
This cosmopolitan spread of volunteers gives a crude indication of (the absence of) potential 
genetic polymorphisms, although this was not formally tested in this study. 
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Table 5.1 Participant characteristics 
Participant 
ID 
Sex 
Age 
(years) 
BMI 
(kg/m2) 
Country of Birth Outcome 
1 Male 48 32.5 Republic of Ireland Completed 
 Male   Albania Withdrew 
2 Female 26 16.8 
People’s Republic of 
China 
Completed 
 Female   Italy Withdrew 
 Female   United Kingdom Withdrew 
3 Female 24 20.1 United Kingdom Completed 
4 Female 30 20.3 Iran Completed 
5 Female 27 18.7 Germany Completed 
6 Male 22 21.6 United Kingdom Completed 
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5.3.5.2 Consumption of homogenates produces biologically significant levels of 
sulforaphane in blood 
Plasma sulforaphane levels were determined from blood specimens obtained immediately 
prior to homogenate consumption and then at various time points up until 24 hours following 
homogenate consumption  (Figure 5.13).   
 
Two-way analysis of variance revealed that the effect of time on plasma levels of 
sulforaphane were significant, F(3,12) = 78.02, p<0.0001, as was the effect of homogenate 
consumed, F(1,4) = 424.7, p<0.0001.  Post-hoc evaluation using the Dunnett multiple 
comparisons test showed plasma levels of sulforaphane were significant at 1 hour (mean 
30.68 ± 2.88 ng/mL, p<0.0001) and also at 6 hours (mean 10.84 ± 0.87 mg/mL, p<0.0001), 
becoming undetectable at 24 hours.  Plasma levels of sulforaphane were undetectable in the 
ASH group at points of measurement.   
 
These data suggest that the BSH preparations can generate biologically active levels of 
sulforaphane in the plasma, and ASH is a suitable experimental control.  The levels measured 
are approximately 1/10th of those found in the porcine model dose delivered by intravenous 
injection.  By visual inspection, the plasma half-life was in the order of approximately 1-2 
hours. 
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Figure 5.13 Plasma sulforaphane levels following consumption of homogenates 
Six healthy volunteers consumed either BSH or ASH alternatively over a 24h period.  Blood was 
sampled at 0 (prior to consumption), 1, 6 and 24 hours after.  Plasma sulforaphane levels were 
detected using Liquid chromatography-Mass spectroscopy methods.  Values presented are means ± 
SEM.  ND = not detected, #p<0.0001 by Dunnett’s multi-comparison test compared to 0 time point. 
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5.3.5.3 Consumption of broccoli homogenates was associated with early attenuation of 
constitutive ROS and p38 MAP kinase levels 
Given the cross-over longitudinal design of the trial with multiple measures, a mixed-
regression model of statistical inference was conducted with the assistance of Professor 
Barnaby Reeves, Imperial College trials unit.  The data presented in the figures of the 
following section are based on raw un-adjusted values derived directly from the experiments, 
and plotted in the graphs.  Descriptive statistics (means ± SD) are presented in the text 
between time points of interest.  For comparative analytical purposes, the data distribution 
was log-transformed (to improve the distribution towards a Gaussian spread) and the log-
transformed data was fitted to statistical models, where indicated.  Main effects of time; time-
plus-homogenate and time plus-homogenate-plus-interactions between-time-and-homogenate 
consumption were considered in the regression model analysis.   
 
Analysis of whole blood samples revealed considerable variation in ROS levels and p38 MAP 
kinase and NF-κB phosphorylation in granulocytes and mononuclear cells between 
individuals that consumed ASH or BSH (Figure 5.14).   
 
Basal constitutive levels of ROS in granulocytes in the ASH group were 25 ± 12.99 FITC 
MFI units and in the BSH group were 21.04 ± 13.37 FITC MFI units.  The final regression 
model selected for ROS effects included time, intervention and interaction effects to achieve 
the best fit (Wald Chi-square = 8.59 with 2 df, p = 0.014).  Within this model, there is a rise in 
granulocyte ROS at 1 hour that is more pronounced in the control ASH group (48.71 ± 43.22 
FITC MFI units) compared to the BSH intervention group (30.29 ± 27.31 FITC MFI units); 
mean difference 0.4078 log units, 95% CI 0.0645 to 0.7510, p = 0.02 (Figure 5.14A) .  There 
were no statically significant differences between groups at 6 or 24 hours between groups for 
granulocyte ROS.   
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Under ex-vivo stress conditions, both ASH and BSH group granulocytes manifest a strong 
induction of ROS.  There appeared to be a rise in PMA-enhanced ROS at 1 hour which 
appeared to be more pronounced in the ASH group (mean 2936 ± 2441 FITC MFI units) 
compared to the BSH group (mean 1989 ± 2858 FITC MFI units).  However, the regression 
models for these stressed conditions did not reveal any significant differences between time, 
intervention nor interaction (Wald Chi-square p = 0.37)(Figure 5.14 B). 
 
The constitutive levels of phosphorylated p38 MAP kinase in granulocytes were 79.84 ± 
89.36 PE-Cy7 MFI units compared to 98.85  ± 75.62 PE-Cy7 MFI units in the control ASH 
group.  The final regression model selected for p38 MAP kinase effects included time, 
intervention and interaction to achieve the best fit (Wald Chi-square = 8.93 with 2 df, p = 
0.012).  In this model, there was a greater rise in p38 MAP kinase at 1 hour in the ASH group 
(113.73 ± 94.256 PE-Cy7 MFI units) compared to the BSH group (67.96 ± 85.03 PE-Cy7 
MFI units); mean difference 1.8045 log units, 95% CI (0.5168 – 3.0901), p=0.006 (Figure 
5.14C).  A difference between groups was not apparent at later time points in the study 
(Figure 5.14C).  Under stress conditions, there was no change between baseline levels of p38 
MAP kinase in either BSH and ASH conditions, and the statistical model did not achieve 
significance (p=0.74)(Figure 5.14D). 
 
The statistical models for constitutive levels of phosphorylated p65 in granulocytes did not 
reach significance for time or intervention or interaction between ASH or BSH groups (p = 
0.26)(Figure 5.14E).  However, the models for levels of stress-induced p65 showed a strong 
time effect (Wald chi-square p=0.0001), but no effect from interaction. There was a decline in 
levels of p65 over time with a strong effect seen at 24 hours compared to baseline for both 
groups but no statistical interaction, thus implying no differences between homogenates being 
consumed; but an effect of consumption itself. 
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Effects in monocytes, lymphocytes and mononuclear cells did not reach significance in 
statistical modelling of the parameters of interest. 
 
Together, these data show the most proximate measures of pro-inflammatory activation 
differed at 1 hour between ASH and BSH groups.  These effects were for ROS and p38 MAP 
kinase activation in the granulocyte cell sub-population.  This inflammatory modulation was 
lost at later time points under study.  In contrast, homogenate consumption did not alter p65 
constitutively but there was strong attenuation of inducible p65 at later timepoints, 
irrespective of type of homogenate being consumed.   
 
?????
?
  
Figure 5.14 Effect of homogenate consumption on pro-inflammatory signalling 
Six healthy volunteers consumed either BSH or ASH alternatively over a 24h period.  Blood was 
sampled at 0 (prior to consumption), 1, 6 and 24 hours after.  Leukocytes were loaded with the APF 
ROS-sensitive probe and left as controls (A) or stressed with PMA (B) with analysis by flow cytometry. 
Alternatively blood was immediately fixed and permeabilised prior to staining with antibodies to 
phospho-p38 MAP kinase (C) or phospho p65 (E) or subject to TNFα 20ng/ml stress for 30 minutes 
and then fixed/permeabilised/stained for phosho-p38 (D) or phospho-p65 (F) with subsequent 
analysis by flow cytometry.  Pooled data (n=6) is shown ±SEM.  Statistical results from mixed-
regression modelling are shown.  *p<0.05; ***p<0.005. 
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5.4 CONCLUSIONS 
Investigation of the effects of sulforaphane in this chapter has led to the following summary 
observations: 
 
 Pre-treatment of human leukocytes with sulforaphane in the micro-molar range for 1 
hour’s duration can reduce the induction of ROS and NF-κB activation, with a trend 
towards attenuation of p38 MAP kinase activation, ex-vivo. 
 
 Surgery with CPB in pigs was associated with histological appearances of ATN and this 
response was suppressed by pre-treatment of animals with sulforaphane intravenous 
sulforaphane injections.  This injection generated micro-molar concentrations of 
sulforaphane in the plasma throughout the duration of exposure to CPB.   
 
 Surgery with CPB in pigs did not activate ROS, p38 MAP kinase nor NF-κB significantly 
in circulating leukocytes.  Sulforaphane attenuated levels of p38 MAP kinase and NF-κB 
at 1-2hours  
 
 CPB lead to the induction of IL-6 and IL-8 in circulating leukocytes and these 
inflammatory responses were reduced by sulforaphane pre-treatment, administered prior 
to CPB. 
 
 Ingestion of sulforaphane-rich homogenates attenuates constitutive levels of leukocyte 
ROS and p38 MAP kinase 1 hour post-consumption. 
 
 Ingestion of sulforaphane-rich homogenates generates sulforaphane concentrations in the 
0.1µM range in humans. 
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5.5 DISCUSSION 
5.5.1 Context and rationale for studies 
When dealing with patients in a clinical setting, there can be considerable variability in their 
pathophysiology and response to treatment.  For example, gender variation, age, degree of 
coronary disease, medical co-morbidities and variation in concurrent medication use.  
Operatively, variability arises in the duration of surgery and, inherently, the duration of 
exposure to CPB depending on the complexity of the operation.  These variations in clinical 
and surgical characteristics may give rise to variable responses to treatment and to discrepant 
findings in research settings.   Because of these factors we studied the influence of surgery 
and CPB on leukocyte activation in young healthy pigs under well-controlled experimental 
settings, and also assessed leukocyte responses using isolated cells.   
 
Given the known role of p38 MAP kinase and NF-κB in the transcriptional induction and 
stability of pro-inflammatory molecules, we reasoned that targeting of these may dampen 
systemic inflammation in response to CPB.  To test this hypothesis we pre-treated cells and 
experimental animals with sulforaphane and conducted a trial in human volunteers with 
precursor dietary form.  Sulforaphane was selected for study because it is a potent indirect 
antioxidant that induces numerous endogenous anti-oxidant enzymes (e.g. HO-1, ferritin) via 
the transcription factor Nrf2. Moreover sulforaphane can suppress arterial inflammation in 
rodents and can inhibit MAP kinases and NF-κB in cultured vascular cells and 
leukocytes322,374,484-486,492-494.  Sulforaphane appears to have relatively fast biological effects 
within 1-2 hours of treatment including induction of mRNA expression in leukocytes within 
one hours501; suppression of TNFα-induced p38 MAP kinase phosphorylation (but not JNK), 
reduced mRNA and protein levels of MCP-1 and VCAM-1 and reduction in TNFα-induced 
NF-κB activity within 1 hour of treatment493,494 and down-regulation of iNOS and Cox-2 
mRNA and protein expression within 2 hours494.  Together, these observations suggest that 
Nrf2 is a fast-acting transcription factor and sulforaphane may possess anti-inflammatory 
effects independent of genes activated via the Nrf2/ARE pathway.  The bioactivity of the 
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metabolites and sulfur components of this molecule also have effects independent of gene 
transcription.  Further studies are required to distinguish between all these possible molecular 
scenarios. 
5.5.2 The benefits of porcine models in cardiovascular research 
In view of the complex multicellular nature of the mechanisms involved in systemic 
inflammation it is recognised that in vivo models are important for studying these processes. 
In vitro models of inflammation exist and there has been extensive work predominantly using 
human primary endothelial cells and human primary peripheral blood leukocytes. In vitro 
studies have generated a body of data, thus allowing focused questions to directed in vivo, so 
reducing significantly the number of animals required.  The pig/large animal model was 
selected because pigs have a circulation that is anatomically and physiologically similar to 
humans.  These animals possess arteries that develop comparable atherosclerotic lesions524. 
As an omnivore, the pig is also more similar metabolically to the human than rodents.  Aside 
from these considerations, the pig is becoming an increasingly attractive species for vascular 
biology research, with sequencing of the porcine genome near completion and an expanding 
reagent base525-527.  Importantly, the animal is of a suitable size to be connected to a 
conventional CPB circuit ordinarily used in clinical practice, without any adaptation.  In the 
study presented, adult female landrace pigs were connected to a conventional CPB circuit for 
a uniform duration of 2 hours.  This allowed assessment of the kinetics of leukocyte 
activation in response to cardiac surgery and CPB under well-controlled experimental 
conditions in young healthy animals.  It also allowed detailed examination of inflammatory 
genes in various tissue compartments (heart, kidney, lung) not normally procured in human 
subjects.   
 
A pure reductionist approach was taken with the large animal study in relation to 
cardiopulmonary bypass.  The experimental design focused exclusively on the inflammatory 
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effects of cardiopulmonary bypass on leukocyte activation and tissue injury.  The aim was not 
to reproduce the clinical scenario in its entirety but to address the important question of what 
was the isolated direct effect of surgery and cardiopulmonary bypass on pro-inflammatory 
signalling.  A secondary consideration was what was the effect of surgery and bypass on 
tissues and the relative influence of sulforaphane on this process.  There was no assessment of 
organ function at any point in the study (no echocardiography, no spirometry, and no renal 
assessment).  This approach was taken to isolate alone the effect of CPB, without introducing 
the variable influence of heparin reversal, weaning off bypass (hypoxia re-oxygenation) and 
recovery.  These are other important considerations for future studies. 
5.5.3 Responses to sulforaphane 
Sulforaphane administration in human and porcine models exhibited similar and contrasting 
effects (Table 5.2).  NF-κB phosphorylation was reduced by sulforaphane in one or either 
leukocyte subsets in the isolated leukocytes and the large animal study but not in the BSH 
study.  Sulforaphane inhibited p38 MAP kinase induction in pigs undergoing CPB selectively 
in mononuclear cells but not in TNFα-activated p38 MAP kinase in human leukocytes. ROS 
activity was attenuated in human isolated leukocyte and human homogenate studies but not in 
the porcine model.  Several possibilities may afford an explanation for these observations.  
Firstly, although these are mammalian systems, it is possible that species differences alone 
can account for the differing reactivity of the individual leukocyte-activation pathways. 
Another consideration is the selective targeting of sulforaphane on the activated form of p38 
MAP kinase, rather than the basal form. If we compare the levels of constitutive p38 MAP 
kinase in healthy controls (Table 4.7, first column) and to sedated animals in the antibody 
validation studies (Table 5.2, first column), we see that pigs have approximately double the 
magnitude of phosphorylated p38 MAP kinase, on the same scale; but possess similar degrees 
of reactivity to a stressor.  This pattern is reversed in the levels of phosphorylated p65 NF-κB; 
humans have constitutively double the level, on the same scale.  The biological relevance of 
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this is uncertain but may contribute to the varied responses seen between the porcine CPB and 
mini CPB study.  Indeed, in the human CPB studies, p38 MAP kinase was inducible and p65 
was to a large degree not inducible by CPB.  The reverse pattern was observed in the large 
animal CPB study; the higher constitutive p38 MAP kinase levels may have approached 
maximal, thus minimising any enhancement in response to surgery and CPB, whereas lower 
basal constitutive levels of p65 NF-κB may allow activation.  Indeed, the magnitude of the 
basal p38 MAP kinase response in the large animal CPB study (Table 5.2, third column) is 
almost twice that of the maximal response in the human mini CPB study (Table 4.7, third 
column).   Perhaps accounting for some of the differences; the humans in the clinical trial 
were older adults (mean age of 67 years) whereas the large animals were considerably 
younger pigs (approximately 4-6 months old) without co-morbidity.  The animals used in the 
study were all female, whereas the population in the clinical study was predominantly male 
(18 out of 26 subjects).  The precise effects of sex on inflammation and cardiovascular risk 
have not yet been precisely defined.  However, population studies have shown a reduced 
cardiovascular risk in women528 and a potential mechanism for this is the capacity to resist 
oxidative stress from hormonal influences529,530.  This may account in part for the observation 
of relatively little ROS induction in response to exposure to CPB seen in pigs, compared to 
the clinical study (compare  and Figure 5.8).  Of course, there may be species differences to 
explain the divergent findings; a possible explanation is that CPB in pigs was associated with 
NF-κB activation, by phosphorylation, at Ser529 but in humans, other NF-κB 
phosphorylation sites may be the key position which we have not been able to detect (e.g. Ser 
536) as these are known to respond differently to other upstream DAMP-signalling cascade 
events214,531. 
 
The other significant difference between experiments is the physiological dose and 
distribution of sulforaphane between experiments (Table 4.7, second row).  Plasma levels 
ranged between 0.1 µM - 10µM.  However, it is the kinetic of distribution and tissue 
bioavailability that is important, and not measured.  This is an important consideration when 
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reviewing the differences between leukocyte and lung, kidney and myocardial effects and 
different mRNA expression kinetics.. 
 
Sulforaphane has previously been shown to have a protective effect in reducing inflammation 
and suppression of p38 MAP kinase and NF-κB in small animal models by our group374.  This 
study has also shown for the first time that sulforaphane pre-treatment protects against renal 
damage and systemic inflammation in response to CPB.  This mechanism is associated with 
inhibition of p38 MAP kinase activation and NF-κB activation in leukocytes and may involve 
reperfusion injury and contact-activation of blood components223,532.  Notably, IL-6 induction 
in leukocytes was evident at the time of cannulation prior to CPB, indicating that median 
sternotomy and/or cannulation of the aorta and right atrium per se was sufficient to activate 
inflammatory signalling in leukocytes. It is likely that sternotomy and cannulation trigger 
inflammatory pathways by promoting the release of damage associated molecular patterns 
into the circulation181,207, however further studies are required to identify the particular 
molecular triggers that are responsible. Although treatment with sulforaphane reduced the 
early appearance of acute tubular necrosis in response to CPB, it did not influence 
inflammatory signalling or cytokine expression in renal tissues.  This was an unexpected 
histological finding as gross tissue architecture was not disrupted in the lung nor the 
myocardium.  The incidence of acute kidney injury is approximately 30% in patients 
undergoing cardiac surgery with CPB, the effects manifest in the first few days following 
surgery, with approximately 1/100 patients needing some form of support therapy102.  Other 
groups have reported histological features of tubular injury after 2 hours of CPB exposure533.  
These precede any functional manifestations of kidney injury (oligouria), acidosis, 
hyperkalaemia as well as biomarker changes; traditionally creatinine but experimentally 
including neutrophil gelatinase-associated lipocalin.  Our experiments were targeted to 
evaluate the distinct effect of CPB alone, the study was terminated and organs immediately 
harvested.  There was no functional data for the kidney nor other biochemical markers.  These 
may be useful in future studies on the effects of CPB on physiology and influence of 
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sulforaphane on these processes.  Nevertheless, our data suggest that sulforaphane protects 
the kidney from injury in response to CPB via inactivation of inflammatory signalling 
pathways in circulating leukocytes.  Although the mechanism underlying the differential 
effects of sulforaphane on leukocyte and non-immune tissues remains uncertain, it is plausible 
that the bioavailability of this compound is elevated in the circulation and/or that leukocytes 
are particularly sensitive to endogenous antioxidants.   
 
The clinical trial of homogenate consumption was notably different to investigations in 
isolated leukocytes and the large animal study.  The study was designed to assess whether 
delivering a precursor form of sulforaphane could generate biologically significant levels in 
the plasma and whether this in turn would influence pro-inflammatory signalling.  In a 
previous study, consumption of  broccoli homogenate, purchased from a local supermarket, 
generated a peak plasma concentration of 12.15ng/ml achieved412.  The plasma levels 
achieved in our human study presented at peak was 30.68 ng/ml (and the context of these in 
relation to the other studies is set out in Table 5.2, row 2).  This is one order of magnitude 
lower than in the large animal study, but the comparison also needs to take into account the 
absorption from the jejunum, passage through the enteric circulation; hepatic metabolism and 
then controlled plasma distribution prior to accumulation in tissues.  This, of course is 
physiologically different to the mode of pure sulforaphane administration intravenously 
which results in rapid high levels of sulforaphane in the plasma. 
 
Previous studies have shown that 1µM plasma concentrations occur transiently with oral 
consumption of sulforaphane-rich preparations.  In the isolated human leukocyte pre-
treatment studies, 1µM concentrations appear to have effects on ROS and p65 activation 
under the conditions evaluated, and less so on p38 MAP kinase phosphorylation.  The effects 
appear to be most manifest with 5-10µM concentrations used.  It is possible that the stimuli 
utilised (TNFα 20ng/ml and PMA 200ng/ml) could not be overcome by pre-treatment, and 
future studies should assess the effect of sulforaphane on responses to lower concentrations of 
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TNFα or PMA.  Given the actual dose measured in the plasma (approximately 0.1µM in 
humans fed broccoli), future experiments may be directed at these levels of concentrations 
and titrating effects to external stressors. 
 
NF-κB was unaffected and ROS and p38 MAP kinase suppressed in the BSH study.  The 
influence of BSH appeared most prominent 1 hour following ingestion, in keeping with the 
known pharmacokinetics of sulforaphane411,412,505.  At later timepoints, there was no effect in 
leukocytes despite the induction and persistence of anti-inflammatory gene expression 
reported in the literature505.  It is difficult to interpret data at later timepoints due to the other 
interactions and metabolic changes with trial participants and firm conclusions cannot be 
reached.  The constitutive levels that are measured are influenced throughout the day by 
multiple stimulating events.  There were no restrictions on what participants did throughout 
the duration of the study after the homogenate was consumed.  Thus, going for a curry and 
ingesting curcumin534 or drinking red wine and ingesting resveratrol535 could potentially lead 
to variable responses between individuals.  There is a whole host of biologically active 
nutriceutical research taking place and any one of these factors may influence the results seen.  
In addition, exercise can enhance NF-κB and ROS-interactions in mammalian systems536,537.  
Thus, the time point which we can be most confident of our data is at 1 hour (before too many 
confounding factors have taken place).  Ex-vivo stress was applied to leukocytes to test their 
reactivity.  Patterns of activation appear to be different but because of the variability of 
response, it was difficult to draw sound conclusions on the basis of the data.   
 
It is also plausible that other additional compounds in BSH (and ASH) are responsible for 
some part of these observations, or that individuals exhibit differing pharmacokinetic and 
pharmacodynamic profiles to the ingestion of this preparation with perhaps an underlying 
genetic polymorphism.  It is also possible that study participants were able to tell the 
difference between homogenates, and in doing so modify subsequent behaviour.  Despite this 
potential for bias, allocation concealment was found to be adequate; in post-study electronic 
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questionnaires, 3 out of 6 participants correctly guessed the order in which they had received 
their homogenates.  The appearance, smell and taste of the preparations of the homogenate 
aliquots was unappealing.  This needs to be improved in future studies using homogenate 
preparations (e.g. with other flavourings), or abrogated using purified forms of this agent.  
Reassuringly, there were no adverse effects reported, but clearly the study was not powered 
for untoward events.  Further studies are required to examine whether consumption of 
sulforaphane-containing vegetables prior to surgery with CPB can benefit patients by 
reducing systemic inflammation. 
 
One final interesting observation arises when considering the levels of pro-inflammatory 
marker activation in the homogenate study population (Table 5.2, fourth column) and the 
other healthy population from chapter 3 (Table 4.7, first column).  The healthy population in 
the BSH study is well-defined with stringent inclusion and exclusion criteria, characterised by 
low BMI and youth and a non-smoking history (defined in 2.2.17.2, page 120).  Blood from 
otherwise ‘healthy volunteers’ comes from a much broader population (of individuals of 
apparent good health, willing to donate blood).  The clear differences between these two 
populations are the levels of constitutive ROS as well as the attenuated degree of reactivity to 
inducible ROS forms.  This may represent better long-term redox status and health.  Data 
from the healthy sulforaphane leukocyte pre-treatment population (Table 5.2, second column) 
are not comparable to other groups due to the inherently different experimental design which 
accounts for the differences in pro-inflammatory markers, particularly p38 MAP kinase levels 
– reflecting the effect of DMSO vehicle/sulforaphane treatment and then conventional assay 
applications. 
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APF Basal 
G: 53.0 ± 31.5 
Mx: 84.3 ± 38.9 
L: 4.1 ± 0.3 
 
APF Peak 
G: 4133 ± 984 (+PMA) 
Mx: 673 ± 286 (+PMA) 
L: 17.1 ± 7.5 (+PMA) 
APF Basal 
G: 9.92 ± 4.55 
M: 4.90 ± 5.98 
 
APF Peak 
G:12.25 ± 7.37 (CPB 2h) 
M:6.41 ± 9.50 (CPB 2h) 
APF Basal 
G: 25.0 ± 12.99 
Mx: 18.9 ± 11.8 
L: 3.3 ± 0.9 
 
APF Peak 
G: 2936 ± 2441 (+PMA) 
Mx: 570 ± 388 (+PMA) 
L: 15.2 ± 19.7 (+PMA) 
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 Basal 
G: 101.2 ± 25.3 
M: 4.1 ± 8.7 
 
Peak 
G: 172.3 ± 15.0 (TNF) 
M: 8.7 ± 1.9 (TNF) 
Basal 
G: 13.42 ± 14.52 
M: 1.5 ± 1.44 
 
Peak 
G: 33.38 ± 34.59 (TNF) 
M: 2.62 ± 2.34 (TNF) 
Basal 
G: 241.9 ± 79.3 
M: 5.0 ± 3.6 
 
Peak 
G: Same as Basal 
M: 11.55 ±  (CPB 1h) 
Basal 
G: 79.84 ± 89.36 
M: 15.5 ± 16.2 
 
Peak 
G: 113.73 ± 94.3 (1h) 
M: 35.4 ± 57.6 
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Basal 
G: 1.01 ± 0.1 
M: 1.22 ± 0.2 
 
Peak 
G: 5.6 ± 0.6 (TNF) 
M: 7.0 ± 1.5 (TNF) 
Basal 
G: 5.26 ± 4.24 
M: 3.18 ± 1.99 
 
Peak 
G: 8.53 ± 4.70 (TNF) 
M: 8.55 ± 5.03 (TNF) 
Basal 
G: 2.46 ± 1.18 
M: 2.18 ± 0.72 
 
Peak 
G: 3.46 ± 0.68 (CPB 1h) 
M: 3.12 ± 0.58 (CPB 1h) 
Basal 
G: 3.36 ± 1.75 
M: 1.43 ± 1.41 
 
Peak 
G: Same as basal 
M: Same as basal 
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ROS ↔ ↓ ↔ ↔ ↓ ↔ 
p38 MAP kinase ↔ ↔ ↔ ↓ ↓ ↔ 
p65 NF-κB ↓ ↔ ↓ ↓ ↔ ↔ 
Table 5.2 Comparative levels of intracellular pro-inflammatory markers and summary of 
sulforaphane experiments 
Summary data from experiments presented for granulocytes (G), monocytes (Mx), lymphocytes (L) or 
mononuclear cells (M).  Values are given in their respective MFI units. 
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CHAPTER 6. DISCUSSION 
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6.1 SUMMARY  
6.1.1 Main conclusions of study 
 
 The inflammatory response to cardiac surgery with CPB involves induction of ROS and 
activation of signalling pathways (e.g. p38 MAP kinase, NF-κB) as early events in 
leukocyte activation. 
 
 Although molecular changes in response to cardiac surgery with CPB were broadly 
similar in the porcine model and patients undergoing CABG, there were also notable 
differences. 
 
 Activation of leukocytes was observed following surgical access but prior to CPB 
initiation, demonstrating that surgical preparation is sufficient to drive inflammatory 
signalling. 
 
 Activation of p38 MAP kinase and induction of ROS were lower in patients exposed to 
mCPB compared to cCPB, suggesting a potential molecular mechanism for the anti-
inflammatory effects of mCPB. 
 
 Pre-treatment with sulforaphane reduced NF-κB and p38 MAP kinase activation in 
leukocytes in response to CPB in the porcine model. 
 
 A small clinical trial suggested that consumption of sulforaphane-rich broccoli sprouts 
may reduce p38 MAP kinase and ROS activation in humans. 
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6.1.2 Global context for studies  
The thesis presented addresses an important aspect of clinical care, one where there remains 
many unresolved challenges.  The focus of this research endeavour was directed towards 
reducing the morbidity and mortality associated with the use of extracorporeal circulation in 
adults. This was conducted by (1) assessing the effects of optimisation of cardiopulmonary 
bypass technology in the form of miniaturised cardiopulmonary bypass; (2) application of 
novel ways of measuring the early events in the leukocyte activation cascade and (3) 
consideration of a pharmacological agent capable of inducing a more favourable cellular and 
end-organ tissue response following surgery. The pinnacle of cardiac surgery is the ability to 
restore the optimal function of the heart, without causing neither morbidity nor mortality, in 
the most elegant way possible. Cardiac surgery has progressed tremendously with constant 
improvements and technological innovations moving ever-closer towards this apotheosis. 
There have been many significant developments. Over the last six decades, as surgery on the 
heart became a reality and a routine aspect of clinical care, there have been refinements in 
surgical techniques; improvement in peri-operative care management and a more detailed 
understanding of the molecular mechanisms that drive disease processes. This has made us 
better clinicians and enhanced the lives of our patients. 
 
Here the novel hypothesis that cardiac surgery promotes systemic inflammation via ROS 
induction and activation of p38 MAP kinase and NF-κB in leukocytes was tested. This is an 
important consideration in the recovery and survival of patients undergoing surgery with the 
use of cardiopulmonary bypass.  
6.1.3 The research question and experimental model selection and design  
The focus of the research here from the outset was what is the contribution of 
cardiopulmonary bypass to pro-inflammatory activation in patients?  The use of 
cardiopulmonary bypass support technology is only one factor in the complex process of 
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surgery that contributes to inflammation. There are other factors to consider including the 
type of surgery (the operative approach), the anticoagulation, cross-clamping, aortic de-
clamping, protamine reversal, re-ventilation and recovery from anaesthesia in the immediate 
peri-operative period. These are important events clinically but have the potential to 
overshadow the scientific question addressed here (ie. miniaturised vs conventional CPB) as 
they themselves may influence inflammation and injury. There needs to be a balance between 
replication and reductionist approaches to scientific interrogation. In many ways the situation 
can be considered to the analogous set up of cell culture being truly reflective of functional in 
vivo endothelium? Can a large animal model truly represent the human condition? The 
important point to note is, what is fundamentally the question being asked and the degree of 
certainty, the power, that is required of the study. 
 
A criticism of the clinical study was that the timing of blood sampling did not correspond 
with clinical events, and that changes at time points such as at the termination of bypass and 
cross-clamp release would be of interest. There is no question that these are important 
transition periods, and a potential rebuttal to these suggestions was that these time points 
occur variably with the conduct and progression of the surgery and do not reflect a dynamic 
change in kinetic activity of the effect of CPB.  However, if the aim of a study is to 
understand both dynamic kinetic changes and also the changes at operative transition points 
then both types of measurements can take place in parallel in future experiments – i.e. (a) in 
the first run specimens being taken at baseline; post anaesthetic; start of bypass up until 6, 12, 
24 hour periods as required and (b) in the parallel run: specimens taken for post-sternotomy, 
post-aortic cannulation, post initiation of bypass; post cross clamp application; post-
cardioplegia; post aortic declamping etc. The approach of parallel blood sampling could yield 
mechanistic links between intervention and temporal changes observed with the use of 
cardiopulmonary bypass systems. Of note, in the clinical miniaturised CPB study, the median 
bypass times were 71-74 minutes in the two groups.  This means the CPB exposure was 
variable, and in fact 5/26 patients were off CPB support at the 1 hour time point.  Therefore 
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the only reliable time point where we are certain the CPB stimulus is ongoing is between the 
start (0 time point) and 30 minutes.  This is a very short time frame to make any inferences 
regarding the direct influence of CPB.  Correspondingly, there is variation in how long CPB 
has been discontinued for at the 2 hour mark, but may be an observation that correlates with 
the falls in p38 MAP kinase levels that are induced at the earlier time points in the 
miniaturised CPB study (Figure 4.3)(Figure 4.7) and to a far less convincing observation in 
the large animal study (Figure 5.6A).  The duration of CPB exposure was considered to be a 
relatively short period of time that clinically is not usually associated with the induction of 
SIRS (and we could not ethically justify prolonging the exposure to CPB for research 
purposes).  The alternative consideration of extended bypass times (e.g. 4-6 hours) has the 
criticism that this is not representative of the actual conduct in practice.  Therefore, to achieve 
balance, in the large animal study presented in chapter 5, a duration 2 hours of CPB was used 
so that an effectively long period of CPB was ensured and that blood sampling at ‘late’ time 
points were taken whilst the stimulus of CPB was ongoing.  
 
For a similar reason a criticism of the large animal cardiopulmonary bypass study was the 
poor homology and replication with the human clinical scenario. In particular the absence of 
cardioplegia, cross-clamping, protamine reversal, weaning from bypass and recovery.  The 
approach used in the animal study was centred on the influence of CPB exposure only.  
Future work could easily replicate these clinical scenarios and address these aspects of the 
study design to focus on the transition points of interest. 
 
Cardiac surgery is a team exercise and a functional team determines a good functional 
outcome for patients.  The miniaturised cardiopulmonary bypass trial was designed around 
the practice of one surgeon to minimise variability in practice (and therefore conceptually 
facilitates tight experimental control).  However, the team itself may be variable given the 
surgical assistants; nursing staff; anaesthetic staff and perfusion staff.  We took great care in 
standardising anaesthesia for all patients in the clinical trial, as well as in the large animal 
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study.  The second aspect of this is that the study has generated surgeon-specific data that 
may not translate appreciably with the practice of other surgeons. Indeed, for example, the 
trial surgeon uses a method of cardiac arrest that employs cross-clamp fibrillation. The 
findings may not be translatable to the scenario of blood cardioplegia that is used more 
widespread and there are inherent myocardial energetics derangements between these 
different cardioprotection techniques.  Future small studies therefore should be well-
controlled in well-defined populations to eliminate noise or expanded to multi-centre large 
studies to even out the distributions of variability.  Indeed, a criticism of the human study 
miniaturised bypass study was that the patient population was meticulously well-defined, 
well-controlled and low risk and therefore unlikely to benefit from the (presumably protective) 
effects of bypass optimisation.  
6.1.4 Alternative perspectives on considering the question of CPB and injury 
From a technological perspective, the question arises of whether there are further gains to be 
made in the optimisation of bypass systems or are we approaching a plateau with the 
technology?  This leads to two follow-on considerations (1) can there be any better approach 
with the application of the technology or (2) do we need to fundamentally do something 
different?  
 
The first consideration is one around engineering, and the answer is yes there are better 
versions of bypass available, with caveats.  If the starting point is that cardiopulmonary 
bypass is deleterious because it is not physiological due to flow differences and that 
biomaterial effects trigger inflammation and injury, then truly physiological bypass is 
possible in the form of cross-circulation.  This was an idea of Lillihei in the 1960s using a 
larger adult to provide the circulatory support for a smaller child. Lillihei had a successful run 
of patients and no reported deaths83.  However, this technique has never since been used given 
the potential risk of 200% mortality.  These approaches were developed at a time when 
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research was less stringently regulated; when there were no alternatives readily available (like 
CPB) and when there were no effective cures for some of these heart conditions.  The world 
is now a different place.  However, experimentally, this approach affords the opportunity to 
provide a means of ‘extracorporeal’ circulation using lungs and heart of ‘donor’ for a 
‘recipient’.  Such an experimental design could be conducted in inbred animals.  This would 
allow the delineation of the effect of surgery alone and the independent effect of 
physiological bypass in cloned animals.  Of course, the degree of control of physiological and 
haemodynamic parameters would be difficult in this scenario and it would be difficult 
(impossible) to identify the source of DAMPs and cytokines from ‘donor’ or ‘recipient’ if the 
circulations are interconnected.  However, what this proposed model would be able to 
distinguish is the effects on end-organ injury with physiological bypass only driven by 
surgery and presumed DAMPs generation.  
 
The second consideration is about application. Can we apply cardiopulmonary bypass better 
or what can we do differently?  The scenario of off-pump surgery allows for some 
mechanistic insight into surgery and is often used as a negative control group for comparisons 
with CPB.  The answers that arise from OPCAB studies are not always clear and in agreement 
with each other.  OPCAB can cause SIRS and a multitude of deleterious effects and clearly, is 
restricted to operations on the surface of the heart, and not open-heart procedures.  
Miniaturised CPB systems use smaller volumes of prime to reduce blood dilution and are 
associated with less blood loss and blood transfusion requirements.  The inflammatory 
mechanisms of miniaturised optimised systems was investigated in this thesis.  Alternative 
manipulations in providing pulsatile blood flow (with intra-aortic balloon counter-pulsation) 
and maintaining the lung as a physiological oxygenator (using the Drew-Anderson bypass 
technique) have been used independently with reported improvements in inflammatory 
markers91,95,170,406-408409,410.  A combination of these approaches may yield a protective 
synergistic effect (e.g. miniaturised bypass with pulsatile flow and maintained pulmonary 
circulation/ventilation).  Finally, the group of patients who undergo valve implantation 
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percutaneously may be a group of interest to evaluate the effect of 
instrumentation/intervention on significant structures in the heart and the associated 
molecular triggers of inflammation.  These are all potential patient groups for consideration in 
future work. 
6.1.5 Detection of in vivo ROS  
The role of ROS during cellular signalling is expanding and we have an understanding that 
sub-lethal changes in ROS events alter signalling cascades and pathways. Fundamentally, 
these events occur in vivo over short time frames, intracellularly, and therefore present 
particularly difficult challenges to localise and quantitatively detect. The assays used 
throughout this thesis has been ex-vivo in nature and in some circumstances evaluated with an 
additional stressor (Figure 3.5)(Figure 4.1)(Figure 4.2)(Figure 5.5B).  These assays therefore 
are only able to describe the very proximate measure of ex-vivo ROS inducibility.  This is the 
major limitation on the interpretation of the data using this assay.  The assays are intrinsically 
measuring a redox flux event that has already been and gone.  The changes that have been 
measured in the studies, in the presumably constitutive levels of ROS, are - or would appear 
to be - very subtle next to the magnitudes of the responses seen with stressors, particularly the 
potent effect of phorbol esters (compare Figure 4.1 and Figure 4.2, with and without stressors].  
A criticism of the molecular probes used (particularly DCF) can be inherent instability and 
auto-fluorescence which presents an unfavourable signal-to-noise ratio. The least auto 
fluorescent probe (APF) was selected for experimentation and gave excellent results in the 
presence of a stressor.  However, adding a stressor may amplify a ROS-response; but this may 
be a pathophysiological response and not necessarily simply amplification of the magnitude 
of a physiological response that was measurable on a smaller scale. Therefore the ex-vivo 
stressed blood from CPB patients in the ROS pilot studies that are particularly enhanced with 
APF (Figure 4.2) must be interpreted with caution for this reason, and also the many 
confounding contributions at this late time point that have been discussed in the summary of 
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chapter 4.  The holy grail of ROS focused research lies in understanding the effectiveness of 
redox signalling within compartments (i.e. spatial differentiation between cytosolic or 
mitochondrial in origin) over miniscule time frames with specific live-cell in vivo markers 
that are sensitive to these ROS changes.  At present there are no markers in routine 
experimental use in humans that facilitates quantitative spatial-temporal resolution of ROS.  
Nanoparticle research is emerging in the literature from animal studies as new forms of in 
vivo probes are developed for molecular interrogation538.  However, there are questions about 
reproducibility of data and the toxicity of the nanoparticle approaches that cloud the 
interpretation of results.  
6.1.6 Reliability and validity of pro-inflammatory assays 
The assays developed in this series of studies show both sensitivity and specificity for 
constitutive and inducible levels of ROS (Figure 3.5), p38 MAP kinase (Figure 3.3B, Fig 
Figure 3.4A) and p65 NF-κB (Figure 3.3C, Figure 3.4B) under well-controlled conditions in 
isolated leukocytes.  However, when applied to different groups of healthy volunteers and 
patients in clinical scenarios, we see there are of variations between different groups and 
across species – e.g. higher basal phosphorylated forms of p38 MAP kinase in complex 
surgical patients compared to health volunteers (Table 4.7, Table 5.2).  The potential 
explanations for these observations have already been covered in more detail in the 
discussions for Chapter 4 and Chapter 5.  The corollary of this is that these absolute values 
need to be interpreted within context.  Flow cytometry is best at describing relative changes 
and much more work is required to standardise and normalise values between patients and 
scenarios.  It is recognised that these signalling molecules exhibit cross-talk phenomena with 
interdependent regulation of cascades.  As such, p38 MAP kinase and NF-κB signalling 
events do not occur independently, in isolation, but are instead key nodes within a multi-
redundant network regulated by ROS.  These markers may be a long way off from being 
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meaningful clinical markers of active inflammation with power to predict clinically 
meaningful events. 
6.1.7 Identification of leukocytes and assessment of leukocyte activation 
Flow cytometry was used as the analytical tool of choice to evaluate leukocyte events 
throughout this thesis.  This approach afforded the opportunity to examine leukocytes on an 
individual cell basis rapidly in multiple samples.  The drawback to this technique is that 
relative changes are measured intrinsically.  Measurements are only directly comparable if 
performed on the same instrument with the same settings for gates, lasers and thresholds.  The 
data in this thesis are presented as absolute direct values from the instrument.  An alternative 
method of presenting the data from the experiments could be on normalised data and may 
have been equally appropriate in the analysis of findings.  Alternative means of assessing p38 
MAP kinase and p65 NF-κB protein expression were considered too slow and required higher 
volumes of blood starting material (e.g. by Western blotting)  – two aspects not compatible 
with the design of the CPB studies.  Pilot experiments with PBMC were conducted but these 
were not pursued further due to the volumes of blood needed; the time effort required for 
separation; the limitation of only the mononuclear cell fraction being available (instead of 
additional assessment of granulocytes) and fundamentally processing and handling the 
leukocytes altered their intracellular signalling characteristics.  
 
The accumulation of leukocytes in tissue was evaluated using the cantharidin blister assay.  
This facilitated the limited assessment margination of leukocytes into skin; a composite 
endpoint of local cantharidin inflammation in addition to the component from systemic 
inflammation induced by surgery and cardiopulmonary bypass.  This demonstrated movement 
into blisters in response to surgery and CPB in keeping with other studies195,278.  However, 
this assay had no discriminating power between the differing types of CPB technology under 
assessment; it quantifies margination at only two time points (in comparison to multi-point 
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analysis in blood) in a single organ compartment that has little direct clinical relevance, 
despite being the largest organ of the body.  Indeed, how skin inflammation and lung or heart 
inflammation are related are not precisely understood.  However, the technique did give 
unique insight into the egression of leukocytes from the vasculature which is a step beyond 
the mechanistic considerations of other clinical studies of inflammation due to CPB.  
 
Alternatively, radiolabelled white cell scanning can be a useful tool to demonstrate tissue 
localisation of leukocytes from the systemic circulation in future studies.  This is expected to 
occur the most in the lung and may be used as an index marker of systemic inflammation.  
PET-CT may be considered as a complementary means for imaging lung inflammation and 
may be of benefit when included in other future studies.  In addition to considering where 
leukocytes marginate to, the origin of leukocytes and mobilisation (e.g. bone marrow versus 
circulating) may be of equal importance.  Proximate measures may include plasma levels of 
G-CSF, SDF-1 and distinguishing markers of old and new leukocytes in the circulation such 
as CXCR4 expression. 
6.1.8 Upstream events from pro-inflammatory signalling  
As the clinical study progressed in parallel with the animal studies, the observation that ROS 
(Figure 4.6), p38 MAP kinase (Figure 4.3A, Figure 4.7A) and IL-6 induction (Figure 5.9B) 
were activated early, in some cases preceding the start of CPB, directed attention away from 
CPB being the initiating molecular trigger and more upstream events that influence leukocyte 
behaviour were considered.  These were the DAMPs, as discussed in 1.4.4, page 46.  Future 
studies should consider the release of DAMPs into the circulation; receptor expression and 
receptor distribution for these molecules.  A starting group of DAMPs that may be suitable 
are mtDNA fragments which signal via TLRs.  Having identified the kinetics of release of 
mtDNA, follow up experiments could assess the activation of inflammatory in the dose 
ranges identified (mimicking the kinetics of release) with readouts such as the ROS; the 
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general family of MAP kinase markers (such as the ones evaluated here); but also on the 
presumed negative regulation of apoptosis markers of immune cells and expression of 
adhesion molecules phenotypically.  Furthermore, TLR-receptor antagonism may be assessed 
using molecular inhibitors or assessment of inflammation in mice where TLR is genetically 
deleted in specific cell types (using cre/lox technology)539.  
6.1.9 Downstream events from pro-inflammatory signalling 
ROS, the MAP kinases and NF-κB have been presented as pro-inflammatory molecules and 
have a plethora of effects downstream from activation including the expression of adhesion 
molecules, the promoting of migration and upregulation of inflammatory cytokines.  But in 
addition, along this spectrum of activity are the apoptosis regulatory pathways as well as 
cytoprotective effects necessary in the resolution of inflammation.  In the pig model, pro-
inflammatory gene expression was assessed in leukocytes as well as tissue compartments.  
The genetic networks that are activated following CPB and OPCAB have been mapped 
linking inflammation-ischaemia-reperfusion as well as cytoprotection223,224.  These need to be 
probed and explored further and precisely defined in miniaturised CPB scenarios.  A true and 
complete mechanistic understanding of the activating cascade, the genetic induction, the 
message transcription, the protein expression and regulation with resultant phenotypical 
effects on cells and tissues would be very powerful and convincing in future studies.  The 
large animal study reported here made attempts at linking together mechanistic pro-
inflammatory signalling events with cytokine gene transcription in leukocytes within the 
vascular compartment with effects on gene transcripts, protein expression and histological 
manifestations.  In leukocytes, the attenuation of p38 MAP kinase and p65 NF-κB (Figure 
5.7) correlated with reduction in mRNA transcripts for IL-8 and TNFα (Figure 5.9).  
However, the up-regulation of these transcripts in control animals did not correlate with an 
expected enhancement of p38 MAP kinase nor and expected enhancement of p65 NF-κB.  
The reasons for these apparent discrepancies may lie in the multi-redundant nature of 
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inflammatory signalling and other MAP kinases (such as JNK or ERK) or different sites of 
phosphorylation in NF-κB may drive inflammation in porcine leukocytes preferentially at the 
points of sampling in the study, and reduction of constitutive p38 MAP kinases and p65 NF-
κB are more tightly linked to inflammatory suppression.  The interpretation of these 
interactions can be complex and underlies the results in tissues where there are no 
phosphorylated forms of p38 MAP kinase or p65 NF-κB, yet changes at a transcriptional level 
genetically (Figure 5.10-Figure 5.12). 
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6.2 FUTURE WORK 
6.2.1 Evaluate the role and mechanisms of DAMPs in CPB 
To define the specific factors that are responsible for ROS and p38 MAP kinase activation in 
cardiac surgery patients, further studies should be carried out on patients in different surgical 
and clinical contexts.  This should be considered for the off-pump group for coronary 
revascularisation in a randomised-controlled trial to evaluate the true effect of CPB (or its 
absence).  Additionally, analysis of patients undergoing coronary artery bypass graft surgery 
via a minimally invasive approach (e.g. through minimal access surgery via anterior 
thoracotomy, or with a minimalist robotic-thoracoscopic approach) with general anaesthesia 
would allow the potential response of leukocytes to anaesthetic induction to be assessed 
independently from median sternotomy.   It would be important to correlate the changes in 
ROS, p38 MAP kinase, NF-κB with biochemical changes in DAMPs such as the release of 
mitochondrial DNA fragments and their signalling interactions in these proposed scenarios. 
 
Use of electrocautery, with a Bovie device, channels electrical energy through a patient’s 
body and causes controlled diathermy burns at localised points directed by the tip of the 
device.  This is a safe and effective means of achieving dissection and haemostasis during 
operative procedures.  The use of an alternative dissection tool, causing only localised tissue 
damage, without the necessity for whole body electrical energy conduction, exists in the form 
of a harmonic scalpel (which dissects using vibration) would facilitate the evaluation of the 
effects of diathermy on DAMPs and pro-inflammatory signalling. 
6.2.2 Evaluate the inflammatory stress profile during prolonged CPB 
It is in the scenarios of long CPB exposure that mCPB is hypothesized to be of most benefit 
and utility, considering the counterpoint position of prolonged conventional-CPB to be 
deleterious clinically.  Prolonged CPB scenarios are expected in complex cardiac procedures 
(e.g. double valve replacement, re-do valve surgery, aortic root and arch surgery) where the 
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patient also possesses concurrent, inherent, increased peri-operative risk.  These are patient 
populations to be considered for future evaluations of the effects of conventional versus 
miniaturised CPB systems.  However, when one considers these groups, they represent 
diverse patient populations (even more so than coronary disease) with multi-systemic 
complications from their heart disease (e.g. associated pulmonary hypertension and hepatic 
venous congestion in mitral and tricuspid valvular disease) which may lead to high variation 
in inflammatory responses and complexities in the interpretation of data.   
6.2.3 Delineate the pro-inflammatory changes in aortic valve implantation without the 
use of cardiopulmonary bypass 
A stepping stone between these high-risk, prolonged CPB patients, would be to consider the 
evaluation of pro-inflammatory signalling in the context of aortic interventions.  Aortic valve 
replacement surgery is the commonest valve procedure performed in the UK and as yet no 
detailed evaluation of leukocyte signalling has been formally conducted with this procedure.   
This also affords the opportunity to evaluate a comparable procedure on the aortic valve that 
does not require the use of CPB, namely Transcatheter Aortic Valve Implantation (TAVI) 
with aortic valve replacement surgery.  The process of TAVI involves implantation of an 
expandable tissue aortic valve performed percutaneously.  This scenario lends well to the 
evaluation of intracardiac intervention, with anaesthesia, in the absence of cardiopulmonary 
bypass.  Two complicating factors to consider for this are firstly, the current practice of 
offering TAVI to those patients who are considered unsuitable for surgery (i.e. usually having 
an adverse mortality profile for open heart procedures), and secondly the TAVI valve results 
do not compare favourably to the characteristics of the valves implanted by open heart 
procedures.  This trial really should only be considered when the technology has reached a 
standard of non-inferiority, and the procedure can be offered to all patients, rather than 
selectively, so meaningful inflammatory comparisons can be made in equivalent patient 
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populations.  Pilot data would be illuminating and a TAVI programme exists at the 
Hammersmith site for a trial of this nature to take place.   
6.2.4 Establish a robust multi-faceted model for evaluation and optimisation of CPB 
technology 
There is a need to establish a meaningful way to precisely assess the inflammatory response at 
multiple levels of the activating cascade.  This is of particular importance to CPB and can be 
applied to other inflammatory systems and conditions.  A multi-modality assessment in pigs 
is possible given their favourable research characteristics.  This can build upon the work in 
this thesis by assessing plasma markers of injury; intracellular assessment of markers of 
leukocyte activation; multiple cascades of skin blisters to assess leukocyte movement at 
multiple timepoints; intravital microscopy of porcine peritoneum under anaesthesia; tissue 
biopsy to assess gene and protein expression (e.g. using RNA sequencing and proteomic 
technologies to provide an unbiased approach to determine effects on CPB on expression 
profiles).  Furthermore, this can be combined with imaging modalities to provide functional 
data; echocardiographic assessment of myocardial function; myocardial perfusion imaging to 
assess ischaemia; PET-CT imaging can determine areas of increased metabolic activity in the 
lung and combined with haemodynamic monitoring and lung function monitoring whilst 
anaesthetised and ventilated.  The logistics of this is difficult but application of this would 
yield tremendous mechanistic insights.   
6.2.5 Evaluate the combined effect of miniaturised CPB with sulforaphane pre-
treatment 
The data presented in this thesis has shown that mCPB and sulforaphane can reduce 
inflammatory activation in response to cardiac surgery with CPB.  The molecular basis for the 
attenuated inflammatory effects of mCPB remains unknown. Nevertheless, it is plausible that 
these two interventions may have additive or synergistic effects to attenuate pro-inflammatory 
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activation.  This hypothesis could be tested in a porcine model involving 4 groups of animals.   
Adult pigs would receive cCPB or mCPB with either sulforaphane or a saline injection as 
control.  Similarly, this concept could be tested clinically in future studies in patients about to 
undergo cardiac surgery. 
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